var title_f5_29_5584="Thyroid nodule PI";
var content_f5_29_5584=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F76248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F76248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Thyroid nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 482px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows a thyroid nodule on the left side of the thyroid. Thyroid nodules feel round or oval-shaped, and differ from the surrounding normal thyroid tissue. A person may have one or more thyroid nodules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_29_5584=[""].join("\n");
var outline_f5_29_5584=null;
var title_f5_29_5585="Wavelengths of light used for venous laser therapy";
var content_f5_29_5585=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F69001&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F69001&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    Wavelengths of light used for venous laser therapy (skin surface)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 296px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEoAe4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiisGTxRYp4gvtJCXDyWFqLu7nVAYrdTkqrHOdxAJAAPAqoxcthN2N6vE7nxT4uufGGv2Wi3moXU9lq8Nvb2SWCNa/ZyAZPNm8vK4GcEyA+xr0Sy8e+HrzSZtVju7mPTIYfPa8uLG4hhKZAyrugVjkgAKST6VTg8Z+DbHTdU1mGeK1iW4RL5xYyRzea2AnmR7BISQRgkV00Yyp35qd3tt1uRJp7M4D/hM/Etroup66dZe5ktvEj6XFpckEIjni8xVCKVQPvAY87j06V3vwy1zUNal8XDU7jzxYa9dWVv8irshTbtX5QM4yeTk+9aPh/TPDV3cyavpegW9re+Y264m0lrScseWP7yNXOc/e6E5561dj8L+H49UOpR6HpS6iZDL9qW0jEu89W34zk5POaqrVpyTjy2fovuCMWtbmxRRWND4htZPFVx4feK4hvorZbtDIoCTxk7SyEE52ngggHkdRXGot3saXNmiiikAUUUUAFFFFABRRXjXjjSbab4p6jd6z4evtUsH0FYLZ4dOkuALjzWICuqkI+P4sjGeorajSVRtN2JlKx7LRXhNlD4+0OCIxacbrWrfwoFFxJapI3n/AGr/AFZnxlmWI58vcQSM4Oc1dm17x2kN2LM6zPpX2+yjGoT6SEvY4GU/aGWARDdtYKAfLPU/e6jZ4N/ZkifaeR7BY39nfpK1hdW9ysUjQyGGQOEdfvIcHhh3HWrNfPWiv430LRZY9HtNSgtrvXb+W5upbNhcbSqGJzGIJCFY5JKxHpj5ete1eC59SufC2nS646PqTR/v3SGSEMwJGdkiqy5AHBUflUV8N7L3k7ocZ82ht0UUVzFhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcBp1jfWPj/wAZxmyaSLWbeG4tLiaFntyyReU0UjDgcgHaeoJxXf0VcJ8l13/zv+gmrnkJ+F896+vveafo+nWmoafHaLpWlXLxwPKkgcTs/kgIwKgDEbcdc81f0nwLrFrBrt7qy6Rr2patcW7TWupENB5UKlVBdYQC+Dnd5QHA4716fRW7xdRq39dP8kT7NHH/AA48LXPhjSNSt7l7dTeXst3Ha2zMYLRHxiKMkA4GPQdegrzvTPg9rFjoenW0M2kx3iaPqGnXksbuBO8xfyiTsyyruGc8jHAOBXsk+qwQ6/ZaQySm5urWe7RgBsCRPCrAnOckzpjjsenGdClHF1Ittdf+Cv1BwTPDL34OajJpeoW9sdGinm0mytoWBZQl3CV8ybITgkBgGHzHPOMmu2axvdQ+LOm3RtpktNH0ySOW7eJlSeWYrhEYj5sBSSR0Jx1rvaKcsXUn8Xn+KS/IFTS2CiiiuUsKKKKACiiigDzSX4j3Vr4R1jxRPp8c2mRagbOyjjJQ+Wr+WZZpPmwpcHovAwOc0zT/AIqNqGl2Mlpo8ct9faq+l2qreZt5doyZhL5e7Zj/AGM57Vcsfh4G0O+0LU7gjTYtTOo6ZPaSbZ4CWMmGDKVyrM2PvAg8gYqdPhjo6Rb0vNRXUv7Q/tP+0VaMTCfGM7dnl4xxt2YNeg3hdbrr57dP+D1MvfMi3+LDX8FlFpmhiXVJUu5J7ea78uOEW+Q+JAjFsnhflHviuss/GmkyeBLfxZeyPZaVJAszl0LtHuIXBCgk/MccCsYfCvRYrKyisrzVLO5tlnQ3sMqGaYT/AOt37kKnOeyjHbFbGo+CdJvfAZ8Ij7Rb6T5KQAwuPMCqwbqwIySOcjuazqPDOyimtdfT+rW/Ea5+pEfiH4YEF3K+oyILS4itp0e0mV0kk/1Y2FN2GxwcY96dYfEDw1fX1vZ29/L9onuHs0WW0mixOvLRMWQBXH91sGqOo/DTRr+81O5mudQWTULizuZQkiAK1su1AvycAjrnPtinRfDfSI79btbm/wDMGtProBkTHnuACv3fucdOvvSthrbu/wDwPTuHvl3wZ4gvNT1HxBpWrxwJqOkXYiZoEKpJC6h4nwWYglTyMnkV1Nct4M8P3mmaj4g1XV5IH1HV7sSssDlkjhRQkSZKqSQo5OBya6msa3Lz+75flr+Jcb21CiiishhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHK6l/yVPw9/wBgXU//AEfYV1VcrqX/ACVPw9/2BdT/APR9hXVUAFFFFABRRRQAUUUUAFFFFABRRRQAVi6Bqs+o6t4ltZ0iWPTdQS0hKAgshtbebLZPJ3TMOMcAe5O1XK+Df+Rj8d/9hqP/ANN1nQB1VFFeNeONWtofinqNprPiG+0uwTQVntkh1GS3BuPNYAqisA74/hwc46GtqNJ1W0iZS5T2WivCLLxx4n0mCOfU9Olu9Yh8KC/khd5lZn+1eWGeINsGEw7EIH4I3AcVem+KesQw3SxnRby3S+srRdchjdbGNZ1JdnHmEnYRg/OOSM46HZ4Gp01J9oj2mivnHwv431Pwzod3/Z0VlcLqHiHUfN1GUKLZCoQrjfMijeTxuk4A43Hivc/Beq3Ot+FtO1G+itorqePdIltOk8QYEg7XQspHGeCfSor4WVHVvT+ug4zUjbooormLCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorA8Z+Iv+Ec0y3mitDeXl3dRWVrbCTyxLK54BbB2jAJJweBVRi5vlW4m7am/Xl/xq1TXNNvPCQ8NO5vp750W384xxznyyQr4OGGecH9OtbOrfEbTtM8V/8I5LZXUuqCONyEnto0bf0CGWVC59gM+1Xbzxpb2Ov2emX2larbLeXRs7a7kjj8qWQDPAD79v+0UA4610UYTpyU3G+l7fImTTVrnk+t6gJvgTca7p2v6+2vWssaXUr6jPFJDO00ayo0auFAAJCjGAOnOa1PGdtqcPxHPh/QZfEVyn/COPPbQw6zKnl3BnYLNI8kwLAZwQS3GBtIHHo0fjO2Hiay0S807UrG4vmnWzluEjCXHlcuQA5dRgZG5VyOlaeqeI9E0m4+z6rrGm2U+wSeXc3SRttJwGwxBwSCM+tb/WJxduTe7Xz9O1mTyp9STw7DfW2gabBq8y3Gox20aXMq9HkCgMfxOa0ax7jxPoFtemzudc0uG7DKpgku41cFhlRtJzkjkeorN8SeM7TTfC8uv6V9m1nTraVVuntLpW8uPIDsCoIZlyDtyOO9cXs5zltuXdINS/5Kn4e/7Aup/+j7CuqrkryRJvid4bliYPG+iakysDkEGawINdbWZQUUUUAcp8UfETeGPA+pX8GTesn2e0VfvNNJ8qY+hOfwNeIXmp63Z+A9f8KeLpr2TV7O6sLyFr6YSyvC80YPzBmBCuPU/e/AfTVc/4k8RNpOq6HplpZ/bL/VZ2jjQy+WqRou6SRmwfujHGOSQOK7cNX5FyKF3e/wB2v+f3mc431ucAvxL1x/HNzpL2mlWNpDfvZst7PFFMIgPlnG6dWcE87VjwR0cnpS0L4taldWmtz6u2m2UOn2hngkis5pTfDzmQXESF1zEMAEZzk5LAV32r+Nk0jxDpukXuh6usupXJtrWZPs7pJj7z4EpcIAcklRgdqp+GfiXpXiO9u7fT7K8H2XzfNaSa2BXy85PliYyYJGAdmOe1aaOPN7LTTW/9b7E9dzhrD4t67d2sypBpTTprFlp6TCPKNFcKx3bUmcbhtHSQjn1qdvibrciJYX39jWUjatf6VcalLE4tlEEYZcIZAQ7lsAF+3eu68BfEHTfG+5tJtLqOIRmQvNNbFl+bGGjSVpFJ5xuUDjr0zuXHiTQ7bUTYXOtaZDfB1jNtJdRrJvYZVdpOckEYHelOcYycXS1/ry+Y0m1fmPFvhN4l8Rx6Z4M8NeH4tIMEumSX08l6JNwUXbowUqcZ29AR16ntTdE8U6zPrvgS6fVU07TrqXUYJI55Z5YZXSRgqu0k3zMwwEBb5W6AghR7M/izw5HcSW8mv6Qs8TOrxtexhkKffBG7IK9/SqOv+MLbS4dEv4FgvtF1C6W1e+guAywl+EcYBDKWG0nIx71TruUm1T+K/wCN+68/w8xctlucd8O/iPrfiXxPDY6hY6da28omElv58SXVsyE7QYzMZHBA5PlJjPcc12Hg3/kY/Hf/AGGo/wD03WddVXK+Df8AkY/Hf/Yaj/8ATdZ1xVpxnK8Y2RpFNLVlBfiJZR6Nq2s3VpMmlWt9/Z9o8Tb5b2QNsO1MAKN+QMtzgk4pT8StKEXlmy1L+1P7Q/sz+zNkf2jz8Zxnf5e3HO7fjHes7RfBV0/g7WfCuqWtt9mjv5J7G6mBljkjeXzQ22ORJFdSWU/MvOCCRkUy3+FSWkFpc22sSnXoNSGpm+uI3mSR9u3YUaTcU28cuW77jXVy4ZNpvrp6dP8Ag9SLzLo+Keiy2dlJZWep3l1crO5soY0E0Ig/1u/c4UY9mOe2a6nT/EOl33huDXkvIotKmhE4nnYRqqn+8W4HpzXBW3wmewt7KXTNd8rVYo7uOe5ms/MjmFx9/EYdduDyvzH3zXRXfgaB/hi3g21vHih+yi1W5dN7DkEsVyM854yKipHD6KD6/hr/AMCw059TYTxV4ektpbiPXdJaCKRYpJBeRlUdvuqTnAJwcA0tl4o0C+uIILLXNLuZ7jPkxw3cbtJjrtAOTjHOK4bU/hOL6/vrkayIzdPp7Ffsudv2Vcdd/O79PerMHwx8rVVvRq2SviKXXtv2bH31A8nO/tj736UnTw9vj/Dy/wAwvLsdN4S8RnXJ9YtLq0FlqOl3Ztp4BL5gIwGSRW2rlWU5HHrXRVx3gXSNQg1vxTrmr25tLjVrtPKty6sUgiQJGWKkjcwySMnFdjWNZRU7R20/LX8So3tqFFFFZFBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXI/EjR7/UrHSLzSIBc32k6lDfpblwhmVcq6BmIAJVjgnuK66irhNwkpITV1Y4nxp4Qv8AxfBJY3urRw6HPJDK9p9iBnTYQSqzB8DJHJ2seSAcVFqXgW61Pxdp+tXuq2oNhd/aYXt9PEV0YxnEDzh/mi+YgjaMjqa7uirWIqRVk/wXUXKmed+HvAGp6b43ufEmo+ILfVriYlV+1WDb7eI5/dxETbU7c7D39TVjxf8AD0eItd1bUTqQtxf6IdH8v7Pv8vMvmebncM+m3A9c13lFP6zU5ue+u2yDkVrHlc/wk82PU0/trH22TTZP+PT7n2SPZj7/ADv69se9T674K1Oy8LeLtP0Vhf3PibUHlJZViS0jm2q5bLfMFUHpySRxXceLNX/4R/wrrOs+R9o/s6ymvPJ37PM8tC+3dg4zjGcHHpWrVfW6t1d3/wCBb/JC9nE41rVbL4i+FbWMlkg0HUYlJ6kLNYAZ/KuyrldS/wCSp+Hv+wLqf/o+wrqq5m76lhRRRQAVx/i7Sb+Txb4W17TLb7X/AGfJNBcwh1RvJmUAupYgHaVBxnJGcV2FFXCbg7r+r6Caucxb+FT/AMJ5c+JtQvRdSC3FrY2/k7RaJ1c5ydzMe+BxxWcvgvUbrxNp+t6zrsVzd6bBPDZtb2AhYGUbS8hLsHIHQAKM84ruKKpV5rr0t02Fyo5DRPCV3B4u/wCEk1zU4L7UlsRp8f2a0NsgTfvLMC7lmJ9wB6VjeIvhgNZvvE1ydWEJ1q5sbgL9m3eR9mGMZ3jdu9eMe9ekUVSxFSMuZPX5dHcORPQ83s/hj9n1SC8OrbvK8QXGu7Ps2M+aoHlZ39sfe7+gqlP4B1Cw8GaF4PspDeWf9pi6vb4qsQihWUzbQhYksThRjPcnFeq0VX1urpd3t/wf8xciCuV8G/8AIx+O/wDsNR/+m6zrV1nV/wCzdR0K18jzf7UvWs92/HlYt5pt2Mc/6nbjj72c8YOV4N/5GPx3/wBhqP8A9N1nXMWavizV/wDhH/Cus6z5H2j+zrKa88nfs8zy0L7d2DjOMZwcelatcr8WP+SWeMv+wLe/+iHrqqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDlfix/ySzxl/2Bb3/wBEPXVVyvxY/wCSWeMv+wLe/wDoh66qgDldS/5Kn4e/7Aup/wDo+wrqq5XUv+Sp+Hv+wLqf/o+wrqqACiiigAooooAKKKKACiiigAooooA5Xxl/yMfgT/sNSf8ApuvKPBv/ACMfjv8A7DUf/pus6PGX/Ix+BP8AsNSf+m68o8G/8jH47/7DUf8A6brOgA+LH/JLPGX/AGBb3/0Q9dVXK/Fj/klnjL/sC3v/AKIeuqoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorI1rxNoOhzRxa3rel6dLIu9Eu7uOFmGcZAYjIzRcDXorlv+FieCv+hw8Of+DOD/AOKo/wCFieCv+hw8Of8Agzg/+KoA6miuX/4WH4K4/wCKv8Oc/wDUTg/+Kq1pnjHwxqt2trpfiPRr26YErDb30UjkDqQqsTxQJtLVm9RXNXHj3whbzyQ3HivQIpomKSRvqMKsjDgggtwR6Uz/AIWH4L7+L/Dv/gzh/wDiqATT1R1FFcv/AMLD8F4z/wAJf4d/8GcH/wAVV7UPFfh3TYLWfUde0m0gul328k95HGsy8coScMORyPWgHJLRs2qK5f8A4WH4K/6G/wAOf+DOD/4qj/hYfgr/AKG/w5/4M4P/AIqgZ1FFcv8A8LD8F5/5G/w7/wCDOH/4qj/hYfgv/ob/AA7/AODOD/4qgDqKK5f/AIWH4K/6G/w7/wCDOD/4qgfELwWTgeLvDpPtqcP/AMVQB1FFYuq+K/DukTpBq2v6TYzOgkWO5vI4mKngMAxBx71R/wCFheC/+hv8O/8Agzh/+KoEpJ6o6iiuYHxC8Fk8eLvDp7f8hOH/AOKq5P4s8OQaXBqU+v6THp07+XFdPeRiKRhn5Vctgn5TwD2NANpbm3RXMf8ACwfBmM/8Jb4e/wDBlD/8VR/wsHwZ/wBDd4e/8GUP/wAVQO509Fc9a+NvCl3cRwWvibQ555WCRxx38TM7HoAA2ST6Vc1PxFomlXCwaprGm2U7IJBHcXSRsVzjdhiDjIIz7Ur3dg8zVornv+E48J8f8VPoXPA/4mEXPb+9VrUPEuhabcLBqOtaZaTsodY57uONip4BAJzjjrWipyeyIdSC3aNeisz+39H+zQ3H9raf9nmz5cv2lNr/AEOcHp2po8R6Gc41nTTj/p6T/Gs5tU9J6eolVpvaS+887/ad17V/D/wp1CbSILSaC7zYXvnozGOCZGQuhDDDBioGcjnpXR/BrxJrHi/4e6br3iGCzt7y9LusdqjIgjDlVOGZjkgZ69xTfiVbaZ4z+HniHRbbULCWS5tG8vFwm0SL80ZJzwN6jn2rb8MRaboXhvStJtry18mytYrZCJF5CKBnr3xms5V6cEnKSV/M0h7/AMOp4b4/+IXi/Sf2jtH0CxsdJeJ0FnaSSwyktb3LQNI7YkGSrQEAjAwDwe30fXnWu+F9O1P4t+GvFxurQjTLK4hkJlXJY4EXGewkmPtxXd/2jZd7y2/7+r/jUfW6H86+9F+zn2ZaoqtJf2cZXzLu3TcARukAyD0PWon1fTUBL6hZqB1JnUf1qniaKdnNfegVOctky9RWTJ4k0OP/AFms6Yv+9dRj+tMbxV4eX72vaSO3N5H/AI1SqwezRosNWf2H9zNmisI+L/DQxnxDo/P/AE+xfX+9QfGHhkDnxFo3/gdF/wDFVXNHuH1Wv/I/uZu0Vg/8Jj4Y/wChj0b/AMDov/iqP+Ex8Mc/8VHo3HH/AB/Rf/FUcy7h9Vr/AMj+5m9RWD/wmXhjGf8AhI9F9P8Aj+i/+Ko/4TLwx/0Mei/+B0X/AMVRzLuP6rX/AJH9zPE/2kfiF4p8G+OvCkGj2Gm3NsGN5ZmeKQu9wUlt2RiHAK7ZwRjByRzjgs/Z7+IfizxT8TPFOmaxYaVbQ73vb8wRSBknRIbZUQlyAMRA8g9G56Ad5460vw9488TeCJ7TWNJurjSNU+1GOO7jdmjEZcgKDk/PHFx6ZNQ+Erbwt4G8dePNQv8AxBolncavfRzeTNexI6KIwx3AtkEySSHB7YNPmT6mU6c4O000yH9qHxDq/hz4W3kukQ2k1vfFtOvfPRmZIpo3XehDDBBwOcjkcV1fwg8Q6v4s+Hula74hhtIL2+V5RHaoyoqbiE4ZmOSAD171z/xW1jwj4y+Heu6HB4q8ONc3Vufs4bUoQPNUho8ndxlwoz711NtrHhfwdpem6Hea/pNj9jtIooo7m8jiYxqoVW2s2cHb1pmd1ex1NFcx/wALB8GZx/wl3h7P/YSh/wDiqT/hYXgv/obvDvr/AMhOH/4qgZ1FFcv/AMLC8Fn/AJm/w7/4M4f/AIqr9j4q8PX9rdXNjrulXNtaLuuJYbyN0hGM5cg4UYGeaBNpbmzRXMn4geDR18W+Hh9dSh/+KqfT/GXhfUruO10/xHot3dSEhIYL6J3YgZOFDZPAJ/CgG0tWb9Fc9eeNvCllcyW974m0O3uI2KPFLfxIysOoILZBqH/hYPgz/obvD3/gyh/+KouCaep09FY2l+KfD+rPKml67pV68SeY6213HIUX+8dpOB71R/4WD4MwD/wl3h7B6H+0of8A4qgOZPS509Fcv/wsLwX/ANDf4d/8GcP/AMVQfiH4KHXxf4cH/cTg/wDiqB3Ooorlj8RPBX/Q4eHP/BnB/wDFVLa+PPCF3dQ2tp4q0Ce5mdY4oo9RhZ5GY4CqA2SSSAAKAOkooooAK+Rf2zmB8ZaEuORp5P8A5FP+FfXVfIP7Zpz470Rew0zP/kV/8KzmtY+v6Ma2f9dUfPBOTikBzig0VZIo6DFeufswjPxVs8YyLSf09BXkYH+cV7B+y2M/FSHjpYzHp/u0Pp6r80cmN/gSPPfHRz418QnnJ1G4P/kRqws/h/k1s+Mzv8X68Rn5tQuD/wCRGrF6dqqW5eGX7mHovyJFPyt67T+eDXuH7QA2+A/hkmOmnE/T93HXhy8I3+6en0r3P9olPK8HfDSPOSunEHB7hI6Se/8AXVHLif8AeKPz/I8LJ570maKQf5/Wg9AUH/OKUGmjnoOKWkA4Hr3qa3AaQBj8pIyR6ZqD61Ytf9fGTjG9QcgY6ih7Ez+Fns/7Vgx460ogcf2VEMnr99/8/jXigPP0r2z9q8EeO9LHGf7Lj/8AQ2rxH/8AWKt6M48v/gK/n+bJYzyK9t8WZX9mPwZxkHU5D1/2568Qj+9+te4eMwR+zF4IwX51Jycj3n4pLf8Arugxi1h6o8SJx/LIFKrc8Gmd/wDPFKvvnFB2WOy+Fhz8QfDI5z/advj/AL+CvYv2mif+E7tOvGlR44/6bSfn0rx/4S8/ETwwD31ODtnPz167+05/yP1qD0/smPP/AH9l47f5/Cs6LtivkvzkaJfun8//AG08ct8m6gC/306em4evtXq/7QYA8e6duGSNPTnH+21eTW4Jv7cfKCZEyO33hxXq/wC0H/yUDTwOo06M4AH95v8AP419hQX7yH9dj5HEfxY/P8mdNenb8OvB4JG0mQ8HHRW5rITJRBz02nAGD7/ifwrWvl2/DvweAdoCyHuAOCf0FZA+ZSDwzD7vB4/pXw3F38b7/wA2cGC+J/L8jtPCo/4l2rcDHkL0BHdu35/lXTxZ8lc+nNcx4X/5B2rgD/liM8e7f4V1CHMakcn361+d8R/7rhfSf/pTPu+Fv4lb/t38g7HjP1pj9yMdCBTieg454qNzwc/4V8pE+ziW/EHBssYH+ip/OuW1UH7NJhc8cn6f5FdT4gHzWQxz9mTj865XVcmA9SB2Azj0/wA+9e1iv97l8vyRrlX8OH9dThtRbJPJGeSSemPWucvDjOeWx6d/X/P9a6HVSdx4wcDJJOK5695yQfl44xyOvX06e3WvqsFsj7nDrQxrhuRt5BGMj/P+c1WJHJ5z6/galueTkjOR1I9/17/pUJ5ORn8K9+C0OoVjnv8Aj/n/AD0pu7v+VNPuPw/pRnk859/WtEhEgb349M/SlRj3PbGc1Fznvn+dOXPBPbGeKVgPQfgs2PiNpGfm4m5/7Yt+VcV+0G2Pix4hIPIeEZPH/LJa7b4Jj/i4+k5BI2zc5PH7s9eP5/zrhv2gmJ+K3iIk8+bGOe37pf0pYb+L9/6H51xd/vq/wL/0qR55Ynfe24+9maMc55O8en9K9a/atcj4jWOP+gVEc/8AbR68j0znUrPHzEzxjB4yN44r1n9q5v8Ai5VmMdNKhPU5xvkr018TXp/7cfn9X/eYfM8XLZ+mRTd31oY0yqO0kDe5r3P4JA/8Kj+KLgncLI4ySB/qn54rwkE575r3n4Ikf8Kd+J2QCPsrZXGePJaoqbff+TOHMP4XzPCmOAADxtx6dq9D/Z++b4weHgRkb5jyP+mL15yf6entXov7PZP/AAuDw/3+abj1/dPWq+IvGf7vP0f5Gf8AGRv+LoeJwpOPt0n8/auK3E811/xgAHxP8UDn/kIS5z0zmuNHX6VnBe6vQ0oL91H0Pef2WsNdeLs4wNNHGM/388f5zXhLEqMckDuTXu/7K4JbxmQDxp6dOn8deDydenc/zoXxP5fqc2G/3qt8vyQ3d2yfwpCxx1NJ3pM8d6o9AcWJzkmup+FbH/haHhDk86zZ8Z/6bpXJ11Xwq/5Kh4P54/tiz/8ARyUAfo9RRRTGFfHv7ZbZ+IWkL/1CkP8A5Gk/wr7Cr46/bKP/ABcjShu/5hMfH/baWpe6Gtn/AF1R8/Hr70DtSkdev+cUY9sf/rpkiDHHAr2b9lcZ+JznBO3Tpj9PmTpXjQ6A17P+ysp/4WXOfTTJs84/ij/Cmt16r80cWYP/AGeX9dUeXeK23+J9aY976c4/7aGsmtHxBzrmpHGM3Uxx/wADNZ2P5dc0bm9DSnH0X5Dh9x/908+vBr3X9pLC+G/h0ox/yD26cj7kfevC1+45/wBk/wAjXu37TI26H8PY8MNtg+c9jtjpLf5fqjjxP+80f+3vyPBz1/Gk/wA9ad3+n8qaBx0oPQD1+lLQPzpffqPWgAHfj9ParVhj7XDx1dQf++hVUD/GrmmDN/bgnH71Mnp/EKUnZMip8LPYv2r+PH+mD/qFx8f8DevE+g/zzXtv7WQA+IengdtLi4H++9eJ960nucuA0oL5/mx6ct19a9v8b/8AJsvgfC5P9oP+HM/T/P8AjXiCY3V7l46wP2aPA2Dgfbmzx/12qOv9d0Tjfih6r80eGfSnL14/Skxg85pQP69aZ3Hb/B/n4keGP+wlD0Gf4q9a/ab58fWwAwTpMP8A6Olryn4OAH4leGi3H/Exi5z3zXqn7TYB8fQ5HH9kwg7uAP3sv+NZ0f8Ae/kvzkXf90/+3vyieO25H9oWuSSTLGcAEkfMK9W/aEAPxCsRkAjT4+e/33ryuxBOpWuQVzMn0Hzj/H9a9U/aEJ/4WHZ7Sd32BMY5/ievsaOtWF/62PkcR/Fj8/yZ02og/wDCvvBoAJykgIyem05478fhzWQrgkEsQeoGR054HPPT/GtbVwB4D8FjB5jcD1zsJHXtkVlKfunadvoO/wCZP4etfC8XfxV8/wA2cOC3fy/I7Lwt8umaqAQf3KYGR6tzx7c108ZxEp5AxXMeGDnStWzlv3KDAHfc3pXTRj9yvIyBjp1r874i/wB1wvpP/wBLZ93wt8db/t38kKeM+tRv3Oc8ZH0p5GevHr/n86jboTjse3518qj7OJb1/rZ88fZV/ma5fUyFt2z0PBB59a6rxD1tM9Psy/hya5PVc/ZnO7BGeQMkmvaxf++S9V+RplWtKBw2pk7jkn5j3Nc3ekEt3+g68fX/AD+VdHqfOWPcZwTx09fSuduxknrjJwMH06/rxX1WB0SPusPsjFuPv8ZHqf6H3qt1HbPv2qzOvTAyO3HHrVc8855/P/8AXX0ENjpY09z6+h60c55J/wDrYpWHqOOhzTcdv6VYBjj0HcmngYOCMD0xSEfnmnDAHYdT6UCPQvgicfEXSgeMrMBz/wBMz+dcH+0F/wAlX8SE4H72P1/55J/9au8+CHHxF0vB2jZMCPUCM8e3b8q4P9oH/kq/iMc8TRj/AMhIanC/xX8//bT864t/31f4F/6VI8+0cH+1rJR1a4iH5yD/AD+NerftXH/i5VpyD/xKoTgH/ppJ/n8K8p0YZ1ewBxzcwjPT/loterftXYPxMtQF6aXDzzz88nFel9r7v/bj8/q/71H0PFD6k03nFPI5pnqeKs7RR09hXvPwUK/8KY+Ju7BH2d8g9P8AUtXg2K96+CwH/Ck/iaWAIMD53dMeUaipt9/5M4Mw/hfP9GeDN1HPtn1r0X9nnP8AwuLw9ggfNN1/64vXnR+vavRv2eBn4w+HiCODNwe/7p62j8a9TXGf7vP0f5GR8Xx/xc7xOB/0EJRwMd640Hmux+Lo/wCLmeKMcD+0Zu3+0a4/vWcfhRpQ/hx9D3n9lghR41JGf+JemOnpJXg0h6/U/wA696/ZZIWLxsxwQNPQkHuMSV4K44HbrS+235L9Tlw3+81vl+SGd6T64zS96Q9Pwqj0APTiup+FX/JUPB//AGGbP/0elct647V1Pwr4+KPg/wD7DNn/AOj0oA/R6iiimMK+Uv2r/CviDXPiFp9zo2harqNsmlxxmW0s5JlD+dMSuVBAOCDjryK+raKA6WPzl/4V34z/AOhR8R+v/ILn/wDiaB8O/Gf/AEKHiP8ADS5v/ia/RqigVj85l+HfjPj/AIpDxGMcf8gub/4npXrP7NnhLxHo3j64udW8P6xY27adKgluLKWJd25CFyyjng/ka+wKKa01Ma9D21Nwb3Pzx1TwB4ym1K7lXwl4iKyTyMCNMn5BcnP3feqg+HfjQ/8AMoeI+uM/2ZN/8TX6M0UjSMOVKKPzpX4deNNrZ8JeIeVP/MMm9P8Adr2T9obwr4i1e08Gx6XoWrXptrBllFtZSP5bYTg4HB46HFfWVFGzuY1MMqlSFRv4b/ij85z8OvGn/QoeIj/3DJv/AImj/hXPjT/oUPEPp/yDZv8A4mv0YooOix+c/wDwrrxr/wBCh4h5/wCobN/8TS/8K58an/mUfEJ9P+JbN/8AE1+i9FAWPzo/4Vz406Hwj4h/8Fs3/wAT71c034eeMo763eXwlr6osqEk6bMQBuH+zX6F0UpK6aJlDmVj5F/aV8IeIta8fWlxo/h7Vr23XTIo2mtrOSRQwd/lyAeeRx715L/wrnxp/wBCl4hP/cOm/wDia/RSiqbu7mdCgqMFBM/O6P4c+NA3/Ip+IP8AwXTf/E17B418KeIbj4BeCdMttB1aXUIbotPbpaOZYhiXlkAyByOvrX1jRU21v/XT/IVXDqq029nc/O7/AIV14z6/8Il4gx/2DZv/AImlHw78Zjr4S8Qf+C6b/wCJr9EKKZtynxF8KfBHinT/AIg+Hrq88N61b28V/G0ksthKioueSSV4HvwK9G/aF8Na7q3jqG40vRtSvIF0yKPzLe2eRdwklyMqDyARx6GvpeiphHkqe066fhf/ADHb3eX1/G3+R8LWPgTxYmo2rN4Y1oKkiAn+z5QBhl74/X/CvRfjl4Z17U/HsFxpmjandwLZRo0lvaSSKGDMSNwHXkce9fUleJ/Afx9/wlXjz4j2bTb4l1EXVn/tQgeTke2Ioj/wKvVhmc4SUlHb/gf5Hl1MqhOak5P+r/5mVqWg6w3gvwlBHpF+09vG3mx/ZmLRkqR8wwcd+uOtZX/CM64Bxo2pHr1tX/XivpaivGzSj/aMuabt/wAO2Y0ckp0tVJni/h7R9UhsNTE2m3qNJGgUNA4LfM2cZ68EV0UWnXvljNncg9/3Tf4V6NRXg4/huljadOnKbXJdbLq2/wBT2stX9nynKOvNb8FY84GnXoGRZXHA4/dH/CmSadfY4tLogD/nk3P6V6VRXmrgqgv+Xr+5HrLNZr7KOA12wvJHthHaTvtgVSVjJwcmuZ1XR9TkgdU0+9Y7egt2P0HT8a9lorsq8K0qlV1XUevkisLm88PFRUU7HzNqHhrXXLbdF1I/S1k9/Y1h3vhHxAwONA1Y4yc/Y5Dz+A9/evrWivSo5RCltJnsw4wrQX8Nfez41m8GeJSePDurnt/x5S/l0/zioT4M8TsR/wAU7rXPU/YZOv5frX2hRXasIl1NP9dK/wDz6X3s+Lf+EL8Tgf8AIuaz7f6DJ/h0oPgvxOf+Zd1k/wDbjL/8TX2lRT+rLuH+ulf/AJ9L72fFv/CFeJsHHhzWcf8AXjL/AIc05fBnidT/AMi7rOQc/wDHjKc/+O19oUUfVV3D/XSv/wA+l97Pmj4QeGNb0/x3YXF/oupW0MaS5lltnRQTHgckY9q4j42+DvE+p/EzxBd6d4c1m5tpJ0McsFjK6OPKUZVgpB5z09/pX2dRRTwqpy5r/wBaf5HgZpms8xre2nFLRL7m3+p+fui+APF8OsWDy+FNfREuIiWOnTAKA65JO3p35r0X9pbwn4i1v4iw3OkaDq1/brp0MbS21lLKoYPIdpKrjOCDjrzXuH7SPiI+HPg/rk0UhjubxVsYSDgkyHDYP+5vP4Vx37MXxGufG2teMk1JsXEk0N9FGey+WsTY9h5cf/fVdCjZ3/rr/meHKipVFUvsfMzfDzxp/wBCh4i/8Fk3/wATSf8ACu/Gn/QoeIsf9gyf/wCJr9GKKdjc/OcfDzxoP+ZQ8R/+C2b/AOJr2j4TeFvEFl8HPH9pd6JqsF1dxsIIJbORJJsx4+RSMtzxwK+jfiPrw8MeA9e1ncFezs5JIif+emMIPxYqK5n9nTxAfEfwf8PzySF7i1iNlMSckGI7Vz7lAh/GlKN1b+trGFegq0eVux8Yt8PPGh/5lHxEf+4bN/8AE13vwJ8GeKNL+Kuh3epeG9ctLSMy75p7CWNFzE4GWKgDnA59a+2qKtOzuVVpKpBwfU+DfiZ4F8W3vxA8R3Nr4W124glv5njli06VkdS5wQQuCD6965cfDvxr/wBCh4i/8Fk//wATX6NUVNtLDhT5IqPY+Tv2c/CviHSbTxkNU0PVbEz2KJCLqykjMrYk4XcBk89vUV4u/wAO/Gnbwh4j/wDBZN/8TX6M0UW1uZ08OoVJVE/it+CsfnH/AMK78a/9Ch4j/wDBZP8A/E0n/CuvGo/5k/xH/wCCyb/4mv0dopm9j84j8OvGv/Qn+I//AAWT/wDxFdH8NPAfi6z+I3hW6u/CuvQW0Oq2kkssunTIkaiVSWYlcAAZJJr76ooCwUUUUDCiiigAorm7bxlpc0OtzMt3BDpGPtDTwGMnK7htU/N+YFVF8f6UlnfT3kF7ZtaQxTtDMi73STGwrtYg5JAwSCO+Ky9vT7nSsHXeig+n42/zX3nX0VkaBr1vrMt9AkFxa3dlII7i3uAu9CRkH5SykEehqSHX9HnnMMGrafJMAzGNLlCwC53HAOeMHPpiqVSLV7mTo1ItprY06Kxx4o0AozDXNL2qASftceBnpnnvWupDAEEEHkEU1JS2YpU5Q+JWFoooqiAooooAKKKKACiiigAooooAKKKKACiiue1rxbp2k63p+lTieW7vZViAhUMIixwpckjGcHHU8HiplOMFeTLp0p1XywV2dDRXK2njjTLnVIrRYrtIpbiS0iu3RRDJKgyyj5t34lQD60/Q/Gum6xf2ttBDdxC8SSS0mmRQlyqHDbcMSMYz8wHFQq9NuyZs8JWim3F6f8H/ACf3M6S4j86CSLe8e9Su9DhlyOoPrXjfwY+Fmg+DvGviq+0ebUBLY3Q02NZZlZXhe1tZzuG0ZO9zg8cAV6tea5pNjcm3vdUsLecY/dy3CI3PTgnPPaqUF/4c0zUtRCalp8F7eXHnXSNdrvaVYkj5UtwQkaDAA6Z6kk3zxXUyVKo9ov7jeoqvY3lrf2y3Fjcw3Nu2dssMgdTjrgjirFNO+qIaadmFFFFMQUUUUAFFFFABRRRQAUUUUAFFFIxKqSFLEDoOpoAWiuSn8cW9rfXlpe6TqlvPaWT30obyXCxqCeSkjAE44BxTLLx/pdzoN1rBhuIrG3VCSZIZGYucKm2ORircjhtvX61j9Yp7XOr6lXtfl7fjsdhRWRoGvW+sy30CQXFrd2UgjuLe4C70JGQflLKQR6GpIdf0eecwwatp8kwDMY0uULALnccA54wc+mKtVItXuYujUi2mtjhv2hfCVh4p+Gmry6lJdL/ZFrcalbrC4VWmjhcruBByOvp1NYnwY+Fmg+DvGviq+0ebUBLY3Q02NZZlZXhe1tZzuG0ZO9zg8cAV6Jq2r+FtX0i+sNQ1fS5rC6ga3uE+2ooaORSpBYMCMgnkEH0qv4MIbxD46IIIOsxEEf8AYOsqakpbMUqcofErHV0UUVRBz3jzwnYeN/DVxoWry3UdjcMjSfZpAjNtYMBkg8ZAP4Vy37PfhSx8L/DHR306W6Yata2+pTpM4ZVmkhQtswBgcDjnpXpVcr8J/wDklng3/sC2X/ohKAOqooooAKKZNIIonkcOVRSxCKWOB6Ack+w5rmU8caW3h661gx3iW9vcm08t4tsryBguFUnuT3wfXFRKpGHxM1p0alTWCv0+b2OporI8P67b619sSKG4t7mzmMFxBOFDxtjP8JKkEdwTWXZeOtKur6GAR3UcE8k0UF3IqiKVohlwPm3DHuozjil7aCSd9ylhqrbSjtv+f5a+h1dFcba/EPR5ozLNFe2sDWz3kMs8agTxISCVCsTnjowBORWp4d8UWut3c1qltd2l1FFHOYblVDNG4yrDazDHtnI7ilGvTk0k9xzwlaCblGyX9f12N6is4a5pLXos11SwN4XMQgFwnmbx1XbnOR6VCfEuhBnU61pgZASw+1x/KAcEnnseKr2ke5n7Go/sv7jXoqO3niuYI5reVJYZFDJJGwZWB6EEdRUlWZtW0YUUUUAcUvgu5nfxGupanBNBraATLDaGJo2VQqlSZG4AHQjk9x0qrJ8O/tlrqA1PVTNd3EEFvHNDb+UIhCQVO0s2SSMnkd8Yrv6KweGpPdfn1/4c7FmGIWql26Lpa3TyX3GD4a0B9JvNVvru7W6vtSlWSZ44vKQBV2qFXcxHGecmueh+HQjTT1/tME2k15Nn7P8Ae89cY+9xt/X2rv6Kbw9NpJrb/O/5kxxtaLclLV+S7W/J2PPB8NgLVYTqucaMdIz9m9ZN/mfe/Db+td1plt9i020td/meREkW/GN20AZx26VZop06MKesUTWxVWurVHf7gooorU5wooooAKKKKACiiigAooooAKKKKACuO13wDp+p6pbX8E1xaTrfJe3BWeUiYqMYA3gIcYAYDIAwK7GionTjUVpK5rRr1KD5qbszhrPwAkGo2zSah5mmW15New2vkYcPIMFWk3cqOcDaDzyal8OeBv7I1HTJpdRNzb6VFNFZReTsZRIcku247sA4GAtdpRWaw1NO6X9af5I3lj8RJNOW/kvP/N676nFeJvAv9t3OuynUPJ/tS2ht8eRu8ry3DbvvDOcdOMVDJ8P9908x1L72rwapt+z/APPNSPL+93z17ehru64DTtdg8P8AinxjHqVlrf8ApWpxXEElto13cxyR/YbVMh4omU/MjjGcgqaHhqTd2v61/wAwjj8RGKipaei8vLyR0fhLQf8AhHrK7t/tP2gT3ct0D5ezbvOduMnp61uVyv8Awnmkf8+fiT/wnNR/+MUf8J5pH/Pn4k/8JzUf/jFaxioLlWxzVKkqknOe7Oqorlf+E80j/nz8Sf8AhOaj/wDGKP8AhPNI/wCfPxJ/4Tmo/wDxiqIOqorlf+E80j/nz8Sf+E5qP/xij/hPNI/58/En/hOaj/8AGKAOqorlf+E80j/nz8Sf+E5qP/xij/hPNI/58/En/hOaj/8AGKAOqorlf+E80j/nz8Sf+E5qP/xiobT4i6DeWsN1Zw+IJ7aZFkili8PagySIRkMrCDBBBBBFAHYUVyv/AAnmkf8APn4k/wDCc1H/AOMUf8J5pH/Pn4k/8JzUf/jFAHVUVyv/AAnmkf8APn4k/wDCc1H/AOMUf8J5pH/Pn4k/8JzUf/jFAEujeGp9NTWbj+0fM1nUpTI175AHlgDCKEJOVUds81mX/gL+1f7Zn1TUVe/1FYVEttb+UkPlEFSFLMScgZy3TgYq9/wnmkf8+fiT/wAJzUf/AIxR/wAJ5pH/AD5+JP8AwnNR/wDjFYvD02uVrT+v8zqjja0ZOaert0XS1um2i02LnhrQH0m81W+u7tbq+1KVZJnji8pAFXaoVdzEcZ5ya56H4dCNNPX+0wTaTXk2fs/3vPXGPvcbf19q1f8AhPNI/wCfPxJ/4Tmo/wDxij/hPNI/58/En/hOaj/8YoeHptJNbf53/MI42tFuSlq/Jdrfk7GMPhsBarCdVzjRjpGfs3rJv8z734bf1rQ+HVt9i1Hxha7/ADPI1SCLfjG7bptkM47dKyPiF4sstX8A+JdN0/TvEk17eaZc28Ef/CPX675HiZVGTCAMkjknFdB4N/5GPx3/ANhqP/03WdOnRhT1iia2Kq11ao7/AHHVUUVXv7y10+0lur+5gtbWIZeaaQIiD1LHgVqlfRHOWK5b4UqyfC7werqVZdGswQRgg+Qlbdvq2m3NxBBb6haSzzwC5ijSZWaSI8CRQDkr/tDio7bXNOutcvdHguN2o2UaSzw7GGxX+6dxGDn2JquWXYV0aVFZc3iHRYYruWbV9Ojis5BDcu1ygEDk4Cuc/Kc9jzU41bTjqg00X9p/aLR+aLXzl80p/e2Zzj3xRyS7BdFqYSGFxCypKVOxnXcAexIBGR7ZH1rho/Adw2g6hpt3q0T/AGi9/tCKaK0KGKYvuOQZG3L2xwevNdTNr+jQakNOn1bT49QIBFq9yglOenyE5/StOsqlFTs5r+mb0cTUo6U3bVPp02OMsvD2raVfCW0vRLPqOo/atSuEiVEWJUOI1RixGTtGck9TVew+HsdvdWaTagZtLspbiW3thDtdTMCCGfdyBk4wo9813dFZ/VqfVf1/Wpt9era2dr76LzX5Oyt0PPIPhoj2yWuo6o9xbQWMljbCOARsiuxO5juO5hwOAo46VueF/C8ukancajfagL27lt4rVSkHlKscYwONzZY9Sc/QCunoojhqcGmlsKpjq9SLjKWj8l69jhn8Ahrw3H9ojd/bi6zj7P6D/VZ3f+PfpUdl8PRazaW51MP9imvJsfZ8b/tC4x97jb+Ofau9oo+q0t7f1uP+0MRa3N+C7NduzZkeEtG/4R/w5Y6V9o+0fZkKebs2buSemTjr61r0UVrGKilFbI5ZzlUk5y3eoUUUVRIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcr8J/8Aklng3/sC2X/ohK6quV+E/wDySzwb/wBgWy/9EJQB1VFFFABRRRQAUUUUAFFFFABXK+Df+Rj8d/8AYaj/APTdZ11Vcr4N/wCRj8d/9hqP/wBN1nQB1Vcl8WNIvte+Hmt6ZpMH2i+uYgsUe9U3Hep6sQBwD1NL8TNbvdE8Nq2kukepXt3BYW8rqGETyuF3kHg4GTg8ZxVbxf4g1fw7q3hSzt4rS5stRvY7G4urhz5xJViSEVVUfdzuzjJxt710UYTTjOO9/wAtSJNapnnFv8OvF+g+JtVbw9JixTRZrfSrhpk3W7u6v5HJzwd+Gxjkcjta0/wl4ntz4ou49M12Oa9sbGKE/wBtRreSSxuPNxOXk2jqeeCvAxnA7Dx94q1zwxqtk0f9nyaddXkFusUlpMCEcgM73O4RRkMThSDkfo3UPGOqWHxI03w8JdKv1vJZDJaWsMnn2cAXKyySbyuT/d2D2NdqrV5q9k7rz6WZnyxRT8UfD/8AtT4s6NrK2btpDJ52ohZVEck8QPkM6E5YjcR0PT655mfwT4yk8YyeOxbR/wBqpqoMemh0EhsgPLx5vmbBlCcrjOec9q3vB3xI1bWdV8LNe2tiumeJHvVto4VcTW32cnG9ixD7gD0Vce9dF4p+I2m+HNU1CyubDU7h7C0S9uJLZIyqRM+3PzOCcHqAKlTxFOSp2TdrfK9mvv0+SsO0Hqclp2h+MvD7XumWWhadqcN5q73VxfXYjkSeF3DBmzKrq6DPGxwTjBGOfY68/uviro0F7PALDVZYoLuCze4jjj2eZMu6PguGwR/s8d6o+JPHk0/gu88S6CbqzOh6j9n1Gxuooi0oR1WWMkFgCA2Qyt2rGpTrVmuaNr/qUnGOzPTqKAcgEdDRXEaBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUV5P4g8d+ItK1Xx3Eh0iS38P2sVzADaSBpPNGVDnzcfKOCQBu/2ela0qMqraj/AFrb9SZSUdz1isvwtpC6B4Y0fRkmM66dZw2glK7S4jQJux2zjOK8lvPitrdt4b8RX9sNG1QadZ2lxHeWsMgt1llkRWgceY2WUNnhh05Fdv8AEjxPrHhyDSpNL095ra4d/tl4tnJdi0ULkExIyk7jxncAMfStHhKikovr/kn+oudbnb0V5te+KPEWqeGND1PwiLPUzcXQS4kt4mWPaJgvR/nTIzuBXjk71wN3odm0rWcDXK7ZzGpkXaFw2ORgMwHPbcfqetZTpOC1/qxSlcmooorMYUUUUAFFc18SdeuvDHgfVtZsI4ZLq0iDxrMpKElgOQCD39a8/wBC+MUsutSWuvWkNjHp2lS3OqRrGzSR3EcgXCfNgowZSOD97rXRTw1SrDngtCHNJ2Z7LWXpGkLpuoa5dLMZDql4t2VK48si3hh2+/8AqQc/7WO1ee6L8QNSn8UeJpbjTdYl0y0srO4ttLitopLoebwWARjnIIbBbgA8DpUniTxr4r0zxuPC1ppljPdahLHJpl2Y38pLfnzjMA+SyY7EZyDgcAv6pU5uXTa+/o/wuHOtztfGnh6PxPoE2nPcPay70mguUXc0MqMGRwO+COncZ6VFrXhLTfED2E+ui5nu7Pa0b295PbIsgz86okgCtycHkgHGa4SX4svH8Xl8M7bBtHE62DzAkT/aSpPA3fcDYQ8de9aGlePbzVZbi8/tHw5pVgb6Sys7TUXZJ7ny3Cu2/eAp5GFCN1AJ5zWnsK9NLot18/8Ahhc0WdVf+CtB1C/N3e2k0ztKk7RtdzeS8iABXaLfsYgAclT0qGy8A+HrDXrnWbG1urbUbqc3E8kN/cIsrltx3oH2sMn7pGPauporm9tUtbmf3l8q7HOaT4K8PaTqw1LT9OWK7UyGM+a7JEZDl/LQsVj3d9oGafq3g7QtXutQudQsfOmv7UWdy3nSL5kIbcFwGAHPcYPvXQUUe1nfm5nf1DlRy7eAfDTednTc+bcQ3b/v5eZYRiNvvdh26Hvmqet+ALC+0yXTLGQWOm3up/2nqcQVpTdtuVmXczfIGKrnAI44ArtKKar1E78zFyrsFFFFZFBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFNlkSGJ5JXVI0BZmY4CgdST6U6uc+I1jd6l4C8QWWmhjeT2MqRqvVyVPyj3PT8aqEVKSTE9ESJ4y8OnSrPUptZsrSxvATbS3kgthMB1KiTaSOnPuD3qxP4n0G3t7SefW9Ligu/+PeR7uNVm7fIScN+FcHf2tn4m8HeGL7StCvtUa3snFnPp9+LSWxm2KuOZE7gg8nG3oc1z2reCvGLW0kl/b/27f3/hv+yJJVnjBt5/M3bmLlcrggllyxK9O9dkcPSfxStr1a/r77GbnLseyXmt6VY38Fje6nY297Pjyrea4RJJMnHyqTk8+lYt14A8O3d5q11c2lzJNqqeXelr+4KzL2BXfgAdsAbRwMV5h4h+HfiVodf0y3tEv/7Ys9Lt4tR89FW0a2CiQsGIfB2lhtB68163c6VLHDqL31zf67azRsP7LmitTGQTnauUTPHA3uRjqSeamUI0knTqb/8AA/Xv2GnzboravD4V1jwTLa6jdWM3hjasTyfbNsIEbDAMoYYwygfe6jBrNn07wZHpNvqVxrTrY7iINQk8QT4BbAKpMZsgHb90NjjpXD6Z4O8RL8OdE01tElhutH11NSazeeDbdQiV32IVcqCAw4YqMjvRp3grxHp+s2HiGTSPtKJrmo6i+kLcReYkdxGqpyWEZZSpJAb+LjNbKlGN0qnV9f637k3b6HqFndeGPCmh2MEN9pmmaW+fspkuVRJM/MSrMfmJznOSTnNdAjLIiujBkYZDA5BHrXgmmfD3xNoekaLu05dUlTRb3TZbaK4jH2eSeR3U5dlBXDBTgnpwDXZ634e8S2fwTtdC0KaY+Ire2tYVe2uPJYFXTeFkLDAChh1GR9cVlVoU+ZWne73+e5Sk7bHpNB4FePXvhvxqNZmt7W41Y6L/AMJDazox1U7/ALD5bCYbzJv27iPlznuBT/CugeNrDWvDtxfT6m9vFe3yXwn1Lzk+ykfuCylzuOSecFh37VLw0bX51/Sv/wAD1Hzvsem6FrWn67ZNd6XcedCkrwvlGRkdDhlZWAIIPYipNZ1Sy0XTLnUdUuEtrK3TfLK2SFH0HJOeAByTxXF/Coi71Txlq1oMaVfaqTasD8spRFSSRfUMwPPfFS/GiKRvB8VyI3ltbHULW8u41XcWgSUF+O4A5PsDUexj7ZU+mn/DevQOZ8tzofEMeiazoqadrzxCx1XbEkFxI1u8xPzBACVbdxnaOeKxtX0LwM/iaT+1Rpi63qNp9gaGa62yXEJwAojLfMflADAbuBg8Vk/EbTLnV9d8I6toWgtqhsruK8kvrd7YFrcBv3as8isclgwH3ec5zXP+MvBHiHUdZ8TxWdiZotdu9PuIb8zRqLNYcbw4LbsjHGwHOetbUYKy/eWv5+aX5a+diZPyOrm8KeAYrq70O5e2N9qUUUMtpcapI9xMkZ3RgBpC+BjjHYY6V0N1b+H7nxhZTTzWreI7OBzBF9pxKkT8MfLDcg46kGvN9M8IeLNN8azT2YuIRca7Jf3Oo/bQbe4smHELwbsmQdAdvH96rXh/wJ4j0j4rWetXN5a6jbvaTfbNQ+zeU8js+QhUzEggBQCBtCrjGeaqcIvV1enfrb+l3BN9jtW8B+G20WXSjp3+hSXf29l8+XeZ858zfu3ZyPWm3fgDw1d6hJeTac3my3C3ckaXMqRSTKciRolYIzZ7la5L4gaB4w1LXvEE+i3Gpx239lxDThbaiYF+1iTJ+UOB93OSwwfyrNvPDvj6e9vbr7RqqyHU7J4VTU9ifZvLxcYQSbcbu2M9xShGTV/a2v5+nn/VgbX8p6trGt6foz2S6lOYBeTrbQsY2KmRvuqWAIXPbcRmtKvD/FFlrFl8Nte0HWnuZtS1LXTb6ElxdefK0RljaJg+5mwoDH5jkAc17gMgDJyfWuerSUIpp31f6f5/gXGV2FFFFYFBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRXEfGjxZfeB/hvq3iDSYraa9tDCES5VmjO+VEOQpB6Me/WgDt6K8u8RePtWsfHfhrQbeKzFrqukXF9NKUYyJIkTMuw7sYyBwQa4jwJ8XfFU9t8NLa905tal8QQ30l3NHHDHNKYpJAqxfvI0UqFUtuABGMEnNAH0RRXnmlfFbTtX8UaloWmaD4jubnT7q4s7i4S0T7MkkSseZS+1QxUqu4jkjOBzVO2+NPh6a81Wy+x6gL/TrKS/e2iktblpI4yd6q0MzpvGCSjMpxQB6fRXlevfFjSbrRZItEl1OG8ufDsuvR3kNrFP9ihVThnRnAL7hgLyCeCQOadpXxTsbbQ9Atmj1fxFrVzoy6tMLW1hilEAXmaRDIEQk5+RWY54GeMgHqVFeOzfE9L34heEZ9L1ZV8Haho93qFxviUf6oNlmJG5du0ggHsetaUPxi0y9iWOy0rVorq90+fUNK+1RRKl+kYYnZiTI4Uth9hI57igD1CiuG+DPjDUvHHgSw1nWNN+xXE6sS8e0QzYdlzGPMdwBtAO/Bz0yK7mgAooooAKKKKACiiigAooooAKKKKACiob37R9jn+xGIXflt5JlBKB8fLuAIJGcZwRXhVl8aNb1Hwb4bFlYacPGWpa22jz2jI5hhKN+8fbvDYCtGeW4yaAPe6K8csPipZaFceLJPEGrajqa2+vnS7O1+wQwNG7bisMbCTDqAP9ZIU6c1r+J/GN5HqvgYiXVNBj1XUjbtaPa2l19rQhSN0iTMI0OThkLN7dKAPTKK8J+F/xfuP7DtX8bi/nN/rk2l2+prBClvG3GyN9pVhxn5thHqeDi54O+Kc1oPFZ8UXFxqE8fiqfRtJs7WCMTSAEBIlA2g4zyzn6npQB7VRXNeCPGWneMINRNhDd2tzp109leWt2irLDKvUHazKR7gkV0tABRRRQAUUUUAFFFFABRRRQAUVmeJ7i8tPD2o3OmSW8V5BA0sbXETSx5UZIKqyk5AI+8MZzz0ryzwp8X54vhv4c8UeMYFmk1++Nla2+kWhXyX3ug3mSY7gfLzkYxnGD1oA9morwz4m/GaW38Ba9c+FrS+sda03UU0y6+1xQs1m5P38b2R84IXBYZ6jFdHafE+30zXofCV3pPi/U9eijhe4f7FbzOiykYaU27eWoXcMkADHqaAPUKK89T4r6InjS08L39rd2OpXczwRb57WYb1/hZYZnePPbeq5/Os7Svjf4dv7LUb9tM8QWmlaespuNQuLIC2V0YL5YkViC7FhtUevOKAPU6K84i+MHh6OPVv7YttT0abTbGPUpIL6JN7wOVCsnlu4OWdVwSCCwBA5xjeEPH2s+IPja2lPFe6foMnh5dRhsLyKASBzIgEhaMsRlW+6W47gGgD2CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5/wAfeFbPxr4Q1Hw/qUksVteooMkWNyMrBlYZ9GUcd66CigDzax+Gt3L4jstb8Ra7FqF7p+mPplmLaxNsiB1KtI4Mj7nIJ6FR7CsjR/g3c6JYeBf7L8RRrqfhU3Yjnn08yRXC3DMWDRiVSuA2Mh//AK3sFFAHm+l/C6O003x/ZTavLJF4sup7hmih8trYShvlB3Hdjd14z6VneDPhFNoPibQ9VvtatL2LStHOjJaw6Z5Cyx5Y7nJlbLEsxbjkntXrNFAHjnhD4HW3hzQvF+nprUly+uWcmn200lv/AMeNuwfCAbzvwXyeVztHSrMHwhn0x9Ku9B8QJaapa6GNBuJ5rHzo7iEAYcIJFKOCM/eYcDIPOfWqKAPJLP4IaVaPoMEeoTHS9N0m70qW3aLL3AuN/mPvz8py7HG00/wb8HoPDn2OAz6HNa20U0Ini0KOG/lV0ZBvud7cgMeVVScc8ZB9YooA4/4W+ErzwP4Vg0C41SHUrS0LC1dbQwSKrOzEOfMYMctwQF6dDXYUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5XpHwcsdN+MV546XUGkSVpJotOMGFhnkUK8m/dzn5jjaPvDnivVKKAPLP+FUOi+KU+26PfQ69qjajJDqmktcJDkEBVCzodwz9/I+lUtB+CcOjWnhiG31tyNG1iTV2X7N8kjOFHlxrv/doNoxy3U17BRQB4vo3wRltbXTdM1LxHHeaHZaw2ti1j08xSSzfwq8hlYbB6BQTk8+jr/4FWd9aaotxqyyXVx4gl1+2eSxWSKJnxmGSJmIlTjnlc+3OfZqKAOX8C+FR4YgvV26MhuZFfy9J0pLCFcLj7oZmY98sx9sV1FFFABRRRQAUUUUAFFFFABRRRQBneIrK51LQ76ysbmG1uLiJolmmhMyoG4JKBlJ4zj5hz69K8pt/grdr4J8L+GrjxLBJb+H9UXUYJo9NKNIoZ3MbgzEZJc4YYwB0PWvZ6KAPG/EfwS/tmx8YW3/CQeT/AMJDqkWpbvsW77PsLHZjzBuzu68fSuy0zwT9i+KGteMP7Q8z+0bKOz+yeTt8vZt+bfu5zt6YHXrXZUUAeKeH/gdLo114bVPEcUthoWpyalDGdOxNMXIJWSXzcMRgAMFHfg8Y2tJ+EFnb/C/WvBepanJd22p3Ul0biOERNEzOrrgFmztZB359q9RooA8fPwUtrrw7qWj39xoUUN3YLZifStBjspyyyJIskj72LndGpKjap54zjGx4Q+HOoaP4+XxVq2vwajcrpC6R5UNgbcFVZSJCTK/Py8j1ORjpXpFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Potassium titanyl phosphate (KTP) lasers emit light at a wavelength of 532 nm. Long pulse dye lasers (PDL) emit light of 595 nm. Diode lasers emit light at a wavelength of 800 or 900 nm. Alexandrite lasers emit light at a wavelength of 755 nm. Neodymium-doped:yttrium aluminum garnet (Nd:YAG) lasers emit light at a wavelength of 1064 nm. Intense pulsed light sources (IPLS) are not lasers. These devices emit light in a range of wavelengths from 500 to 1000 nm simultaneously, with each wavelength emitted at a different intensity.",
"    <div class=\"footnotes\">",
"     * Not a laser.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_29_5585=[""].join("\n");
var outline_f5_29_5585=null;
var title_f5_29_5586="Sources of sodium in your diet PI";
var content_f5_29_5586=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F60316&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F60316&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sources of sodium in your diet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 558px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Original data from: He FJ, MacGregor GA. Reducing population salt intake worldwide: from evidence to implementation. Prog Cardiovasc Dis 2010; 52:363.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_29_5586=[""].join("\n");
var outline_f5_29_5586=null;
var title_f5_29_5587="Periungual desquamation in Kawasaki disease";
var content_f5_29_5587=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F53452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F53452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Characteristic periungual desquamation of the hands and feet seen in Kawasaki disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 251px; height: 573px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin peeling usually begins under the nails during the second week of illness. Peeling of large sheets of skin progresses proximally over the next several days.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_29_5587=[""].join("\n");
var outline_f5_29_5587=null;
var title_f5_29_5588="Collagenase (systemic): Drug information";
var content_f5_29_5588=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Collagenase (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/53/6996?source=see_link\">",
"    see \"Collagenase (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9916615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Xiaflex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9916619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Enzyme",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9916767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Dupuytren&rsquo;s contracture:",
"     </b>",
"     Intralesional: Inject 0.58 mg per cord affecting a metacarpophalangeal (MP) joint or a proximal interphalangeal (PIP) joint.  If contracture persists, finger extension procedure should be performed 24 hours following injection to facilitate cord disruption. If MP or PIP contracture remains, may reinject cord 4 weeks following initial injection; injections and finger extension procedures may be administered up to 3 times per cord separated by ~4 week intervals.",
"     <b>",
"      Note:",
"     </b>",
"     Only one cord should be injected at a time; if other palpable cords exist, inject in a sequential order.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9916768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9916769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F9916770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9916775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xiaflex&reg;: 0.9 mg [contains sucrose 18.5 mg/vial; supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9916617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9916612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM200615.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM200615.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9916771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inject intralesionally into a palpable cord using a 1 mL syringe with 0.01 mL graduations with a 27-gauge",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     inch needle. Divide dose into 3 injections; after correct needle placement, inject",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     of the dose, then reposition the needle in a distal location ~2-3 mm from the initial injection for the second injection (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     of the dose), followed by the final injection (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     of the dose) positioned ~2-3 mm proximal to the initial injection. To avoid tendon rupture when injecting a cord affecting a PIP joint of the fifth finger, needle insertion should not be &gt;2-3 mm in depth or &gt;4 mm distal to the palmar digital crease. Do not administer local anesthetic agent prior to administration due to possible interference with proper needle placement.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9916621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of Dupuytren&rsquo;s contracture with a palpable cord",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9916611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Collagenase clostridium histolyticum (Xiaflex&reg;) may be confused with topical collagenase formulation (ie, Santyl&reg;)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Xiaflex&reg; may be confused with Zanaflex&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9916714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Bruising (70%), pruritus (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Lymphadenopathy (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site hemorrhage (38%), injection site reaction (24% to 35%; includes erythema, inflammation, irritation, pain, swelling, tenderness)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Antibody formation (&ge;86%), peripheral edema (primarily as swelling of injected hand: 73%), pain in extremity (35%), neutralizing antibodies (10% to 21% to AUX-I and AUX-II, respectively)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Laceration (9%), erythema (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Lymph node pain (8%), axillary pain (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Complex regional pain syndrome (CRPS), pulley rupture, ligament injury, sensory abnormalities, tendon rupture",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9916625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9916626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Severe allergic reactions, including anaphylaxis, may occur in response to administration of foreign proteins (ie, collagenase). Healthcare providers should be prepared for the immediate treatment with epinephrine of any possible severe allergic reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bleeding disorders: Use with caution in patients with abnormal coagulation or at an increased risk of bleeding (eg, concomitant anticoagulants).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Tendon rupture: Administration may result in tendon rupture, ligament damage, or other serious injury (eg, pulley rupture, sensory and pain abnormalities); careful injection technique of collagenase into the Dupuytren&rsquo;s cord is required to avoid inadvertent injection into tendons, nerves, blood vessels, or other collagen-containing structures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Anticoagulants: Use with caution in patients who have received anticoagulants (excluding low-dose aspirin) within 7 days of collagenase administration. During clinical trials, a high incidence of patients (not receiving anticoagulants) experienced injection site bruising and hemorrhage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Antibody formation: IgE-anti-drug antibodies commonly developed in treated patients, with higher frequencies and titers seen in patients treated with successive injections. However, no correlation between antibody formation (including high titers or neutralization status) and clinical efficacy or adverse reactions has been observed in clinical trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Only healthcare providers skilled in the treatment of Dupuytren&rsquo;s contractures and injection procedures should administer treatment. Local anesthetic is not recommended prior to treatment due to possible interference with proper needle placement.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F10073091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9916622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9916623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Pharmacokinetic studies in humans did not show quantifiable systemic levels following intralesional injection into a Dupuytren&rsquo;s cord. IgE-anti-drug antibodies commonly develop in treated patients; effects to the fetus are unknown.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9916624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Xiaflex Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9 mg (1): $3997.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9916773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Range of motion",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12992816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Xiapex (CH, CZ, DK, EE, FR, GB, IE, NO, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9916724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Collagenase clostridium histolyticum contains two forms of microbial collagenase (Collagenase AUX-1 and Collagenase AUX-II) isolated and purified from the fermentation of",
"     <i>",
"      Clostridium histolyticum",
"     </i>",
"     bacteria; collagenase lyses collagen, leading to enzymatic disruption of contracted Dupuytren&rsquo;s cord (comprised primarily of collagen)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9916726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Systemic plasma concentrations of collagenase AUX-I or collagenase AUX-II were undetectable for up to 30 days following intralesional injection",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hurst LC, Badalamente MA, Hentz VR, et al, &ldquo;Injectable Collagenase Clostridium Histolyticum for Dupuytren&rsquo;s Contracture,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009 361(10):968-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/29/5588/abstract-text/19726771/pubmed\" id=\"19726771\" target=\"_blank\">",
"        19726771",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9076 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-1D88657B2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_29_5588=[""].join("\n");
var outline_f5_29_5588=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9916615\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9916619\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9916767\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9916768\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9916769\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9916770\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9916775\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9916617\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9916612\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9916771\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9916621\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9916611\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9916714\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9916625\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9916626\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299090\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10073091\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9916622\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9916623\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9916624\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322818\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9916773\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12992816\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9916724\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9916726\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9076\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9076|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/53/6996?source=related_link\">",
"      Collagenase (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/11/41138?source=related_link\">",
"      Collagenase (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/6/31843?source=related_link\">",
"      Collagenase (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_29_5589="Ambrisentan: Patient drug information";
var content_f5_29_5589=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ambrisentan: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/60/29637?source=see_link\">",
"     see \"Ambrisentan: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5032853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Letairis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6772884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Volibris&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700850",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You cannot get this drug from your pharmacy. It comes only from the company that makes it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700267",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691894",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high pressure in the lungs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701484",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ambrisentan or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4015085",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have idiopathic pulmonary fibrosis (IPF).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid or limit drinking wine, beer, or mixed drinks to less than 3 drinks a day. Drinking too much alcohol may raise your chance of liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use 2 kinds of birth control that you can trust during care and for 1 month after care ends.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698229",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to get a woman pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697869",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow tablet whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698521",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a woman of childbearing age, take a pregnancy test before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698519",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a woman of childbearing age, take a monthly pregnancy test.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11710 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-FF4A722CD6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_29_5589=[""].join("\n");
var outline_f5_29_5589=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5032853\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6772884\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026704\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026706\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026705\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026710\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026711\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026713\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026708\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026709\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026714\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026715\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/60/29637?source=related_link\">",
"      Ambrisentan: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_29_5590="Repaglinide and metformin: Patient drug information";
var content_f5_29_5590=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Repaglinide and metformin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/2/9255?source=see_link\">",
"     see \"Repaglinide and metformin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6213591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      PrandiMet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A small number of people may have more acid in their blood. Metformin may cause this. It may happen in people whose liver or kidneys do not work the right way.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702862",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to repaglinide, metformin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Acidic blood problem, very bad kidney disease, or type 1 diabetes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stop this drug for 2 days after you have an x-ray with dye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697748",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you are having surgery, if you have had a heart attack, bad infection, or stroke, or if you are 80 years of age or older and have not had your kidney function tested.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Too much acid in the blood (lactic acidosis) may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698656",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling cold.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695823",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 15 to 30 minutes before meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695102",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If a meal is skipped, skip the dose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it, with a meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12105 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-AEB5EC0217-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_29_5590=[""].join("\n");
var outline_f5_29_5590=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6213591\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018734\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018736\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018735\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018740\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018741\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018743\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018738\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018739\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018744\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018745\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/2/9255?source=related_link\">",
"      Repaglinide and metformin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_29_5591="High-frequency ventilation in adults";
var content_f5_29_5591=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   High-frequency ventilation in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/29/5591/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/29/5591/contributors\">",
"     Anthony J Courey, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/29/5591/contributors\">",
"     Robert C Hyzy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/29/5591/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/29/5591/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/29/5591/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/29/5591/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/29/5591/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-frequency ventilation (HFV) is a form of mechanical ventilation that combines very high respiratory rates (&gt;60 breaths per minute) with tidal volumes that are smaller than the volume of anatomic dead space [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/1\">",
"     1",
"    </a>",
"    ]. The indications for HFV are limited and its use should be coordinated by clinicians who have experience using HFV.",
"   </p>",
"   <p>",
"    This topic review describes the different types of HFV, as well as patient selection, efficacy, and potential harms. Alternative modes of mechanical ventilation are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link\">",
"     \"Modes of mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF HFV",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four basic types of HFV: high frequency jet ventilation, high frequency oscillatory ventilation, high frequency percussive ventilation, and high frequency positive pressure ventilation (",
"    <a class=\"graphic graphic_figure graphicRef54248 \" href=\"UTD.htm?16/11/16574\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     High frequency jet ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;High frequency jet ventilation (HFJV) refers to HFV delivered using a jet of gas (",
"    <a class=\"graphic graphic_figure graphicRef54248 \" href=\"UTD.htm?16/11/16574\">",
"     figure 1",
"    </a>",
"    ). It is initiated by inserting into the lumen of the endotracheal tube a small (14 to 16 gauge) cannula, which is connected to a specialized ventilator. An initial pressure of approximately 35 pounds per square inch (psi) drives the jet of gas from the cannula with an initial respiratory rate of 100 to 150 breaths per minute and an inspiratory fraction less than 40 percent (",
"    <a class=\"graphic graphic_algorithm graphicRef59997 \" href=\"UTD.htm?21/37/22096\">",
"     algorithm 1",
"    </a>",
"    ). The inspiratory fraction is the inspiratory time divided by the sum of the inspiratory and expiratory times. Applied positive end-expiratory pressure (PEEP) can be added if needed.",
"   </p>",
"   <p>",
"    An arterial blood gas should be measured approximately 15 minutes after the initiation of HFJV:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Appropriate adjustments when the arterial carbon dioxide tension (PaCO",
"      <sub>",
"       2",
"      </sub>",
"      ) is elevated include: increasing the driving pressure in 5 psi increments to a maximum of 50 psi, increasing the inspiratory fraction in 5 percent increments to a maximum of 40 percent, increasing the frequency in 10 breaths per minute increments to a maximum of 250 breaths per minute, or adding an another mode of mechanical ventilation (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link\">",
"       \"Modes of mechanical ventilation\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Appropriate adjustments when the PaCO",
"      <sub>",
"       2",
"      </sub>",
"      is low include: decreasing the driving pressure in 5 psi decrements, decreasing the inspiratory fraction in 5 percent decrements to a minimum of 20 percent, or decreasing the frequency in 10 breaths per minute decrements to a minimum of 100 breaths per minute",
"     </li>",
"     <li>",
"      Appropriate adjustments when the arterial oxygen tension (PaO",
"      <sub>",
"       2",
"      </sub>",
"      ) is low include: adding applied PEEP in 3 to 5 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O increments, increasing the driving pressure by 5 psi increments to a maximum of 50 psi, or increasing the inspiratory fraction in 5 percent increments to a maximum of 40 percent",
"     </li>",
"     <li>",
"      Appropriate adjustments when the PaO",
"      <sub>",
"       2",
"      </sub>",
"      is high include: decreasing the fraction of inspired oxygen (FiO",
"      <sub>",
"       2",
"      </sub>",
"      ) or decreasing applied PEEP",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A respiratory rate of approximately 150 breaths per minute is generally required during HFJV. Use of ultrahigh frequency jet ventilation (180 to 400 breaths per minute) in patients with adult respiratory distress syndrome (ARDS) has been reported, although the study had numerous important limitations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/2\">",
"     2",
"    </a>",
"    ]. HFJV always requires sedation and usually requires pharmacologic paralysis also. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15833?source=see_link\">",
"     \"Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43720?source=see_link\">",
"     \"Use of neuromuscular blocking medications in critically ill patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     High frequency oscillatory ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;High frequency oscillatory ventilation (HFOV) uses an oscillatory pump to deliver a respiratory rate of 3 to 15 Hertz (up to 900 breaths per minute) through the endotracheal tube (",
"    <a class=\"graphic graphic_figure graphicRef54248 \" href=\"UTD.htm?16/11/16574\">",
"     figure 1",
"    </a>",
"    ). This rate is so fast that the airway pressure merely oscillates around a constant mean airway pressure. The respiratory rate is set directly by the clinician. The mean airway pressure is set by adjusting the inspiratory flow rate and an expiratory back pressure valve (similar to applied PEEP) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/3\">",
"     3",
"    </a>",
"    ]. Some pumps allow the mean airway pressure to be set directly.",
"   </p>",
"   <p>",
"    The constant mean airway pressure maintains alveolar recruitment, avoids low end-expiratory pressures, and avoids high peak airway pressures. It also impacts oxygenation. Specifically, a higher mean airway pressure is associated with better oxygenation. HFOV induces a higher mean airway pressure than most modes of mechanical ventilation.",
"   </p>",
"   <p>",
"    The tidal volume (also called amplitude) is small during HFOV, usually less than or equal to the anatomic dead space. The amplitude depends on the endotracheal tube size and respiratory frequency: a smaller amplitude results when the endotracheal tube is small or the respiratory frequency is high [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HFOV at a respiratory rate greater than 6 Hz may be required to reduce barotrauma because the usual respiratory rate of 3 to 6 Hz results in airway pressures that are potentially not lung protective. The feasibility of this approach was demonstrated by a single center, prospective cohort study of 30 patients with ARDS who were receiving HFOV after failing conventional lung protective ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/5\">",
"     5",
"    </a>",
"    ]. Among patients whose respiratory rates exceeded 6 Hz (range 6 to 15 Hz), most were able to meet their oxygenation (PaO",
"    <sub>",
"     2",
"    </sub>",
"    55 to 80 mmHg) and ventilatory goals (pH 7.25 to 7.35).",
"   </p>",
"   <p>",
"    Tracheal gas insufflation (TGI) during HFOV may improve gas exchange. This was demonstrated by a single-center, randomized, cross-over trial of patients with early ARDS, in which TGI to a mean tracheal pressure 3 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O above mean airway pressure (Paw) increased the",
"    <span class=\"nowrap\">",
"     PaO",
"     <sub>",
"      2",
"     </sub>",
"     /FiO",
"     <sub>",
"      2",
"     </sub>",
"    </span>",
"    ratio and decreased the PaCO",
"    <sub>",
"     2",
"    </sub>",
"    compared to HFOV alone [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Step-wise increases in the Paw may be superior to other techniques of lung volume recruitment during HFOV, according to one animal study. The study found that an incremental increase in the Paw over six minutes (until it was 12 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O greater than the Paw achieved with conventional mechanical ventilation) improved lung volume, oxygenation, and ventilation to a greater degree than other techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     High frequency percussive ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;High frequency percussive ventilation (HFPV) combines HFV plus time cycled, pressure-limited controlled mechanical ventilation (ie, pressure control ventilation, PCV). It can be conceptualized as HFOV oscillating around two different pressure levels, the inspiratory and expiratory airway pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/8\">",
"     8",
"    </a>",
"    ]. HFPV improves oxygenation, improves ventilation, and lowers airway pressures (peak, mean, and end-expiratory), compared to other modes of mechanical ventilation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link&amp;anchor=H9#H9\">",
"     \"Modes of mechanical ventilation\", section on 'Pressure-limited ventilation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HFPV is possible because of a device called a phasitron. The phasitron is an inspiratory and expiratory valve located at the end of the endotracheal tube. High-pressure gas drives the phasitron to deliver small tidal volumes at a high frequency (200 to 900 beats per min), superimposed on the inspiratory and expiratory airway pressures of PCV. The PCV is typically delivered at a respiratory rate of 10 to 15 breaths per min.",
"   </p>",
"   <p>",
"    HFPV does not require pharmacologic paralysis. In addition, it clears secretions more effectively than other types of HFV [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     High frequency positive pressure ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;High frequency positive pressure ventilation (HFPPV) is rarely used anymore, having been displaced by the types of HFV discussed above. HFPPV is delivered through the endotracheal tube using a conventional ventilator whose frequency is set near its upper limits (",
"    <a class=\"graphic graphic_figure graphicRef54248 \" href=\"UTD.htm?16/11/16574\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no universally accepted indications for HFV. Its use has been described in a variety of clinical situations, including ARDS, bronchopleural fistula, inhalational injury, blunt trauma induced ARDS, and head injuries complicated by high intracranial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/8-11\">",
"     8-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ARDS &ndash; The theoretical benefit of using HFV in patients with ARDS relates to the small tidal volumes. A strategy of low tidal volume ventilation has been proven in randomized trials to improve mortality, possibly due to decreased alveolar distension and ventilator-associated lung injury. Although the trials did not use HFV, many clinicians suspect that HFV confers a similar benefit. Until this is proven, HFV should not be considered routine care for patients with ARDS. HFV is used by some clinicians when there is persistent hypoxemia during the first three days of mechanical ventilation despite maximal conventional therapy, although the data to support this are limited [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link&amp;anchor=H2#H2\">",
"       \"Mechanical ventilation in acute respiratory distress syndrome\", section on 'Low tidal volume ventilation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16182?source=see_link\">",
"       \"Ventilator-associated lung injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Severe airway compromise and stridor &ndash; The use of transtracheal HFJV in the management of patients with severe airway compromise has been described as a less morbid alternative to operative tracheostomy. In one study, the transtracheal catheter was placed with relative ease (84 percent on the first attempt) and adequate ventilation was achieved in 96 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/14\">",
"       14",
"      </a>",
"      ]. Only minor complications were reported, including kinking of the catheter, bleeding, and surgical emphysema. There was no increased morbidity and no mortality.",
"     </li>",
"     <li>",
"      Bronchopleural fistula &ndash; HFJV is approved by the United States Food and Drug Administration for ventilating patients in whom a large and persistent bronchopleural fistula exists. However, the likelihood that HFJV will allow the bronchopleural fistula to close is unpredictable [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. While HFJV may promote fistula closure by limiting alveolar distension, this may be outweighed in some patients by increased plateau airway pressure (alveolar pressure), decreased oxygenation, or worse hypercapnia [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24486?source=see_link\">",
"       \"Management of bronchopleural fistula in patients on mechanical ventilation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    HFV should be avoided in patients with obstructive lung disease. The high respiratory rate used for HFV shortens the expiratory time, which can cause auto-PEEP and related sequelae. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30663?source=see_link&amp;anchor=H9#H9\">",
"     \"Positive end-expiratory pressure (PEEP)\", section on 'Auto (intrinsic) PEEP'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section describes the clinical evidence related to the different types of HFV. Generally speaking, there is evidence that HFOV and HFPV improve oxygenation, although neither has been shown conclusively to improve clinical outcomes (eg, mortality, duration of mechanical ventilation, or length of ICU stay).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     HF jet ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little moderate or high quality data evaluating the efficacy of HFJV in adults. One trial randomly assigned a heterogeneous group of 309 patients with acute respiratory failure to receive HFJV or volume-limited mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/15\">",
"     15",
"    </a>",
"    ]. There was no significant difference in mortality or the duration of ICU stay. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link&amp;anchor=H2#H2\">",
"     \"Modes of mechanical ventilation\", section on 'Volume-limited ventilation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In another trial, seven patients who were already receiving a traditional mode of mechanical ventilation for respiratory failure complicated by a bronchopleural fistula were randomly assigned to either switch to HFJV or continue their mode of ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/10\">",
"     10",
"    </a>",
"    ]. There was no significant difference in the size of the chest tube leak (a measure of the bronchopleural fistula), but the HFJV group developed worse oxygenation and hypercapnia after switching to the HFJV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     HF oscillatory ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies of HFOV have been performed in adults with ARDS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]. Despite evidence that HFOV improves oxygenation, it does not reduce, and may increase, in-hospital mortality compared with a ventilation strategy of low tidal volume and high positive end-expiratory pressure (ARDSNet strategy). However, it is not known whether HFOV would have a role as a rescue strategy for those patients who cannot be maintained on an ARDSNet strategy, such as those with ARDS and a bronchopleural fistula.",
"   </p>",
"   <p>",
"    A number of studies and meta-analyses have examined whether HFOV reduces mortality. In the largest, multicenter trial, the OSCILLATE investigators randomly assigned adult patients with new-onset moderate-to-severe ARDS to HFOV or to an ARDSNet ventilation strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/21\">",
"     21",
"    </a>",
"    ]. This well-designed study was terminated early after enrollment of 548 of a planned 1200 patients. The study was terminated for harm with an in-hospital mortality of 47 percent in the HFOV arm and 35 percent in the ARDSNet arm (relative risk of death with HFOV, 1.33; 95% CI 1.09-1.64; p = 0.005). Thus, HFOV can NOT be recommended as the initial treatment strategy for adult patients with ARDS.",
"   </p>",
"   <p>",
"    The OSCAR trial, involving nearly 800 patients in the United Kingdom, also failed to demonstrate a mortality benefit at 30 days although the detrimental effect of HFOV on mortality observed in the OSCILLATE trial above was not in evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results of the OSCILLATE and OSCAR trials differ from both a Cochrane analysis of eight randomized trials (419 patients), and a meta-analysis of six randomized trials (365 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/19,23\">",
"     19,23",
"    </a>",
"    ]. Neither analysis included OSCILLATE. Both meta-analyses of adults with ARDS who received HFOV had significantly lower hospital mortality or 30-day mortality than those who received conventional mechanical ventilation alone (39 versus 49 percent, RR 0.77, 95% CI 0.61-0.98) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/19,23\">",
"     19,23",
"    </a>",
"    ]. A limitation of these meta-analyses was that some of the trials that were included did not use low tidal volume ventilation in their control groups, which could bias the results in favor of HFOV. When trials that allowed tidal volumes &ge;8",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    were excluded and the meta-analysis repeated, there was a trend toward lower mortality among patients who received HFOV (RR 0.67, 95% CI 0.44-1.03). These results indicate that the repeat meta-analysis was too small to exclude or confirm a clinically important effect and additional trials are necessary to compare the effects of HFOV and low tidal volume ventilation on mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link&amp;anchor=H2#H2\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\", section on 'Low tidal volume ventilation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It was hypothesized that an explanation for a lack of mortality benefit to HFOV might come from the duration of conventional mechanical ventilation prior to HFOV [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/24\">",
"     24",
"    </a>",
"    ]. However, a meta-analysis of nine studies (two randomized trials and seven observational studies) found no such relationship, even after confounding variables were considered [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/25\">",
"     25",
"    </a>",
"    ]. Only the oxygenation index was independently associated with mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=see_link&amp;anchor=H8#H8\">",
"     \"Oxygenation and mechanisms of hypoxemia\", section on 'Oxygenation index'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effects of HFOV combined with another intervention have also been evaluated. Generally speaking, HFOV improves oxygenation when combined with inhaled nitric oxide or recruitment maneuvers, [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/24,26\">",
"     24,26",
"    </a>",
"    ]. It may also prevent worsening of hypoxemia when a patient returns to the supine position following prone ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/27\">",
"     27",
"    </a>",
"    ]. None of these combinations have been shown to improve important clinical outcomes and all of the studies had significant methodologic limitations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     HF percussive ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;HFPV improves both oxygenation and ventilation without hemodynamic instability or clinically evident pulmonary barotrauma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/8,28,29\">",
"     8,28,29",
"    </a>",
"    ]. It may also decrease intracranial pressure in patients with head injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single center, randomized trial of 62 patients with burns and respiratory failure compared HFPV to conventional low tidal volume ventilation [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/30\">",
"       30",
"      </a>",
"      ]. There were no differences in ventilator-free days or mortality, and there was less need for rescue ventilation in the HFPV group (6 versus 29 percent). In addition, there was a trend toward a lower incidence of ventilator-associated pneumonia in the HFPV group. Only 39 to 45 percent of patients in this study had acute lung injury",
"      <span class=\"nowrap\">",
"       (ALI)/ARDS.",
"      </span>",
"     </li>",
"     <li>",
"      A trial randomly assigned 35 patients with inhalational injury to undergo HFPV or volume-limited mechanical ventilation [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/28\">",
"       28",
"      </a>",
"      ]. The HFPV group had significant improvement in the",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      ratio of the initial 72 hours, compared to the volume-limited ventilation group.",
"     </li>",
"     <li>",
"      An uncontrolled trial of 54 patients with",
"      <span class=\"nowrap\">",
"       ALI/ARDS",
"      </span>",
"      demonstrated improved oxygenation, decreased physiologic shunting, and decreased peak airway pressures after changing the mode of ventilation to HFPV [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     HARMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HFV is not risk free. The high respiratory rate shortens the expiratory time, potentially causing auto-PEEP and dynamic hyperinflation. The plateau airway pressure (alveolar pressure) and mean airway pressure are likely to increase if auto-PEEP and dynamic hyperinflation develop, elevating the risk of pulmonary barotrauma and hemodynamic instability. This occurs despite a lower peak airway pressure conferred by the smaller tidal volumes. In one trial, the risk of pulmonary barotrauma or hemodynamic instability was the same for patients receiving HFV compared to those receiving an alternative mode of mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32934?source=see_link\">",
"     \"Pulmonary barotrauma during mechanical ventilation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26119?source=see_link&amp;anchor=H17#H17\">",
"     \"Physiologic and pathophysiologic consequences of mechanical ventilation\", section on 'Hemodynamics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are also complications unique to type of HFV. As an example, HFJV is associated with necrotizing tracheobronchitis, endotracheal tube mucus inspissation, and variability of cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5591/abstract/31\">",
"     31",
"    </a>",
"    ]. Proper gas humidification reduces the likelihood of necrotizing tracheobronchitis or endotracheal tube mucus inspissation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High-frequency ventilation (HFV) combines a very high respiratory rate with tidal volumes that are smaller than the volume of anatomic dead space. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are four types of HFV: high-frequency jet ventilation (HFJV), high-frequency oscillatory ventilation (HFOV), high-frequency percussive ventilation (HFPV), and high-frequency positive pressure ventilation (HFPPV). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Types of HFV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no universally accepted indications for HFV. Its use has also been described in a variety of clinical situations. HFV should be avoided in patients with obstructive lung disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite evidence that HFOV improves oxygenation, it does not reduce, and may increase, in-hospital mortality in adult patients with adult respiratory distress syndrome (ARDS) compared with a ventilation strategy of low tidal volume and high positive end-expiratory pressure. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'HF oscillatory ventilation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HPFV also appears to improve oxygenation, although evidence that it improves clinical outcomes (eg, mortality, duration of mechanical ventilation, or length of ICU stay) is lacking. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HFV is not risk free. Potential harms include intrinsic positive end-expiratory pressure (auto-PEEP), dynamic hyperinflation, and related sequelae (eg, pulmonary barotrauma, hemodynamic instability). In addition, there are specific risks associated with each type of HFV. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Harms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/1\">",
"      Standiford TJ, Morganroth ML. High-frequency ventilation. Chest 1989; 96:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/2\">",
"      Gluck E, Heard S, Patel C, et al. Use of ultrahigh frequency ventilation in patients with ARDS. A preliminary report. Chest 1993; 103:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/3\">",
"      Fessler HE, Derdak S, Ferguson ND, et al. A protocol for high-frequency oscillatory ventilation in adults: results from a roundtable discussion. Crit Care Med 2007; 35:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/4\">",
"      Hager DN, Fessler HE, Kaczka DW, et al. Tidal volume delivery during high-frequency oscillatory ventilation in adults with acute respiratory distress syndrome. Crit Care Med 2007; 35:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/5\">",
"      Fessler HE, Hager DN, Brower RG. Feasibility of very high-frequency ventilation in adults with acute respiratory distress syndrome. Crit Care Med 2008; 36:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/6\">",
"      Mentzelopoulos SD, Malachias S, Kokkoris S, et al. Comparison of high-frequency oscillation and tracheal gas insufflation versus standard high-frequency oscillation at two levels of tracheal pressure. Intensive Care Med 2010; 36:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/7\">",
"      Pellicano A, Tingay DG, Mills JF, et al. Comparison of four methods of lung volume recruitment during high frequency oscillatory ventilation. Intensive Care Med 2009; 35:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/8\">",
"      Salim A, Martin M. High-frequency percussive ventilation. Crit Care Med 2005; 33:S241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/9\">",
"      Carlon GC, Ray C Jr, Klain M, McCormack PM. High-frequency positive-pressure ventilation in management of a patient with bronchopleural fistula. Anesthesiology 1980; 52:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/10\">",
"      Bishop MJ, Benson MS, Sato P, Pierson DJ. Comparison of high-frequency jet ventilation with conventional mechanical ventilation for bronchopleural fistula. Anesth Analg 1987; 66:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/11\">",
"      Eastman A, Holland D, Higgins J, et al. High-frequency percussive ventilation improves oxygenation in trauma patients with acute respiratory distress syndrome: a retrospective review. Am J Surg 2006; 192:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/12\">",
"      Mehta S, Granton J, MacDonald RJ, et al. High-frequency oscillatory ventilation in adults: the Toronto experience. Chest 2004; 126:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/13\">",
"      David M, Weiler N, Heinrichs W, et al. High-frequency oscillatory ventilation in adult acute respiratory distress syndrome. Intensive Care Med 2003; 29:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/14\">",
"      Ross-Anderson DJ, Ferguson C, Patel A. Transtracheal jet ventilation in 50 patients with severe airway compromise and stridor. Br J Anaesth 2011; 106:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/15\">",
"      Carlon GC, Howland WS, Ray C, et al. High-frequency jet ventilation. A prospective randomized evaluation. Chest 1983; 84:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/16\">",
"      Derdak S, Mehta S, Stewart TE, et al. High-frequency oscillatory ventilation for acute respiratory distress syndrome in adults: a randomized, controlled trial. Am J Respir Crit Care Med 2002; 166:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/17\">",
"      Bollen CW, van Well GT, Sherry T, et al. High frequency oscillatory ventilation compared with conventional mechanical ventilation in adult respiratory distress syndrome: a randomized controlled trial [ISRCTN24242669]. Crit Care 2005; 9:R430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/18\">",
"      Mentzelopoulos SD, Roussos C, Koutsoukou A, et al. Acute effects of combined high-frequency oscillation and tracheal gas insufflation in severe acute respiratory distress syndrome. Crit Care Med 2007; 35:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/19\">",
"      Sud S, Sud M, Friedrich JO, et al. High frequency oscillation in patients with acute lung injury and acute respiratory distress syndrome (ARDS): systematic review and meta-analysis. BMJ 2010; 340:c2327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/20\">",
"      Adhikari NK, Bashir A, Lamontagne F, et al. High-frequency oscillation in adults: a utilization review. Crit Care Med 2011; 39:2631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/21\">",
"      Ferguson ND, Cook DJ, Guyatt GH, et al. High-frequency oscillation in early acute respiratory distress syndrome. N Engl J Med 2013; 368:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/22\">",
"      Young D, Lamb SE, Shah S, et al. High-frequency oscillation for acute respiratory distress syndrome. N Engl J Med 2013; 368:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/23\">",
"      Sud S, Sud M, Friedrich JO, et al. High-frequency ventilation versus conventional ventilation for treatment of acute lung injury and acute respiratory distress syndrome. Cochrane Database Syst Rev 2013; 2:CD004085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/24\">",
"      Mehta S, MacDonald R, Hallett DC, et al. Acute oxygenation response to inhaled nitric oxide when combined with high-frequency oscillatory ventilation in adults with acute respiratory distress syndrome. Crit Care Med 2003; 31:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/25\">",
"      Bollen CW, Uiterwaal CS, van Vught AJ. Systematic review of determinants of mortality in high frequency oscillatory ventilation in acute respiratory distress syndrome. Crit Care 2006; 10:R34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/26\">",
"      Ferguson ND, Chiche JD, Kacmarek RM, et al. Combining high-frequency oscillatory ventilation and recruitment maneuvers in adults with early acute respiratory distress syndrome: the Treatment with Oscillation and an Open Lung Strategy (TOOLS) Trial pilot study. Crit Care Med 2005; 33:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/27\">",
"      Demory D, Michelet P, Arnal JM, et al. High-frequency oscillatory ventilation following prone positioning prevents a further impairment in oxygenation. Crit Care Med 2007; 35:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/28\">",
"      Reper P, Wibaux O, Van Laeke P, et al. High frequency percussive ventilation and conventional ventilation after smoke inhalation: a randomised study. Burns 2002; 28:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/29\">",
"      Hurst JM, Branson RD, DeHaven CB. The role of high-frequency ventilation in post-traumatic respiratory insufficiency. J Trauma 1987; 27:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/30\">",
"      Chung KK, Wolf SE, Renz EM, et al. High-frequency percussive ventilation and low tidal volume ventilation in burns: a randomized controlled trial. Crit Care Med 2010; 38:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5591/abstract/31\">",
"      Angus DC, Lidsky NM, Dotterweich LM, Pinsky MR. The influence of high-frequency jet ventilation with varying cardiac-cycle specific synchronization on cardiac output in ARDS. Chest 1997; 112:1600.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1639 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-CAE323FBD7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_29_5591=[""].join("\n");
var outline_f5_29_5591=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF HFV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      High frequency jet ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      High frequency oscillatory ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      High frequency percussive ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      High frequency positive pressure ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HF jet ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HF oscillatory ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HF percussive ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      HARMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1639\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1639|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?21/37/22096\" title=\"algorithm 1\">",
"      Jet ventilator settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1639|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/11/16574\" title=\"figure 1\">",
"      High frequency vent modes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24486?source=related_link\">",
"      Management of bronchopleural fistula in patients on mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=related_link\">",
"      Modes of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=related_link\">",
"      Oxygenation and mechanisms of hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26119?source=related_link\">",
"      Physiologic and pathophysiologic consequences of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30663?source=related_link\">",
"      Positive end-expiratory pressure (PEEP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32934?source=related_link\">",
"      Pulmonary barotrauma during mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15833?source=related_link\">",
"      Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43720?source=related_link\">",
"      Use of neuromuscular blocking medications in critically ill patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16182?source=related_link\">",
"      Ventilator-associated lung injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_29_5592="Treatment of musculoskeletal chest pain";
var content_f5_29_5592=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of musculoskeletal chest pain",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/29/5592/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/29/5592/contributors\">",
"     Kristine Phillips, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/29/5592/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/29/5592/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/29/5592/contributors\">",
"     Don L Goldenberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/29/5592/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/29/5592/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/29/5592/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many causes of chest pain that can be referred to as musculoskeletal. They can be separated into isolated musculoskeletal chest pain syndromes (",
"    <a class=\"graphic graphic_table graphicRef79217 \" href=\"UTD.htm?41/37/42587\">",
"     table 1",
"    </a>",
"    ) and systemic disorders, the latter associated with either rheumatic or nonrheumatic diseases (",
"    <a class=\"graphic graphic_table graphicRef73531 \" href=\"UTD.htm?12/57/13211\">",
"     table 2",
"    </a>",
"    ). The major causes of musculoskeletal chest pain are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2201?source=see_link\">",
"     \"Major causes of musculoskeletal chest pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Musculoskeletal chest pain must be differentiated from chest pain due to potentially life-threatening disorders such as myocardial ischemia or infarction, pulmonary embolism, aortic dissection, or pneumothorax. The diagnostic approach to a patient with chest pain and the differential diagnosis of chest pain are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34042?source=see_link\">",
"     \"Diagnostic approach to chest pain in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26634?source=see_link\">",
"     \"Differential diagnosis of chest pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapeutic interventions for musculoskeletal disorders affecting the chest are generally similar to those for musculoskeletal pain elsewhere in the body. However, in the case of chest pain, a common patient concern, stated or unstated, that the pain is due to heart disease, must be addressed as well. In this regard, the physical examination itself, particularly the examiner's ability to reproduce or exacerbate the chest pain by palpation or with various maneuvers, helps the patient understand the noncardiac nature of the problem. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9335?source=see_link\">",
"     \"Clinical evaluation of musculoskeletal chest pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES OF MUSCULOSKELETAL CHEST PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned in the introduction, there are many local and systemic diseases and disorders that cause musculoskeletal chest pain (",
"    <a class=\"graphic graphic_table graphicRef79217 \" href=\"UTD.htm?41/37/42587\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef73531 \" href=\"UTD.htm?12/57/13211\">",
"     table 2",
"    </a>",
"    ). These causes are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2201?source=see_link\">",
"     \"Major causes of musculoskeletal chest pain\"",
"    </a>",
"    .) A brief summary of some selected causes follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Costochondritis and Tietze's syndrome are both associated with tenderness of one or more of the costochondral joints. Although there is some controversy over whether these two disorders are truly distinct, in this discussion the term Tietze's syndrome is used for the combination of pain, tenderness and",
"      <strong>",
"       swelling",
"      </strong>",
"      , while costochondritis is used when swelling is absent.",
"     </li>",
"     <li>",
"      Sternalis syndrome is a rare disorder characterized by localized tenderness found over the body of the sternum, often with tenderness that causes radiation of pain bilaterally.",
"     </li>",
"     <li>",
"      Xiphoidalgia or xiphoidynia is also a rare syndrome with localized pain and tenderness over the xiphoid process.",
"     </li>",
"     <li>",
"      Sternocostoclavicular hyperostosis is a syndrome characterized by a unique arthropathy that frequently involves the anterior chest wall and is associated with a spectrum of neutrophilic skin lesions. The acronym",
"      <strong>",
"       SAPHO",
"      </strong>",
"      syndrome has been proposed as a unifying term to include the various features that may occur:",
"      <strong>",
"       s",
"      </strong>",
"      ynovitis;",
"      <strong>",
"       a",
"      </strong>",
"      cne;",
"      <strong>",
"       p",
"      </strong>",
"      ustulosis;",
"      <strong>",
"       h",
"      </strong>",
"      yperostosis; and",
"      <strong>",
"       o",
"      </strong>",
"      steomyelitis.",
"     </li>",
"     <li>",
"      Lower rib pain syndromes go by many different names such as slipping or clicking rib syndrome, rib-tip syndrome, or twelfth rib. Pain can be diffuse or localized, and is accompanied by tenderness on the costal margin that reproduces the pain.",
"     </li>",
"     <li>",
"      Fibromyalgia is a common chronic musculoskeletal pain syndrome that presents with diffuse myalgias, multiple tender points, sleep disturbance, and fatigue. Many patients report tenderness over the costochondral junctions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     THERAPEUTIC INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with musculoskeletal chest pain may benefit from one or more of the following interventions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patient education and reassurance",
"     </li>",
"     <li>",
"      Physical measures",
"     </li>",
"     <li>",
"      Topical agents",
"     </li>",
"     <li>",
"      Nonsteroidal antiinflammatory drugs (NSAIDs)",
"     </li>",
"     <li>",
"      Muscle relaxants",
"     </li>",
"     <li>",
"      Antidepressants",
"     </li>",
"     <li>",
"      Anticonvulsants",
"     </li>",
"     <li>",
"      Local glucocorticoid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anesthetic injections",
"     </li>",
"     <li>",
"      Disease modifying anti-rheumatic drugs (DMARDs)",
"     </li>",
"     <li>",
"      Psychiatric evaluation",
"     </li>",
"     <li>",
"      Narcotic analgesics",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a musculoskeletal cause for chest pain has been established and immediate life-threatening disorders have been excluded, a careful explanation of the diagnosis and reassurance may be therapeutic for some patients. For them, watchful waiting without any other specific intervention may be appropriate.",
"   </p>",
"   <p>",
"    Follow up and advice are helpful to such patients and may be appropriately scheduled four to six weeks after the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5592/abstract/1\">",
"     1",
"    </a>",
"    ]. A follow up appointment with a doctor in primary care provides an opportunity for further discussion and may identify patients with uncontrolled symptoms who require further evaluation or additional treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Physical measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overload and overuse, as during weight training, may cause muscle strain. If possible, any activity that causes or reliably exacerbates the problem should be stopped, at least temporarily. This is particularly important for patients with spontaneous sternoclavicular subluxation. Anecdotal reports of benefit from physical interventions are widespread although not assessed in the scientific literature. For muscle spasm, application of heat may be helpful. If no muscle spasm is present, application of cold may reduce swelling and discomfort.",
"   </p>",
"   <p>",
"    Stretching exercises may benefit patients with musculoskeletal chest pain of various causes, particularly if muscle spasm is present. The specific exercises should address the muscle groups involved (eg, pectoralis major versus sternal head of the sternocleidomastoid). For certain patients with intractable symptoms, a short course of physical therapy with a goal of an independent home program is worth the investment of time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Topical agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    cream or salicylate-containing creams or gels may be tried with application three to four times daily for a two week trial period [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5592/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. These agents are widely available at local pharmacies. Where available, topical NSAID preparations (eg, one percent topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    gel or diclofenac patch) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14370?source=see_link\">",
"     ethyl chloride",
"    </a>",
"    spray may also provide some relief and can be used several times per day. Topical use of NSAIDs may be associated the same risks of adverse effects as may occur with systemic use. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Nonsteroidal antiinflammatory drugs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Local pain also often may respond to a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    patch.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nonnarcotic analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mild symptoms and no evidence of an inflammatory disorder (eg, muscle strain, costochondral tenderness without swelling, etc)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    those who have a relative or absolute contraindication to the use of NSAIDs, may benefit from a nonnarcotic analgesic such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (up to 3",
"    <span class=\"nowrap\">",
"     grams/day",
"    </span>",
"    in divided doses in adults).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over-the-counter NSAIDs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    ) are often used, and may be more appropriate than simple analgesics for patients with signs of inflammation. Most patients' symptoms due to musculoskeletal chest problems improve over the course of a few weeks or months.",
"   </p>",
"   <p>",
"    Patients with uncontrolled symptoms from Tietze's syndrome, SAPHO syndrome, costochondritis, sternalis, xiphoidalgia, or the lower rib pain syndromes may require prescription strength NSAIDs. If a maximum dose of a particular NSAID does not relieve symptoms or efficacy wanes, anecdotal reports suggest that switching classes of NSAIDs may prove helpful (from an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    to a propionic acid for example) (",
"    <a class=\"graphic graphic_table graphicRef70067 \" href=\"UTD.htm?23/54/24431\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5592/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should be cautioned that use of NSAIDs may precipitate renal insufficiency, gastritis, peptic ulcer disease, and gastrointestinal bleeding. Those at high risk of NSAID-induced gastroduodenal damage and those requiring concomitant low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy for cardiovascular disease may benefit from ulcer prophylaxis with a proton pump inhibitor or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .) Interference by some NSAIDs with the beneficial anti-platelet effects of aspirin may be a concern for those taking low doses of aspirin for prophylaxis or treatment of cardiovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of a selective cyclooxygenase-2 (COX-2) inhibitor may also be considered for patients at high risk of gastroduodenal damage and for those receiving anticoagulants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link&amp;anchor=H8#H8\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Selective COX-2 inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intramuscular injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    (15 to 30 mg) followed by oral ketorolac (up to 10 mg four times daily) for up to five days may be valuable in moderate to severe acute musculoskeletal pain. However, parenteral administration of this NSAID does not avoid the risk of gastroduodenal damage or of causing acute renal failure in high risk patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Muscle relaxants",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/60/13254?source=see_link\">",
"     Cyclobenzaprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24677?source=see_link\">",
"     methocarbamol",
"    </a>",
"    , and benzodiazepines may be beneficial for treating musculoskeletal chest pain, particularly if there is associated muscle spasm. Muscle relaxants are not recommended for elderly patients or those patients prone to misuse of the drugs. Long-term therapy for musculoskeletal chest pain with muscle relaxants should generally be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Cyclobenzaprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/60/13254?source=see_link\">",
"     Cyclobenzaprine",
"    </a>",
"    at doses of 5 to 10 mg three times daily is more efficacious than placebo in the treatment of neck and low back pain [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5592/abstract/5\">",
"     5",
"    </a>",
"    ]. There are no data that specifically address the efficacy of this agent in chest wall pain. If used, cyclobenzaprine is typically started at a dose of 10 mg PO three times daily and increased if necessary to a maximum daily dose of 60 mg per day. Patients should be warned about drowsiness with this agent and cautioned to avoid hazardous activities while taking it.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Methocarbamol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are also lacking to assess the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24677?source=see_link\">",
"     methocarbamol",
"    </a>",
"    for musculoskeletal chest pain; however, we use it for acute exacerbations of pain. Methocarbamol doses range from 750 mg to 1500 mg three times daily. As with other muscle relaxants, patients should be warned about sedative effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the potential for abuse, benzodiazepines should be avoided for the treatment of isolated musculoskeletal chest pain in the absence of psychiatric indications. Patients should be cautioned about possible sedation and the potential for dependence or addiction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tricyclic antidepressants such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    have been used for chest pain of neuropathic origin. They may also be useful for treatment of subacute or chronic chest pain of musculoskeletal origin, particularly that due to chronic costochondritis or fibromyalgia. A low dose of a tricyclic at bedtime is used initially. The dose may be increased weekly to the maximum tolerated or the equivalent of 150 mg of amitriptyline daily. Adverse effects of tricyclics are common (",
"    <a class=\"graphic graphic_table graphicRef74319 \" href=\"UTD.htm?18/17/18716\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Selective serotonin reuptake inhibitors (SSRI) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    have also been used to treat symptoms of chronic pain. Overall they may be somewhat less effective in relieving pain than the tricyclic antidepressants [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5592/abstract/6\">",
"     6",
"    </a>",
"    ]. However, the advantage in safety of SSRIs over the tricyclics may make an SSRI the antidepressant of choice, particularly if anxiety or depression is present, or if comorbidities (eg, coronary heart disease) that are relative contraindications to the use of tricyclics are present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Anticonvulsants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anticonvulsant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    has been used to treat chronic pain syndromes. The mechanism by which gabapentin produces pain relief is unknown. Somnolence and dizziness are common side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5592/abstract/7\">",
"     7",
"    </a>",
"    ]. An empiric trial of gabapentin might be considered for a patient with chronic chest wall pain that did not respond to other forms of therapy and prior to resorting to more invasive approaches such as local injection. Other anticonvulsants have also been used to treat chronic pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Local glucocorticoid injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy with one or more local injections of a mixture of a glucocorticoid and a local anesthetic may be helpful for patients with arthritis, Tietze's syndrome, costochondritis of one or two joints, xiphoidalgia, or one of the lower rib pain syndromes such as slipping rib or rib-tip syndrome.",
"   </p>",
"   <p>",
"    Local injection of the manubriosternal joint, sternoclavicular joint, or the costochondral junctions must be performed with caution in order to reduce the risk of pneumothorax or laceration of blood vessels in the chest wall or mediastinum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Sternoclavicular joint injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to injection of the sternoclavicular joint is similar to aspiration and injection of larger joints. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=see_link\">",
"     \"Joint aspiration or injection in adults: Technique and indications\"",
"    </a>",
"    .) Careful palpation of bony margins prior to skin preparation is helpful. The joint line of the sternoclavicular joint runs obliquely laterally from superior to inferior and may be identified while the patient retracts the shoulder. For injection of this joint, the patient should lie with the ipsilateral arm in lateral rotation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5592/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To minimize discomfort,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    (one to two mL of 1 or 2 percent solution without epinephrine) should be injected into the skin and subcutaneous tissues. After local anesthesia is achieved, using a 23-gauge or 25-gauge needle and sterile technique, an attempt should be made to aspirate the joint. Any aspirated fluid should be sent for total white cell count, differential white cell count, polarized-light microscopy for crystals, gram stain, and culture if possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=see_link\">",
"     \"Synovial fluid analysis and the diagnosis of septic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After septic arthritis of the sternoclavicular joint has been excluded injection of corticosteroids and a local anesthetic may proceed. Choices of glucocorticoid include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       Hydrocortisone",
"      </a>",
"      acetate (20 mg)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       Methylprednisolone",
"      </a>",
"      (20 mg)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       Triamcinolone",
"      </a>",
"      hexacetonide (10 mg)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     Lidocaine",
"    </a>",
"    (1 mL of a one or two percent solution without epinephrine) may be mixed with the glucocorticoid.",
"   </p>",
"   <p>",
"    Relief of local symptoms within a few minutes of the injection affirms the correct placement and offers reassurance that the chest pain was indeed due to a sternoclavicular joint disorder.",
"   </p>",
"   <p>",
"    Patients should be cautioned regarding the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The immediate pain relief due to the local anesthetic will last for minutes to hours.",
"     </li>",
"     <li>",
"      Pain is likely to return and for up to 24 hours the joint may be more painful than it was prior to the injection. Use of an analgesic such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (up to 3",
"      <span class=\"nowrap\">",
"       grams/day",
"      </span>",
"      in divided doses in adults) or an NSAID may be needed for a few days following the injection.",
"     </li>",
"     <li>",
"      It may take several days for the benefit of the glucocorticoid to become apparent.",
"     </li>",
"     <li>",
"      Sports activities should be limited for five to seven days following injection [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5592/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Longer acting steroids (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      ) may lead to fat atrophy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      depigmentation of the overlying skin.",
"     </li>",
"     <li>",
"      There is a small risk of septic arthritis following joint injection. This risk has been estimated to range from 1 in 2000 to 1 in 15,000 procedures. Symptoms or signs of infection should be watched for and reported immediately if they develop. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28564?source=see_link&amp;anchor=H5#H5\">",
"       \"Joint aspiration or injection in adults: Complications\", section on 'Iatrogenic septic arthritis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Manubriosternal joint",
"    </span>",
"    &nbsp;&mdash;&nbsp;The manubriosternal joint is typically located at or near the 2nd costochondral junction. Local injection of the manubriosternal joint may be valuable in the setting of rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5592/abstract/10\">",
"     10",
"    </a>",
"    ]. The joint is located by palpating for the angulation between the sternum and the manubrium. The choice type and amount of glucocorticoid is the same as for sternoclavicular joint injection. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Sternoclavicular joint injection'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Costochondral junctions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infiltration of the region of the costochondral junctions may be beneficial for the patient with one or two tender areas due to costochondritis or Tietze's syndrome. The best evidence to support the effectiveness of this approach was an observational study in which ultrasonography was used to confirm the diagnosis of Tietze's syndrome in nine patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5592/abstract/11\">",
"     11",
"    </a>",
"    ]. The point of maximal tenderness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ultrasonographically enlarged costochondral joint was injected with a mixture of 15 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    hexacetonide and 1 mL of two percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    . Complete resolution of swelling and tenderness was noted after one week in eight patients and \"substantial\" improvement was noted in the one remaining patient.",
"   </p>",
"   <p>",
"    As with sternoclavicular joint injection, caution is required to avoid inadvertent puncture of the underling lung, blood vessels or heart. If the treating physician is not experienced with costochondral joint injection and if less invasive treatments (eg, rest, heat, NSAIDs) have been ineffective, referral to a pain management specialist, orthopedist, or rheumatologist for the procedure may be appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Intercostal nerve block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe pain due to one or more fractured ribs or malignant disease affecting the chest wall may respond to intercostal nerve block using a local anesthetic for short term pain relief or phenol, a cryogenic probe, or other means for longer-term control of chest wall pain. These approaches are generally arranged though a pain treatment or anesthesia service. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18042?source=see_link&amp;anchor=H7#H7\">",
"     \"Peripheral nerve block: Techniques\", section on 'Intercostal nerve block'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32170?source=see_link\">",
"     \"Psychological, rehabilitative, and integrative therapies for cancer pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Disease modifying antirheumatic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of disease modifying anti-rheumatic drugs (DMARDs) may be useful for patients with systemic rheumatic disease that is causing chest pain as a result of arthritis of the costovertebral, sternoclavicular, manubriosternal, or costochondral joints.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with rheumatoid arthritis agents such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , or anti-tumor necrosis factor (anti-TNF) agents alone or in combination may be beneficial. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"       \"General principles of management of rheumatoid arthritis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with spondyloarthropathies, such as ankylosing spondylitis, may benefit from use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      or anti-TNF agents. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=see_link\">",
"       \"Assessment and treatment of ankylosing spondylitis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When sternoclavicular arthritis is present along with other features of the SAPHO syndrome, DMARDs or anti-TNF therapies may be useful adjuncts to treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2201?source=see_link&amp;anchor=H22#H22\">",
"       \"Major causes of musculoskeletal chest pain\", section on 'Sternocostoclavicular hyperostosis (SAPHO syndrome)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Psychiatric evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concomitant psychiatric problems such as anxiety, depression, panic attacks, or abnormal health beliefs may influence the outcome of treatment of non-cardiac chest pain. Psychiatric referral should be considered for these patients. Evidence from controlled trials has shown an advantage with cognitive behavioral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5592/abstract/12-14\">",
"     12-14",
"    </a>",
"    ], and antidepressant drugs in selected populations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5592/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Narcotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of long-acting narcotics should be avoided in patients with chest pain of musculoskeletal etiology. For isolated acute exacerbations, short-acting mild narcotics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    may be used judiciously. Patients should be cautioned regarding sedation and potential for dependence when using narcotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/27/34225?source=see_link\">",
"       \"Patient information: Costochondritis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data that specifically address the efficacy and safety of the therapeutic interventions discussed above in patients with musculoskeletal chest pain. In general, the use of these interventions in treating musculoskeletal chest pain is based upon analogy with their usefulness in treating pain of similar origin elsewhere in the body (eg, neck and low back pain). This is particularly the case for the treatment of chronic chest pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Nonpharmacologic interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following interventions are generally recommended in the treatment of musculoskeletal chest pain.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Demonstrating that the pain can be reproduced or aggravated by palpation or provocative maneuvers may be reassuring to the patient. This shows that the pain is most likely arising from musculoskeletal structures and helps allay fear that the chest pain is due to heart disease or some other life-threatening problem.",
"     </li>",
"     <li>",
"      Arranging a follow up visit (four to six weeks after the onset of the pain) also provides a way to assess the effectiveness of initial therapy.",
"     </li>",
"     <li>",
"      Temporarily avoiding any physical activity that caused or clearly exacerbates the chest pain is recommended.",
"     </li>",
"     <li>",
"      Stretching and applying heat for muscle spasm or cold for swelling are recommended. Formal physical therapy may be necessary for patients with more chronic pain but with a goal of progressing to a home program.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Pharmacologic interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Escalating pharmacologic interventions are employed according to the acuity and severity of the pain. Approaches for acute and chronic pain of mild, moderate, or severe intensity are described as follows:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Acute pain",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild acute pain &mdash; Topical agents such as sports creams,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"       capsaicin",
"      </a>",
"      may be useful. Nonnarcotic analgesics (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      up to 3 grams per day in divided doses for adults) or over-the-counter NSAIDs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      200 to 400 mg TID with meals) are used unless contraindicated.",
"     </li>",
"     <li>",
"      Moderate acute pain &mdash; Unless there are contraindications, prescription strength NSAIDs are generally used to treat moderate acute musculoskeletal pain (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      600 to 800 mg TID or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      250 to 500 mg BID).",
"      <br/>",
"      <br/>",
"      Patients should be cautioned about possible adverse effects of NSAIDs and prophylaxis with antiulcer agents (eg, a proton pump inhibitor or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      ) or use of a selective COX-2 inhibitor may be necessary if there are risk factors such as advanced age, prior gastric or duodenal ulcer disease, prior gastrointestinal (GI) bleeding, or intolerance of nonselective NSAIDs.",
"     </li>",
"     <li>",
"      Severe acute pain &mdash; Severe musculoskeletal chest pain due to trauma (eg, a rib fracture or significant contusion) may require the short-term use of narcotic analgesics. In patients with a history of substance abuse, an alternative to consider is intramuscular",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"       ketorolac",
"      </a>",
"      (15 to 30 mg) followed by oral ketorolac (up to 10 mg four times daily) for five days.",
"      <br/>",
"      <br/>",
"      Severe pain due to costochondritis, Tietze's syndrome, sternoclavicular or manubriosternal arthritis, may be best managed with a local injection of a mixture of corticosteroids and local anesthetic. However, if the treating physician is not experienced in the injection technique for these disorders, and consultation with a rheumatologist, orthopedist, or pain-management specialist is not immediately available, then one of the following alternatives may be employed while the patient awaits an appointment for a local injection:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Prescription strength NSAIDs",
"     </li>",
"     <li>",
"      Parenteral, followed by oral,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"       ketorolac",
"      </a>",
"     </li>",
"     <li>",
"      Short-term use of a short acting narcotic analgesic such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"       codeine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Chronic pain",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild chronic pain &mdash; Use of a simple nonnarcotic analgesic such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (up to 3",
"      <span class=\"nowrap\">",
"       grams/day",
"      </span>",
"      in divided doses for adults) or over-the-counter strength NSAIDs are recommended pharmacologic therapy for mild chronic pain.",
"     </li>",
"     <li>",
"      Moderate chronic pain &mdash; Addition of an antidepressant of the tricyclic or SSRI class",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      may be helpful when there is moderate chronic pain. Pain due to arthritis, costochondritis, or Tietze's syndrome may benefit from one or more local injection of glucocorticoids and a local anesthetic agent to the painful regions in addition to ongoing NSAID therapy. Local pain often may respond to a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      patch. Pain due to systemic rheumatic disease such as rheumatoid arthritis or a seronegative spondyloarthropathy (eg, ankylosing spondylitis, psoriatic arthritis) may require addition of a DMARD or anti-TNF therapy to NSAID therapy.",
"     </li>",
"     <li>",
"      Severe chronic pain &mdash; In the authors' experience, severe chronic pain does not usually have a benign musculoskeletal origin. The diagnosis should be reconsidered. The possibility of the pain being neuropathic or arising from an occult neoplasm, infection, or a previously unrecognized fracture should be suspected and excluded by physical examination and appropriate imaging (eg, CT, MRI, or technetium labeled pyrophosphate bone scan).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If no underlying neoplastic disorder, infection, or fracture can be found, drug addiction is not suspected, and if local injections are either ineffective or not indicated (eg, when the tenderness is not localized to a joint or to a costochondral or sternoxiphoidal junction), then further treatment is directed along the lines outlined for management of chronic pain. Antidepressants and anticonvulsants play an important role in the treatment of such patients. Psychiatric evaluation may be valuable if anxiety, panic-disorder, or depression is suspected to be amplifying the pain or the patient's behavior in response to it. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic use of narcotic analgesics may be necessary in some cases, but the decision to use this approach is best made in consultation with a pain management specialist. Narcotic analgesics with mixed agonist and antagonist properties, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    , do not completely avoid the risk of development of dependence or addiction and the decision to use this agent chronically should be made with the same care as for other narcotics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    , or hydrocodone.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5592/abstract/1\">",
"      Chambers J, Bass C, Mayou R. Non-cardiac chest pain: assessment and management. Heart 1999; 82:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5592/abstract/2\">",
"      Mason L, Moore RA, Derry S, et al. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 2004; 328:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5592/abstract/3\">",
"      Mason L, Moore RA, Edwards JE, et al. Systematic review of efficacy of topical rubefacients containing salicylates for the treatment of acute and chronic pain. BMJ 2004; 328:995.",
"     </a>",
"    </li>",
"    <li>",
"     Long J. The Essential Guide To Prescription Drugs, Harper Collins, New York 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5592/abstract/5\">",
"      Borenstein DG, Korn S. Efficacy of a low-dose regimen of cyclobenzaprine hydrochloride in acute skeletal muscle spasm: results of two placebo-controlled trials. Clin Ther 2003; 25:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5592/abstract/6\">",
"      O'Malley PG, Jackson JL, Santoro J, et al. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract 1999; 48:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5592/abstract/7\">",
"      Pollack M, Scott E. Gabapentine and lamotrigine: Novel treatments for mood and anxiety disorders. CNS Spectr 1997; 2:56.",
"     </a>",
"    </li>",
"    <li>",
"     Saunders S, Cameron G. Injection techniques in orthopedic and sports medicine, WB Saunders, London 1997.",
"    </li>",
"    <li>",
"     Doherty M, Hazleman B, Hutton C, et al. Rheumatology Examination and Injection Techniques, 2nd, WB Saunders, London 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5592/abstract/10\">",
"      Doube A, Clarke AK. Symptomatic manubriosternal joint involvement in rheumatoid arthritis. Ann Rheum Dis 1989; 48:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5592/abstract/11\">",
"      Kamel M, Kotob H. Ultrasonographic assessment of local steroid injection in Tietze's syndrome. Br J Rheumatol 1997; 36:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5592/abstract/12\">",
"      Klimes I, Mayou RA, Pearce MJ, et al. Psychological treatment for atypical non-cardiac chest pain: a controlled evaluation. Psychol Med 1990; 20:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5592/abstract/13\">",
"      Mayou RA, Bryant BM, Sanders D, et al. A controlled trial of cognitive behavioural therapy for non-cardiac chest pain. Psychol Med 1997; 27:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5592/abstract/14\">",
"      Kisely S, Campbell LA, Skerritt P. Psychological interventions for symptomatic management of non-specific chest pain in patients with normal coronary anatomy. Cochrane Database Syst Rev 2005; :CD004101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5592/abstract/15\">",
"      Cannon RO 3rd, Quyyumi AA, Mincemoyer R, et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 1994; 330:1411.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5623 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-A277839E2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_29_5592=[""].join("\n");
var outline_f5_29_5592=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES OF MUSCULOSKELETAL CHEST PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      THERAPEUTIC INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Physical measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Topical agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nonnarcotic analgesics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Muscle relaxants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Cyclobenzaprine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Methocarbamol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Anticonvulsants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Local glucocorticoid injections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Sternoclavicular joint injection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Manubriosternal joint",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Costochondral junctions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Intercostal nerve block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Disease modifying antirheumatic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Psychiatric evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Narcotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Nonpharmacologic interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Pharmacologic interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Acute pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5623\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5623|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/37/42587\" title=\"table 1\">",
"      Isolated chest pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/57/13211\" title=\"table 2\">",
"      Systemic causes MS chest pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/54/24431\" title=\"table 3\">",
"      Nonopioid analgesic and NSAID table",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/17/18716\" title=\"table 4\">",
"      Side effects TCAs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=related_link\">",
"      Assessment and treatment of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9335?source=related_link\">",
"      Clinical evaluation of musculoskeletal chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34042?source=related_link\">",
"      Diagnostic approach to chest pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26634?source=related_link\">",
"      Differential diagnosis of chest pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28564?source=related_link\">",
"      Joint aspiration or injection in adults: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=related_link\">",
"      Joint aspiration or injection in adults: Technique and indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2201?source=related_link\">",
"      Major causes of musculoskeletal chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=related_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/27/34225?source=related_link\">",
"      Patient information: Costochondritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/39/18042?source=related_link\">",
"      Peripheral nerve block: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32170?source=related_link\">",
"      Psychological, rehabilitative, and integrative therapies for cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=related_link\">",
"      Synovial fluid analysis and the diagnosis of septic arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_29_5593="Evaluation and management of middle ear trauma";
var content_f5_29_5593=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and management of middle ear trauma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/29/5593/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/29/5593/contributors\">",
"     Adele Karen Evans, MD, FAAP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/29/5593/contributors\">",
"     Steven D Handler, MD, MBE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/29/5593/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/29/5593/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/29/5593/contributors\">",
"     Maria E Moreira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/29/5593/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/29/5593/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/29/5593/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Middle ear trauma arises from blunt or penetrating head injury, direct ear trauma, or barotrauma caused by events such as blast injury, air travel, or scuba diving. Pediatric and adult injuries require the same steps in management. Patients with isolated small tympanic membrane perforations may be managed with antibiotic ear drops for contaminated wounds, water precautions (keeping water out of the middle ear), and reevaluation to ensure that the perforation has healed. Patients with significant hearing loss (&ge;40 decibels), vertigo, nystagmus, ataxia, or facial nerve injury warrant prompt evaluation by an otolaryngologist (ENT surgeon) or other specialist as indicated (eg, neurosurgeon for head injury).",
"   </p>",
"   <p>",
"    The management of blunt or penetrating middle ear trauma will be reviewed here. The evaluation and management of ear barotrauma and temporal bone fractures are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35397?source=see_link\">",
"     \"Ear barotrauma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13704?source=see_link\">",
"     \"Skull fractures in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3481?source=see_link\">",
"     \"Skull fractures in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Middle ear injury or injury to adjacent inner ear structures or both occurs in up to one-third of patients with severe head trauma and over one-half of patients with temporal bone basilar skull fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. These injuries include hemotympanum (",
"    <a class=\"graphic graphic_picture graphicRef62387 \" href=\"UTD.htm?31/17/32031\">",
"     picture 1",
"    </a>",
"    ), hearing loss, cerebrospinal fluid (CSF) fistula, otic capsule injury, and traumatic perilymphatic fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Otic capsule injury is four to five times more likely if temporal bone fracture occurs with facial nerve paralysis, CSF otorrhea, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Middle ear injury may also occur after direct blunt trauma to the external auditory canal (eg, hand blow to ear [\"boxed ears\"], fall onto the ear while water or snow skiing, motor vehicle collision, sports injury [eg, wrestling]) or penetrating trauma (eg, Q-tip, matchstick injury, gunshot wound, welding or soldering spark) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/3,4,6-9\">",
"     3,4,6-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Barotrauma with middle ear injury can occur during air travel, scuba diving, or exposure to a blast. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35397?source=see_link&amp;anchor=H3#H3\">",
"     \"Ear barotrauma\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RELEVANT ANATOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Middle ear",
"    </span>",
"    &nbsp;&mdash;&nbsp;The middle ear space is an air-filled cavity between the external ear canal and the inner ear (",
"    <a class=\"graphic graphic_figure graphicRef75010 \" href=\"UTD.htm?20/57/21400\">",
"     figure 1",
"    </a>",
"    ). The ossicular chain and the facial nerve cross the middle ear space. The boundaries of the middle ear cavity are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The tympanic membrane (TM), a three-layered membrane, laterally",
"     </li>",
"     <li>",
"      The otic capsule, containing the cochlea and vestibule, medially",
"     </li>",
"     <li>",
"      The bony tegmental wall under the middle cranial fossa, superiorly",
"     </li>",
"     <li>",
"      The bony jugular wall, encasing the internal jugular vein bulb, inferiorly",
"     </li>",
"     <li>",
"      The carotid wall, containing the Eustachian tube and tensor tympani muscle, anteriorly",
"     </li>",
"     <li>",
"      The entrance to the mastoid cavity, called the aditus ad antrum, posteriorly (",
"      <a class=\"graphic graphic_figure graphicRef74487 \" href=\"UTD.htm?16/51/17204\">",
"       figure 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The posterior aspect of the middle ear space leads into the adjacent air space called the mastoid cavity (",
"    <a class=\"graphic graphic_figure graphicRef74487 \" href=\"UTD.htm?16/51/17204\">",
"     figure 2",
"    </a>",
"    ). The bony roof of these regions separates them from the middle cranial fossa, which is lined by dura; the bony posterior aspect of the mastoid cavity contains the sigmoid sinus in the posterior cranial fossa. Fractures of the temporal bone into these spaces may result in any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CSF middle ear effusion, otorrhea, or rhinorrhea",
"     </li>",
"     <li>",
"      Hemotympanum (",
"      <a class=\"graphic graphic_picture graphicRef62387 \" href=\"UTD.htm?31/17/32031\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Carotid artery aneurysm, or pseudoaneurysm",
"     </li>",
"     <li>",
"      Meningitis days to years after the injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The middle ear space is lined by vascularized mucosa. The pressure in the middle ear cavity is equilibrated to ambient pressure by the action of the tensor veli palatini muscle and the salpingopharyngeus muscle located at the orifice of the Eustachian tube (ET). The ET is supported by cartilage and lined by mucosa as it travels from the middle ear space into the nasopharynx.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ossicles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ossicles (the malleus, the incus, and the stapes) comprise a lever system that amplifies sound by a factor of approximately three. The tympanic membrane (TM) has a large surface area compared with the oval window of the inner ear, and thus it is responsible for amplification of sound by a factor of 17. Sudden changes in sound intensity can be temporized by the activity of the stapedius muscle and tensor tympani muscle, both of which contract reflexively to dampen sound. Absence of air in the middle ear space, loss of TM integrity or disruption of the ossicular chain compromises the amplification system.",
"   </p>",
"   <p>",
"    Middle ear injuries, such as those sustained from a slap on the ear or insertion of a Q-tip, may result in mild conductive hearing loss due to TM perforation with partial loss of sound amplification (",
"    <a class=\"graphic graphic_picture graphicRef65160 \" href=\"UTD.htm?21/31/22015\">",
"     picture 2",
"    </a>",
"    ). Hemotympanum or CSF middle ear effusion caused by temporal bone basilar skull fracture or barotrauma may also dampen TM sound conduction (",
"    <a class=\"graphic graphic_picture graphicRef62387 \" href=\"UTD.htm?31/17/32031\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35397?source=see_link\">",
"     \"Ear barotrauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Middle ear injuries, such as more severe ear canal foreign body penetrations or temporal bone fractures, may result in maximum conductive hearing loss (ie, 60 decibels) if the ossicular leverage system is disrupted at the incudostapedial joint or if the stapes is subluxed (",
"    <a class=\"graphic graphic_picture graphicRef57714 \" href=\"UTD.htm?26/34/27168\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/10\">",
"     10",
"    </a>",
"    ]. Alternatively, such injuries can result in sensorineural hearing loss as a result of a cochlear concussion, otic capsule fracture, or internal auditory canal fracture with impingement of the acoustic nerve (cranial nerve VIII).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Adjacent structures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following structures are present within",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adjacent to the middle ear and often sustain injury when middle ear trauma occurs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oval window &ndash; Sudden changes in pressure, associated with barometric pressure changes, sound waves, or direct cranial injury may result in trauma to the oval window and may cause a perilymphatic fistula between the inner ear and middle ear (",
"      <a class=\"graphic graphic_figure graphicRef75010 \" href=\"UTD.htm?20/57/21400\">",
"       figure 1",
"      </a>",
"      ). The presence of a perilymphatic fistula is associated with hearing loss and \"third window\" signs, such as Tullio phenomenon and a positive fistula test [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/11\">",
"       11",
"      </a>",
"      ] which are manifest as follows [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/5,11-13\">",
"       5,11-13",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In Tullio phenomenon, a loud sound presented to the affected ear causes spinning vertigo and nystagmus.",
"     </li>",
"     <li>",
"      The fistula test is positive when pneumatic otoscopy of the intact tympanic membrane results in spinning vertigo and nystagmus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inner ear (otic capsule) &ndash; The inner ear is encased by the bony otic capsule and contains the cochlea, vestibule, and semicircular canals. The bone of the otic capsule is denser than the surrounding petrous portion of the temporal bone. When the otic capsule is fractured, damage to the cochlea with permanent sensorineural hearing loss usually occurs.",
"     </li>",
"     <li>",
"      Facial nerve &ndash; Usually encased in thin bone, the facial nerve exits the internal auditory canal, crosses the middle ear just superior to the oval window and stapes footplate, and then enters the fallopian canal to exit the mastoid via the stylomastoid foramen. From there, it divides into the branches responsible for activity of the muscles of facial expression. During its temporal bone course, the chorda tympani branch &ldquo;leaves&rdquo; the facial nerve to carry special sensory afferent fibers for taste from the anterior two-thirds of the tongue. Injury to the facial nerve results in ipsilateral facial paralysis, which can be either partial or complete. Injury to the chorda tympani results in a loss of taste or a metallic taste to the ipsilateral aspect of the anterior two-thirds of the tongue, which often resolves over time.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Middle ear trauma is typically identified during clinical evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Awake and alert patients with a history of closed head injury or direct ear trauma should be asked about the following symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ear pain",
"     </li>",
"     <li>",
"      Hearing loss",
"     </li>",
"     <li>",
"      Nausea and vomiting",
"     </li>",
"     <li>",
"      Facial weakness",
"     </li>",
"     <li>",
"      Vertigo",
"     </li>",
"     <li>",
"      New onset otorrhea or clear, particularly unilateral, rhinorrhea that is worse with straining (Valsalva) or positioning of the head in a dependent position",
"     </li>",
"     <li>",
"      Imbalance",
"     </li>",
"     <li>",
"      Tinnitus (suggesting concomitant inner ear damage)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient with suspected middle ear trauma should undergo evaluation and management based upon the patient's mechanism of injury and physical findings. The clinician should evaluate unstable patients and those with a high-risk trauma mechanism (",
"    <a class=\"graphic graphic_table graphicRef57293 \" href=\"UTD.htm?0/42/684\">",
"     table 1",
"    </a>",
"    ) according to the principles of advanced trauma life support (ATLS) (",
"    <a class=\"graphic graphic_figure graphicRef64241 \" href=\"UTD.htm?42/51/43834\">",
"     figure 3",
"    </a>",
"    ). Middle ear assessment should be part of the secondary survey in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link\">",
"     \"Trauma management: Approach to the unstable child\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40119?source=see_link\">",
"     \"Approach to the initially stable child with blunt or penetrating injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examination of the ear requires inspection of the auricle and surrounding area; otoscopy of the external canal, tympanic membrane, and middle ear; and, in patients without obvious tympanic membrane perforation, assessment of tympanic membrane function by pneumatic otoscopy (",
"    <a class=\"graphic graphic_movie graphicRef70700 \" href=\"UTD.htm?24/11/24766\">",
"     movie 1",
"    </a>",
"    ). In patients with an intact tympanic membrane decreased motion or immobility of the tympanic membrane, dullness of landmarks, or an air fluid level suggests fluid in the middle ear.",
"   </p>",
"   <p>",
"    In patients with tympanic membrane perforation, pneumatic otoscopy should be deferred to the specialist because it can potentially push air into the otic capsule leading to nystagmus, vertigo, and nausea or vomiting in patients with otic capsule injuries.",
"   </p>",
"   <p>",
"    In cooperative patients above five to six years of age, Weber and Rinne tuning fork tests allow for the assessment of hearing loss (",
"    <a class=\"graphic graphic_table graphicRef74212 \" href=\"UTD.htm?13/29/13787\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef58032 \" href=\"UTD.htm?40/5/41043\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Blood clots in the ear canal in patients with other signs of middle ear trauma should not be removed until the patient is evaluated by an otolaryngologist. In addition, protruding aural foreign bodies should be left in place until they can be fully assessed and removed under controlled conditions by the specialist and possibly in the operating room.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Findings of middle ear injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Middle ear trauma should be suspected in patients with the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemotympanum (",
"      <a class=\"graphic graphic_picture graphicRef62387 \" href=\"UTD.htm?31/17/32031\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Amber or clear middle ear effusion",
"     </li>",
"     <li>",
"      Otorrhea (clear or bloody ear canal drainage)",
"     </li>",
"     <li>",
"      Hearing deficit by Weber and Rinne tuning fork tests (",
"      <a class=\"graphic graphic_table graphicRef74212 \" href=\"UTD.htm?13/29/13787\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef58032 \" href=\"UTD.htm?40/5/41043\">",
"       figure 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nystagmus",
"     </li>",
"     <li>",
"      Ataxia",
"     </li>",
"     <li>",
"      Retroauricular hematoma (Battle sign) (",
"      <a class=\"graphic graphic_picture graphicRef69660 \" href=\"UTD.htm?39/39/40561\">",
"       picture 4",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Battle sign typically appears two days after injury, but may appear within 6 to 12 hours.",
"   </p>",
"   <p>",
"    In young children and the elderly, certain patterns of ear trauma (eg, bilateral auricular hematomas) or major injuries (eg, basilar skull fractures) that are unexplained by history raise suspicion for physical abuse. A complete physical examination should be performed to identify other signs of abuse in these patients. (See",
"    <a class=\"local\" href=\"#H31100408\">",
"     'Child and elder protection'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17850?source=see_link\">",
"     \"Elder mistreatment: Abuse, neglect, and financial exploitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Facial nerve function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Facial nerve deficit may arise from direct trauma to the middle ear or in association with a basilar skull fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/14\">",
"     14",
"    </a>",
"    ]. Facial nerve function is assessed by observing the response to commands for closing the eyes, elevating the brow, and frowning. Patients with a peripheral facial nerve palsy associated with middle ear trauma will have a facial droop associated with weakness of the forehead and eyelid musculature. These patients should be differentiated from those with stroke, in whom forehead and eyelid strength are preserved. The nasolabial folds and cheeks should be symmetrical as the teeth are displayed. Decreased tearing, hyperacusis, loss of taste sensation on the anterior two-thirds of the tongue,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a metallic taste can indicate facial nerve disruption localized to the fallopian canal.",
"   </p>",
"   <p>",
"    Facial response to a painful stimulus may be helpful in patients who are unable to cooperate or have altered mental status. Early assessment is crucial as a predictor of prognosis, and it directs management steps in the setting of facial nerve weakness or paralysis. After initial examination and stabilization, patients with significant trauma may be sedated or comatose. This situation often complicates further evaluation of facial nerve function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ancillary studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with clinical features suggestive of middle ear trauma warrant the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Evaluation of any ear or nose drainage for the presence of cerebrospinal fluid (CSF)",
"     </li>",
"     <li>",
"      Tests of hearing",
"     </li>",
"     <li>",
"      For patients with head trauma",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      who may require operative intervention, temporal bone computed tomography without contrast including fine axial and coronal cuts",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Evaluation of ear or nose drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;To test for cerebrospinal fluid (CSF) leakage, the clinician may perform a quick bedside test by placing a drop of ear or nose drainage on filter paper (coffee filter or paper towel). A rapidly advancing \"halo\" or ring of clear fluid around red blood defines a positive test [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/15\">",
"     15",
"    </a>",
"    ]. Of note, the halo test does NOT differentiate among CSF, saline, saliva, and other clear fluids and has not been formally studied in a clinical setting.",
"   </p>",
"   <p>",
"    Alternatively, the clinician may test the ear or nose drainage for beta2 transferrin, a desialylated form of the protein transferrin, which is almost exclusively found in CSF. A retrospective observational study of 205 beta2 transferrin tests in 182 patients with suspected CSF leak found a sensitivity of 97 percent and a specificity of 99 percent for beta2 transferrin measured in fluid obtained from the nose or ear although all but 11 patients in this study had rhinorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/16\">",
"     16",
"    </a>",
"    ]. Beta2 transferrin assays may not be immediately available in all settings. Frequently, it is a send-out test that can take 72 hours to complete.",
"   </p>",
"   <p>",
"    Urine dipsticks should not be used to determine the presence of CSF by checking for the presence of glucose. This approach is NOT reliable because both blood and CSF contain glucose.",
"   </p>",
"   <p>",
"    Localization of the fistula may require nuclear medicine or an intraoperative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    dye study in which a lumbar puncture is performed and either a radio-labeled sugar or fluorescein dye is injected into the CSF. The site of leakage is then determined either by collection of radio-labeled sugar on pledgets placed in these cavities or by endoscopic identification of the fluorescein dye in the nose or during operative middle ear or mastoid exploration. CSF leaks that persist are associated with higher risks of complication, such as meningitis. Confirmed CSF leaks are treated according to location with techniques, such as fascia grafting, bone grafting, dura grafting,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lumbar drain or shunting. When in doubt about the presence of a CSF leak, it is best to obtain urgent neurosurgical consultation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13704?source=see_link&amp;anchor=H23#H23\">",
"     \"Skull fractures in children\", section on 'Basilar skull fractures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3481?source=see_link&amp;anchor=H15#H15\">",
"     \"Skull fractures in adults\", section on 'Basilar fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Tests of hearing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cooperative and alert patients over the age of four years should be tested with pure tone audiometry. Pure tone audiometry provides an objective assessment of hearing and is helpful in determining management and prognosis. The ability to hear a whisper and symmetric hearing by report may suffice as an initial screening test if pure tone audiometry is not immediately available. However, patients who do not undergo immediate audiometry should be referred to audiology as soon as possible, ideally within 24 hours.",
"   </p>",
"   <p>",
"    Younger children and comatose patients require audiologic consultation and are typically assessed using auditory brainstem response testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link&amp;anchor=H9#H9\">",
"     \"Evaluation of hearing impairment in children\", section on 'Formal audiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation of hearing impairment in children\", section on 'Brainstem response'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hearing loss at a sound level &ge;40 decibels (dB) is highly suggestive of serious middle ear injury.",
"   </p>",
"   <p>",
"    Hearing loss at a sound level &lt;40 decibels (dB) without CSF drainage, vestibular symptoms (eg, nystagmus, vertigo), or facial nerve injury suggests perforation of the tympanic membrane without middle ear injury, middle ear fluid, or baseline hearing.",
"   </p>",
"   <p>",
"    The clinician should not rely solely upon subjective evaluation of the status of the patient's hearing because this approach may miss small tympanic membrane perforations, middle ear fluid, or ossicular discontinuity with the potential for permanent conductive hearing loss. However, when subjective evaluation suggests hearing loss, audiometry and consultation with an otolaryngologist is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporal bone computed tomography (CT) without contrast, including fine cuts in the axial and coronal planes, should be obtained in patients with the following findings [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evidence of basilar skull fracture (eg, CSF otorrhea or rhinorrhea, postauricular hematoma)",
"     </li>",
"     <li>",
"      Patients with head or middle ear trauma and peripheral facial nerve dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Blunt or penetrating middle ear canal trauma with hearing loss at &ge;40 dB or with vestibular symptoms (ie, Tullio's phenomenon, nystagmus or vertigo)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CT may provide better evaluation of the blood-covered structures in patients with hemotympanum and guide medical and surgical decision making. If it is unclear as to whether a CT scan should be obtained, consultation with an otolaryngologist can facilitate judicious management.",
"   </p>",
"   <p>",
"    Of note, a routine head or brain CT scan is inadequate to assess serious middle ear trauma because it contains cuts that are too broad to image the otic capsule, ossicles, and facial nerve accurately. Furthermore, the coronal images are usually reconstructions, which provide significantly less detail than the directly-obtained coronal image (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72168 \" href=\"UTD.htm?41/5/42068\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef78613 \" href=\"UTD.htm?42/21/43344\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61979 \" href=\"UTD.htm?42/24/43398\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In cases where there is suspicion for associated vascular abnormality, a CT-angiogram or CT-venogram may be indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/17\">",
"     17",
"    </a>",
"    ]. A contrast CT of the temporal bone can hamper visualization because extravasation of contrast into the middle ear space as a result of ongoing bleeding may white-out the mastoid cavity and prevent visualization of fractures or identification of the vascular culprit. Thus, the noncontrast temporal bone CT should be obtained before contrast is given. Depending upon the mechanism of injury, a head CT may also need to be obtained in additional to temporal bone imaging.",
"   </p>",
"   <p>",
"    <br/>",
"    Although magnetic resonance imaging can be used preoperatively to evaluate the central nervous system and cerebrovascular anatomy; it does not add additional information to the evaluation of the bony structures such as the ossicles and the fracture line than temporal bone CT [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR OTOLARYNGOLOGY CONSULTATION OR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following findings warrant prompt involvement of an otolaryngologist after middle ear trauma once life-threatening conditions are addressed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hearing loss &ge;40 dB by formal audiometry or subjective decreased perception of normal speech, marked asymmetry, or persisting feelings of fullness in an ear",
"     </li>",
"     <li>",
"      Basilar skull fracture in conjunction with evaluation by a neurosurgeon",
"     </li>",
"     <li>",
"      Suspected cerebrospinal fluid otorrhea or rhinorrhea",
"     </li>",
"     <li>",
"      Facial nerve",
"      <span class=\"nowrap\">",
"       paralysis/paresis",
"      </span>",
"     </li>",
"     <li>",
"      Vestibular symptoms (nausea, vomiting, nystagmus, ataxia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment recommendations are based upon observational studies and case series [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/4,5,10,19,20\">",
"     4,5,10,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Initial stabilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Victims of major trauma require an initial primary survey for life-threatening injuries before the emergency provider focuses on middle ear injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link\">",
"     \"Trauma management: Approach to the unstable child\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with significant facial injury sustained during major trauma warrant cervical spine immobilization until appropriate assessment and diagnostic imaging of the neck are performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=see_link\">",
"     \"Pediatric cervical spine immobilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Protruding aural foreign bodies with bleeding should be left in place until they can be fully assessed and removed under controlled conditions by a specialist and possibly in the operating room.",
"   </p>",
"   <p>",
"    Contaminated middle ear wounds are considered tetanus prone and require tetanus prophylaxis, as needed (",
"    <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Minimal hearing loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tympanic membrane perforation with minimal hearing loss (decreased perception of whisper, minor asymmetry or &lt;40 dB on formal audiometry) and absence of vestibular findings (eg, nystagmus, vomiting, ataxia) or facial nerve weakness is treated as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Water precautions (keeping water out of the ear)",
"     </li>",
"     <li>",
"      Antibiotic ear drops (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"       ofloxacin",
"      </a>",
"      otic drops, five drops in the affected ear two times per day for three to five days) for contaminated wounds (eg, external puncture, perforation with water contamination) and canals occluded with blood or drainage in patients with findings of middle ear trauma",
"     </li>",
"     <li>",
"      Reexamination by the primary care provider in four weeks with audiometry to evaluate for healing of the tympanic membrane and restoration of normal hearing",
"     </li>",
"     <li>",
"      Otolaryngological evaluation for patients with persistent perforation or hearing loss longer than four weeks after injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Perforation of the tympanic membrane (TM) that is less than 25 percent of the total drum surface area will often heal spontaneously within four weeks in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/21\">",
"     21",
"    </a>",
"    ]. Persistent perforations typically require operative repair.",
"   </p>",
"   <p>",
"    Although most TM perforations have clean margins, those that fold portions of the membrane into the middle ear may develop into cholesteatomas. Recognition of these lesions requires microscopic otoscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42808?source=see_link\">",
"     \"Cholesteatoma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Marked hearing loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that patients with middle ear trauma and hearing loss (decreased perception of normal speech, marked asymmetry or &ge;40 dB on formal audiometry), vestibular signs (eg, nystagmus, vomiting, ataxia), findings that indicate basilar skull fracture, or facial nerve injury undergo prompt evaluation by an otolaryngologist. Definitive treatment depends upon the specific injury that is identified. Additional measures include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Water precautions (keeping water out of the ear)",
"     </li>",
"     <li>",
"      Antibiotic ear drops (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"       ofloxacin",
"      </a>",
"      otic drops, five drops in the affected ear two times per day for three to five days) for contaminated wounds (eg, external puncture, perforation with water contamination) and canals occluded with blood or drainage in patients with findings of middle ear trauma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional treatment depends on the specific injury:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ossicle injury &ndash; Ossicular disruption, such as footplate subluxation or ossicular discontinuity requires diagnosis and surgical repair within 48 hours of the injury to obtain the best outcomes. Surgical treatment involves middle ear exploration under general anesthesia with relocation or replacement of ossicles [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/10\">",
"       10",
"      </a>",
"      ]. Neglected injuries may result in permanent fixation of the ossicles with significant conductive hearing loss.",
"     </li>",
"     <li>",
"      Facial nerve injury &ndash; Immediate facial nerve paralysis after middle ear or head injury warrants urgent consultation with an otolaryngologist and typically requires surgical intervention [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/4,14,19\">",
"       4,14,19",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Delayed paralysis of the facial nerve occurring more than one day after injury typically reflects swelling of the nerve within its bony canal and is predominantly managed medically with intravenous glucocorticoid therapy. Studies of operative decompression suggest no improvement in outcome and note the potential risk of iatrogenic facial nerve injury during surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Perilymph fistula &ndash; Suspected perilymph fistula requires evaluation by the otolaryngologist to determine the need for urgent middle ear exploration and closure of the fistulous connection with the inner ear [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/5,12,13\">",
"       5,12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Basilar skull fracture with CSF leakage &ndash; The management of basilar skull fracture with CSF leakage is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3481?source=see_link&amp;anchor=H10#H10\">",
"       \"Skull fractures in adults\", section on 'Basilar skull fracture'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13704?source=see_link&amp;anchor=H23#H23\">",
"       \"Skull fractures in children\", section on 'Basilar skull fractures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cochlear concussion &ndash; Cochlear concussion can cause temporary or permanent sensorineural hearing loss and has no specific therapy. Patients with permanent hearing loss should protect the unaffected ear from loud noises or excess barometric pressure (eg, scuba diving).",
"     </li>",
"     <li>",
"      Otic capsule injury &ndash; Otic capsule disruption usually causes profound sensorineural hearing loss and has no specific therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/20\">",
"       20",
"      </a>",
"      ]. Patients with permanent hearing loss should protect the unaffected ear from loud noises or excess barometric pressure (eg, scuba diving).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31100408\">",
"    <span class=\"h2\">",
"     Child and elder protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cases where child abuse is suspected, involvement of an experienced child protection team is crucial and in many parts of the world (including the US, UK, and Australia) reporting to a governmental agency is mandatory.",
"    <strong>",
"    </strong>",
"    The safety of other children in the home must be ensured by local Child Protective Services. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=see_link&amp;anchor=H3#H3\">",
"     \"Child abuse: Social and medicolegal issues\", section on 'Reporting suspected abuse'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly, suspected elder abuse often requires involvement of social work, law enforcement, and, if available, adult protective services. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17850?source=see_link\">",
"     \"Elder mistreatment: Abuse, neglect, and financial exploitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with simple tympanic membrane perforation and hearing that is normal or shows a deficit of &lt;40 dB may be discharged to home care with appropriate treatment and follow-up as previously discussed. If audiometry is not urgently available, it should be performed within 24 hours of injury so that ossicle disruption or subluxation, if present, is detected and operative intervention can occur. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Minimal hearing loss'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following conditions warrant hospital admission for observation, operative repair, or both:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute basilar skull fracture (especially with cerebrospinal fluid leak)",
"     </li>",
"     <li>",
"      Ossicular disruption",
"     </li>",
"     <li>",
"      Acute traumatic facial nerve paralysis",
"     </li>",
"     <li>",
"      Perilymph fistula",
"     </li>",
"     <li>",
"      Refractory",
"      <span class=\"nowrap\">",
"       nausea/vomiting",
"      </span>",
"      may require intravenous fluid management and antiemetics, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"       ondansetron",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these conditions and when audiometry is available, patients with hearing loss at &ge;40 dB often have an associated condition that warrants hospital admission for definitive otolaryngological evaluation and treatment. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Marked hearing loss'",
"    </a>",
"    above.) For example, ossicular disruption may be associated with a perilymph fistula and persisting, severe, acute nausea and vomiting or nystagmus and gait instability with significant fall risk. The former may be treated with hospitalization for intravenous fluid administration and treatment with non-vestibulosuppressive antiemetics, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    ; the latter may require restriction to bedrest until gait symptoms subside.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hearing loss, persistent facial nerve palsy, and cerebrospinal fluid fistula with significant risk for meningitis comprise the major long-term complications of middle ear trauma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hearing loss &ndash; When hearing loss accompanies middle ear trauma, recovery rates vary depending on the type of injury [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/9\">",
"       9",
"      </a>",
"      ]. Conductive hearing loss is often reversible and is amenable to surgical therapy. Sensorineural hearing loss is generally anticipated to be permanent. There are no surgical interventions and it may not be amenable to amplification with hearing aids. Specific outcomes include [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/22\">",
"       22",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Conductive hearing loss caused by tympanic membrane (TM) perforation, hemotympanum, or serous or CSF middle ear effusion will resolve with healing of the TM pathology or resolution of the middle ear fluid [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/23\">",
"       23",
"      </a>",
"      ]. Persistent tympanic membrane perforations can be repaired with good results. Persistent middle ear effusion can be alleviated with resultant improved hearing with myringotomy with or without ventilation tube placement. A persistent serous drainage after tube placement is concerning for ongoing CSF leak which should be evaluated. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Evaluation of ear or nose drainage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with persistent pure conductive hearing loss related to ossicular disruption or stapes footplate subluxation, surgical repair or hearing aids are likely to fully or partially restore lost hearing. Ossicular disruption can be treated by ossiculoplasty; however, it remains nearly impossible to guarantee that surgical intervention would be completely restorative. Hearing losses less than 40 dB are less likely to benefit from surgical intervention.",
"     </li>",
"     <li>",
"      Sensorineural hearing loss in association with ossicular disruption or stapes footplate subluxation may be stabilized by urgent surgical repair within 72 hours; complete recovery of hearing in this setting is unlikely.",
"     </li>",
"     <li>",
"      Cochlear concussion results in temporary or permanent sensorineural hearing loss. When hearing loss is persistent, it varies from an isolated sensorineural deficit at less than 40 dB to profound hearing loss.",
"     </li>",
"     <li>",
"      Sensorineural hearing loss in association with otic capsule disruption is usually severe to profound and is not improved by surgery or hearing aids. Bilateral injuries resulting in profound hearing loss would qualify a patient for consideration for cochlear implantation as therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have sustained a perilymphatic fistula, sensorineural hearing loss usually persists, but vestibular symptoms typically resolve spontaneously within 48 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/24\">",
"       24",
"      </a>",
"      ]. Patients with prolonged vertigo caused by middle ear trauma often benefit with full recovery after surgical repair.",
"     </li>",
"     <li>",
"      Traumatic facial nerve injuries &ndash; Outcomes for traumatic facial nerve paralysis vary dramatically depending upon the mechanism of injury, time at diagnosis, medical treatment steps taken and surgical treatment steps required [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/4,25\">",
"       4,25",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Injuries that present with initial facial movement and are later complicated by the development of facial nerve paralysis tend toward full functional recoveries. However, bone shards clearly visualized as embedded in the nerve on CT scanning can be removed with similar good outcomes.",
"     </li>",
"     <li>",
"      Post-injury edema can often be managed with intravenous steroids. Functional recovery is good in most patients who by electroneurography (ENG) continue to have no more than 90 percent degeneration and is unlikely to warrant surgical intervention. Debate remains regarding the benefit of nerve decompression if there is greater than 90 percent degeneration between days 3 and 14 after injury.",
"     </li>",
"     <li>",
"      A clear impaction (eg, bone shard in nerve) or transection injury (eg, gunshot wound) with nerve tissue loss usually presents with immediate and complete facial nerve paralysis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/4\">",
"       4",
"      </a>",
"      ]. In this event, it is unlikely that the nerve will regain function and highly likely that a facial nerve reinnervation procedure will be necessary. Reinnervation procedures via interposition nerve grafting are complicated by synkinesis, wherein there is lack of organization to the reinnervation process and multiple motor units fire simultaneously. In the case of repair of facial nerve injury delayed by years, results are less predictable and the restoration of function using the nerve itself is less successful due to motor unit atrophy caused by the prolonged lack of nutritive footplate signaling.",
"      <span class=\"nowrap\">",
"       Nerve/muscle",
"      </span>",
"      tissue transfer procedures are more successful but remain limited by the donor",
"      <span class=\"nowrap\">",
"       nerve/muscle",
"      </span>",
"      group placement (eg, gracilis muscle to cross facial jump graft) to and donor nerve function (ie, hypoglossal or trigeminal jump graft).",
"     </li>",
"     <li>",
"      Delayed facial nerve paralysis in the setting of basilar skull fracture of the temporal bones is associated with normal or near normal recovery in most patients by three months. Recovery may take as long as one year in some patients [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Traumatic CSF fistula &ndash; Observational evidence suggests that the risk of meningitis is significantly increased in patients with a CSF leak after a middle ear injury, especially those patients whose drainage lasts longer than seven days. In a case series of 122 patients, most of whom had otorrhea, the risk of meningitis was 3 percent among patients who experienced spontaneous resolution of the leak within seven days [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/4\">",
"       4",
"      </a>",
"      ]. The frequency of meningitis increased to 22 percent in patients with CSF leakage beyond seven days. Prophylactic antibiotics did not appear to prevent meningitis unless obvious local infection was present. However, an adequate course of antibiotics was administered in only 22 percent of patients in this case series [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5593/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/45/36561?source=see_link\">",
"       \"Patient information: Ruptured eardrum (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Middle ear injury may occur after head injury and blunt or penetrating trauma to the ear. Damage may involve the ossicles, facial nerve, oval window,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inner ear. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Relevant anatomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Clinical findings",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient with suspected middle ear trauma should undergo evaluation and management based on the patient's mechanism of injury and physical findings. The clinician should evaluate unstable patients and those with a high risk trauma mechanism (",
"      <a class=\"graphic graphic_table graphicRef57293 \" href=\"UTD.htm?0/42/684\">",
"       table 1",
"      </a>",
"      ) according to the principles of advanced trauma life support (ATLS) (",
"      <a class=\"graphic graphic_figure graphicRef64241 \" href=\"UTD.htm?42/51/43834\">",
"       figure 3",
"      </a>",
"      ). Middle ear assessment should be part of the secondary survey in these patients. The immediate functional status of the facial nerve should also be observed and documented as part of the secondary survey. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blood clots in the ear canal should not be removed until the patient is evaluated by an otolaryngologist (ENT surgeon). In addition, protruding aural foreign bodies should be left in place until they can be fully assessed and removed under controlled conditions by an otolaryngologist. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Historical features that suggest serious trauma to the middle or inner ear include hearing loss, facial weakness, vertigo, nausea and vomiting, otorrhea,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ataxia. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Concerning findings on physical examination include otorrhea, rhinorrhea, hemotympanum (",
"      <a class=\"graphic graphic_picture graphicRef62387 \" href=\"UTD.htm?31/17/32031\">",
"       picture 1",
"      </a>",
"      ), serous middle ear effusion, facial nerve weakness, abnormal Rinne and Weber tuning forks tests, nystagmus, or Battle sign (ecchymosis over the",
"      <span class=\"nowrap\">",
"       mastoid/occiput).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Facial nerve function'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Findings of middle ear injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with clinical features suggestive of middle ear trauma warrant the following studies (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Ancillary studies'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Evaluation of any ear or nose drainage for the presence of cerebrospinal fluid (CSF)",
"     </li>",
"     <li>",
"      Tests of hearing",
"     </li>",
"     <li>",
"      For patients with head trauma, temporal bone computed tomography without contrast including fine axial and coronal cuts",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following findings warrant prompt involvement by an otolaryngologist after middle ear trauma once life-threatening conditions are addressed (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Indications for otolaryngology consultation or referral'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hearing loss &ge;40 dB if formal audiometry is available, or a subjectively decreased ability to hear a whisper or asymmetric appreciation of sounds between the two ears",
"     </li>",
"     <li>",
"      Basilar skull fracture in conjunction with a neurosurgeon",
"     </li>",
"     <li>",
"      Otorrhea or rhinorrhea",
"     </li>",
"     <li>",
"      Facial nerve paralysis",
"     </li>",
"     <li>",
"      Vestibular symptoms (nausea, vomiting, nystagmus, ataxia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with small isolated tympanic membrane perforation &lt;25 percent in size and minimal hearing loss (&lt;40 dB, decreased perception of whisper or minor asymmetry) may be managed with water precautions (keeping water out of the ear), antibiotic otic drops (for contaminated wounds), recommendation for audiometry within 24 hours if not previously obtained, and follow-up in four weeks to ensure that the perforation is closed and hearing deficit has resolved. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Minimal hearing loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with middle ear trauma and hearing loss &ge;40 dB, vestibular signs (eg, nystagmus, vomiting, ataxia), findings that indicate basilar skull fracture, or facial nerve injury undergo evaluation by an otolaryngologist emergently if possible, but at least within 48 hours of injury (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Definitive treatment depends upon the specific injury that is identified. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Marked hearing loss'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31329955\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5593/abstract/1\">",
"      Ort S, Beus K, Isaacson J. Pediatric temporal bone fractures in a rural population. Otolaryngol Head Neck Surg 2004; 131:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5593/abstract/2\">",
"      Lee D, Honrado C, Har-El G, Goldsmith A. Pediatric temporal bone fractures. Laryngoscope 1998; 108:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5593/abstract/3\">",
"      Zimmerman WD, Ganzel TM, Windmill IM, et al. Peripheral hearing loss following head trauma in children. Laryngoscope 1993; 103:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5593/abstract/4\">",
"      Brodie HA, Thompson TC. Management of complications from 820 temporal bone fractures. Am J Otol 1997; 18:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5593/abstract/5\">",
"      Kim SH, Kazahaya K, Handler SD. Traumatic perilymphatic fistulas in children: etiology, diagnosis and management. Int J Pediatr Otorhinolaryngol 2001; 60:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5593/abstract/6\">",
"      Mirza S, Richardson H. Otic barotrauma from air travel. J Laryngol Otol 2005; 119:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5593/abstract/7\">",
"      Keogh IJ, Portmann D. Drop weld thermal injuries to the middle ear. Rev Laryngol Otol Rhinol (Bord) 2009; 130:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5593/abstract/8\">",
"      Wohlgelernter J, Gross M, Eliashar R. Traumatic perforation of tympanic membrane by cotton tipped applicator. J Trauma 2007; 62:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5593/abstract/9\">",
"      Lasak JM, Van Ess M, Kryzer TC, Cummings RJ. Middle ear injury through the external auditory canal: a review of 44 cases. Ear Nose Throat J 2006; 85:722, 724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5593/abstract/10\">",
"      Neuenschwander MC, Deutsch ES, Cornetta A, Willcox TO. Penetrating middle ear trauma: a report of 2 cases. Ear Nose Throat J 2005; 84:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5593/abstract/11\">",
"      Friedland DR, Wackym PA. A critical appraisal of spontaneous perilymphatic fistulas of the inner ear. Am J Otol 1999; 20:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5593/abstract/12\">",
"      Minor LB. Labyrinthine fistulae: pathobiology and management. Curr Opin Otolaryngol Head Neck Surg 2003; 11:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5593/abstract/13\">",
"      Maitland CG. Perilymphatic fistula. Curr Neurol Neurosci Rep 2001; 1:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5593/abstract/14\">",
"      Iloreta AM, Malkin BD. Facial nerve paralysis following transtympanic penetrating middle ear trauma. Ear Nose Throat J 2011; 90:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5593/abstract/15\">",
"      Dula DJ, Fales W. The 'ring sign': is it a reliable indicator for cerebral spinal fluid? Ann Emerg Med 1993; 22:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5593/abstract/16\">",
"      Warnecke A, Averbeck T, Wurster U, et al. Diagnostic relevance of beta2-transferrin for the detection of cerebrospinal fluid fistulas. Arch Otolaryngol Head Neck Surg 2004; 130:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5593/abstract/17\">",
"      Johnson F, Semaan MT, Megerian CA. Temporal bone fracture: evaluation and management in the modern era. Otolaryngol Clin North Am 2008; 41:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5593/abstract/18\">",
"      Aguilar EA 3rd, Yeakley JW, Ghorayeb BY, et al. High resolution CT scan of temporal bone fractures: association of facial nerve paralysis with temporal bone fractures. Head Neck Surg 1987; 9:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5593/abstract/19\">",
"      Evans AK, Licameli G, Brietzke S, et al. Pediatric facial nerve paralysis: patients, management and outcomes. Int J Pediatr Otorhinolaryngol 2005; 69:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5593/abstract/20\">",
"      Fitzgerald DC. Head trauma: hearing loss and dizziness. J Trauma 1996; 40:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5593/abstract/21\">",
"      Orji FT, Agu CC. Determinants of spontaneous healing in traumatic perforations of the tympanic membrane. Clin Otolaryngol 2008; 33:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5593/abstract/22\">",
"      Yetiser S, Hidir Y, Birkent H, et al. Traumatic ossicular dislocations: etiology and management. Am J Otolaryngol 2008; 29:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5593/abstract/23\">",
"      Orji FT, Agu CC. Patterns of hearing loss in tympanic membrane perforation resulting from physical blow to the ear: a prospective controlled cohort study. Clin Otolaryngol 2009; 34:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5593/abstract/24\">",
"      Weber PC, Bluestone CD, Perez B. Outcome of hearing and vertigo after surgery for congenital perilymphatic fistula in children. Am J Otolaryngol 2003; 24:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5593/abstract/25\">",
"      Greywoode JD, Ho HH, Artz GJ, Heffelfinger RN. Management of traumatic facial nerve injuries. Facial Plast Surg 2010; 26:511.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6544 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-60.18.131.125-8F74BD76B3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_29_5593=[""].join("\n");
var outline_f5_29_5593=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RELEVANT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Middle ear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ossicles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Adjacent structures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Findings of middle ear injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Facial nerve function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ancillary studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Evaluation of ear or nose drainage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Tests of hearing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      INDICATIONS FOR OTOLARYNGOLOGY CONSULTATION OR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Initial stabilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Minimal hearing loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Marked hearing loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31100408\">",
"      Child and elder protection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Clinical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31329955\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6544\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6544|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/5/42068\" title=\"diagnostic image 1\">",
"      Middle ear CT axial view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/24/43398\" title=\"diagnostic image 2\">",
"      CT middle ear trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6544|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/57/21400\" title=\"figure 1\">",
"      Ear anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/51/17204\" title=\"figure 2\">",
"      Mastoid anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/51/43834\" title=\"figure 3\">",
"      Initial trauma management in the severely injured child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/5/41043\" title=\"figure 4\">",
"      Weber and Rinne tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/21/43344\" title=\"figure 5\">",
"      Temporal bone fx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6544|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/17/32031\" title=\"picture 1\">",
"      Traumatic hemotympanum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/31/22015\" title=\"picture 2\">",
"      Perforation of TM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/34/27168\" title=\"picture 3\">",
"      Ossicular disruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/39/40561\" title=\"picture 4\">",
"      Battles sign",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6544|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?24/11/24766\" title=\"movie 1\">",
"      otoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6544|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/42/684\" title=\"table 1\">",
"      High risk trauma mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/29/13787\" title=\"table 2\">",
"      Interpreting Weber and Rinne tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/52/8013\" title=\"table 3\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40119?source=related_link\">",
"      Approach to the initially stable child with blunt or penetrating injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=related_link\">",
"      Child abuse: Social and medicolegal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42808?source=related_link\">",
"      Cholesteatoma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35397?source=related_link\">",
"      Ear barotrauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17850?source=related_link\">",
"      Elder mistreatment: Abuse, neglect, and financial exploitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/45/36561?source=related_link\">",
"      Patient information: Ruptured eardrum (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=related_link\">",
"      Pediatric cervical spine immobilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3481?source=related_link\">",
"      Skull fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13704?source=related_link\">",
"      Skull fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_29_5594="Definition and staging of chronic kidney disease";
var content_f5_29_5594=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Definition and staging of chronic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/29/5594/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/29/5594/contributors\">",
"     Andrew S Levey, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/29/5594/contributors\">",
"     Lesley A Inker, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/29/5594/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/29/5594/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/29/5594/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/29/5594/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/29/5594/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H27258226\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition and classification of chronic kidney disease (CKD) guidelines were introduced by the National Kidney Foundation (NKF) Kidney Disease Outcomes Quality Initiative (KDOQI) in 2002, and were subsequently adopted with minor modifications by the international guideline group Kidney Disease Improving Global Outcomes (KDIGO) in 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These CKD guidelines shifted the concept of kidney disease from that of an uncommon life-threatening condition requiring care by nephrologists to that of a common condition with a range of severity meriting attention by general internists, and demanding strategies for prevention, early detection, and management [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The guidelines had a major effect on clinical practice, research, and public health, but also generated substantial controversy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/6-11\">",
"     6-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most recent definition and classification of CKD will be addressed here. Discussions pertaining to the assessment of kidney function, the epidemiology of CKD, screening for CKD, evaluation of patients with CKD, overview of the management of CKD, and the association between CKD and cardiovascular disease are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/32/521?source=see_link\">",
"     \"Epidemiology of chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28966?source=see_link\">",
"     \"Screening for chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=see_link\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1054473\">",
"    <span class=\"h1\">",
"     CONTROVERSIES ADDRESSED BY THE NEW GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2009, KDIGO convened a Controversies Conference to address key areas of controversy and review data on more than 1.5 million individuals from 45 cohorts that was assembled by the CKD Prognosis Consortium [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. The following controversies were among those discussed:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Should the albuminuria threshold to define CKD continue to be 30",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (or equivalent)?",
"     </li>",
"     <li>",
"      Should the GFR threshold to define CKD continue to be 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      ?",
"     </li>",
"     <li>",
"      Should the glomerular filtration rate (GFR) threshold used to define CKD depend upon age?",
"     </li>",
"     <li>",
"      Should patients diagnosed as having CKD be staged based upon albuminuria in addition to GFR?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Conference attendees recommended, by at least a two-thirds majority vote, that the previous KDOQI and KDIGO definitions of CKD be retained, but that the classification be modified to include the cause of disease and albuminuria staging [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/12\">",
"     12",
"    </a>",
"    ]. The rationale behind these decisions is discussed in the sections that follow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27258404\">",
"    <span class=\"h1\">",
"     DEFINITION AND STAGING OF CHRONIC KIDNEY DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27258373\">",
"    <span class=\"h2\">",
"     Framework and conceptual model",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with KDOQI and KDIGO that CKD is a heterogeneous group of disorders characterized by alterations in kidney structure and function, which manifest in various ways depending upon the underlying cause or causes and the severity of disease (",
"    <a class=\"graphic graphic_figure graphicRef77385 \" href=\"UTD.htm?1/55/1919\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. Risk factors for CKD include genetic or sociodemographic predisposition, or the presence of diseases which can initiate and propagate kidney disease. Kidney failure is the end-stage of CKD and is defined as severely reduced kidney function or treatment with dialysis. The term \"end-stage renal disease\" (ESRD) generally refers to chronic kidney failure treated with either dialysis or transplantation. Acute kidney injury (AKI) may complicate CKD and hasten its progression [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28966?source=see_link&amp;anchor=H24215381#H24215381\">",
"     \"Screening for chronic kidney disease\", section on 'Risk factors for CKD'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the management of chronic kidney disease in adults\", section on 'Natural history of renal disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42773?source=see_link\">",
"     \"Definition of acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CKD is usually asymptomatic in its early stages. Symptoms appear in later stages in association with complications (",
"    <a class=\"graphic graphic_figure graphicRef77385 \" href=\"UTD.htm?1/55/1919\">",
"     figure 1",
"    </a>",
"    ). In addition to commonly recognized hormonal and metabolic complications such as anemia and hyperparathyroidism, CKD complications include increased risks for systemic drug toxicity, cardiovascular disease, infection, cognitive impairment, and impaired physical function [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. Complications are more likely to occur at later stages, and may lead to death before kidney disease progresses to kidney failure. Complications may also arise from the adverse effects of interventions used to prevent or treat the disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the management of chronic kidney disease in adults\", section on 'Treatment of the complications of renal dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27258481\">",
"    <span class=\"h2\">",
"     Definition of CKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the KDOQI and KDIGO guidelines that CKD is defined by the presence of kidney damage",
"    <strong>",
"     or",
"    </strong>",
"    decreased kidney function",
"    <strong>",
"     for three or more months",
"    </strong>",
"    , irrespective of the cause (",
"    <a class=\"graphic graphic_table graphicRef80632 \" href=\"UTD.htm?21/62/22509\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/23\">",
"     23",
"    </a>",
"    ]. The persistence of the damage or decreased function for at least three months is",
"    <strong>",
"     necessary",
"    </strong>",
"    to distinguish CKD from acute kidney disease. Kidney damage refers to pathologic abnormalities, whether established via renal biopsy or imaging studies, or inferred from markers such as urinary sediment abnormalities or increased rates of urinary albumin excretion. Decreased kidney function refers to a decreased glomerular filtration rate (GFR), which is usually estimated (eGFR) using serum creatinine and one of several available equations.",
"   </p>",
"   <p>",
"    A discussion of the limitations of GFR estimation, including problems associated with using the serum creatinine in patients who are not in steady-state (such as hospitalized patients) and those with diminished creatinine generation, is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An important aspect of the definition is that the criteria are objective and can be ascertained by means of simple laboratory tests. Identifying patients with CKD can therefore be done without identification of the underlying cause and without consultation with a nephrologist. However, many patients should, under the circumstances outlined below, be referred to a nephrologist or other specialist with expertise in evaluating and managing patients with CKD in order to identify the cause of the CKD and to provide recommendations for therapies to reverse the kidney disease, slow progression, or treat complications. (See",
"    <a class=\"local\" href=\"#H923217\">",
"     'Referral to a specialist'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25640?source=see_link\">",
"     \"Late referral to nephrologists of patients with chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27258566\">",
"    <span class=\"h3\">",
"     Kidney damage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kidney damage includes pathologic abnormalities in the native or transplanted kidney. Kidney damage is identified in most cases by the presence of one of the following clinical markers (",
"    <a class=\"graphic graphic_table graphicRef80632 \" href=\"UTD.htm?21/62/22509\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Albuminuria &minus; In clinical practice, albuminuria is the most frequently assessed marker of kidney damage. Albuminuria reflects increased glomerular permeability to macromolecules [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/24\">",
"       24",
"      </a>",
"      ]. Albuminuria may reflect primary kidney disease or kidney involvement in systemic disease. In particular, albuminuria may represent widespread endothelial dysfunction, such as can be seen with hypertension, diabetes, hypercholesterolemia, smoking, obesity, and other disorders.",
"      <br/>",
"      <br/>",
"      Although a number of different measurement methods have been used to assess and define albuminuria (",
"      <a class=\"graphic graphic_table graphicRef56286 \" href=\"UTD.htm?38/25/39324\">",
"       table 2",
"      </a>",
"      ), the albumin-to-creatinine ratio (ACR) in an untimed \"spot\" urine has many advantages [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. The generally accepted threshold for an abnormally elevated ACR is 30",
"      <span class=\"nowrap\">",
"       mg/g",
"      </span>",
"      (3.4",
"      <span class=\"nowrap\">",
"       mg/mol)",
"      </span>",
"      or greater. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=see_link\">",
"       \"Microalbuminuria in type 1 diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=see_link\">",
"       \"Microalbuminuria in type 2 diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=see_link\">",
"       \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32041?source=see_link\">",
"       \"Overview of heavy proteinuria and the nephrotic syndrome\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      We agree with the KDIGO recommendation that albuminuria above this threshold, regardless of cause, should be considered part of the definition of CKD. Individuals with a urine ACR &gt;30",
"      <span class=\"nowrap\">",
"       mg/g",
"      </span>",
"      (or equivalent) have a significantly increased risk for all-cause and cardiovascular mortality, ESRD, AKI and CKD progression compared with those who have a lower ACR (",
"      <a class=\"graphic graphic_figure graphicRef68921 \" href=\"UTD.htm?40/46/41701\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef58089 \" href=\"UTD.htm?27/44/28360\">",
"       figure 3",
"      </a>",
"      ), even when eGFR is normal [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/12,14-16,23\">",
"       12,14-16,23",
"      </a>",
"      ]. As an example, individuals with an ACR of 30 to 299",
"      <span class=\"nowrap\">",
"       mg/g",
"      </span>",
"      (3.4 to 34",
"      <span class=\"nowrap\">",
"       mg/mmol)",
"      </span>",
"      or equivalent and an eGFR of 90 to 105",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      had an 11-fold higher relative risk for ESRD than those whose eGFR was similar but whose ACR was below 30",
"      <span class=\"nowrap\">",
"       mg/g.",
"       <br/>",
"       <br/>",
"       In",
"      </span>",
"      the KDOQI and KDIGO definition, the threshold value for abnormally elevated urine ACR (30",
"      <span class=\"nowrap\">",
"       mg/g",
"      </span>",
"      or higher) is applied to adults of all ages, both men and women, and all racial-ethnic groups, despite differences in creatinine excretion rate by age, sex and race. When this single threshold was applied to a population-based cohort in the United States, the prevalence of albuminuria was significantly greater in women compared with men [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/27\">",
"       27",
"      </a>",
"      ]. Although urinary albumin concentrations were similar, women had lower urinary creatinine concentrations. Thus, sex-specific ACR thresholds that better predict a 24-hour urinary albumin excretion of 30 mg or higher (&ge;25",
"      <span class=\"nowrap\">",
"       mg/g",
"      </span>",
"      for women and &ge;17",
"      <span class=\"nowrap\">",
"       mg/g",
"      </span>",
"      for men) have been used in some studies [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/28\">",
"       28",
"      </a>",
"      ]. However, we agree with the KDIGO recommendation to use a common albuminuria threshold for all adults due to the ease of widespread implementation. Albumin excretion rate in a timed urine collection can be used for confirmation when clinical circumstances require more accurate measurement.",
"     </li>",
"     <li>",
"      Urinary sediment abnormalities &minus; Urinary sediment abnormalities such as red or white blood cell casts may indicate the presence of glomerular injury or tubular inflammation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link\">",
"       \"Urinalysis in the diagnosis of kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Imaging abnormalities &minus; Kidney damage may be detected by the presence of imaging abnormalities such as polycystic kidneys, hydronephrosis, and small and echogenic kidneys. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39509?source=see_link\">",
"       \"Radiologic assessment of renal disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pathologic abnormalities &minus; A kidney biopsy may reveal evidence for glomerular, vascular, or tubulointerstitial disease.",
"     </li>",
"     <li>",
"      Kidney transplantation &minus; Patients with a history of kidney transplantation are assumed to have kidney damage whether or not they have documented abnormalities on kidney biopsy or markers of kidney damage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27258759\">",
"    <span class=\"h3\">",
"     Decreased GFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;GFR is generally considered to be the best index of overall kidney function, and declining GFR is the hallmark of progressive kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/29\">",
"     29",
"    </a>",
"    ]. Measured GFR varies in normal individuals by age and sex (",
"    <a class=\"graphic graphic_figure graphicRef73824 \" href=\"UTD.htm?41/31/42486\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/30\">",
"     30",
"    </a>",
"    ], dietary protein intake, and possibly by race-ethnicity, although the magnitude of racial variations are not well known. Based on a clearance measurements in healthy people and in people with kidney disease, the widely accepted threshold defining a decreased GFR is less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ; kidney failure is defined as a GFR &lt;15",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    or treatment by dialysis (",
"    <a class=\"graphic graphic_table graphicRef80632 \" href=\"UTD.htm?21/62/22509\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    We agree with KDIGO that a measured GFR below this threshold should be considered part of the definition of CKD. GFR can be measured directly using the clearance of exogenous filtration markers such as inulin or iothalamate [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/31\">",
"     31",
"    </a>",
"    ]. However, these measurement methods are complex to implement. Thus, in clinical practice, GFR is typically",
"    <strong>",
"     estimated",
"    </strong>",
"    (estimated GFR, or eGFR) from the serum concentration of creatinine, an endogenous filtration marker. The eGFR is now reported routinely by more than 75 percent of clinical laboratories in the US whenever the serum creatinine is measured [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/32\">",
"     32",
"    </a>",
"    ]. Serum creatinine is measured frequently (about 280 million times per year in the US), and eGFR reporting has led to increased detection of CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In routine practice, therefore, individuals who have an eGFR below 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    are defined as having CKD. These individuals have a significantly increased risk for all-cause and cardiovascular mortality, ESRD, AKI and CKD progression in compared with those whose eGFR is 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    or higher (",
"    <a class=\"graphic graphic_figure graphicRef68921 \" href=\"UTD.htm?40/46/41701\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef58089 \" href=\"UTD.htm?27/44/28360\">",
"     figure 3",
"    </a>",
"    ), even if the ACR is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/12,14-16,23\">",
"     12,14-16,23",
"    </a>",
"    ]. As an example, individuals with an eGFR of 45 to 59",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    and a urine ACR less than 10",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    had a fivefold higher relative risk of ESRD compared than those with a similarly normal ACR but with an eGFR of 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    or greater.",
"   </p>",
"   <p>",
"    However, as noted below, we do not generally recommend that patients who have an isolated decreased eGFR (eg, an eGFR of 45 to 59",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    without an elevation in albuminuria) be referred for care by a nephrologist or other specialist with expertise in caring for patients with kidney disease. (See",
"    <a class=\"local\" href=\"#H923217\">",
"     'Referral to a specialist'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26100367\">",
"    <span class=\"h4\">",
"     Similar thresholds for the elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large meta-analyses have also found that the associations between eGFR and adverse events such as death and ESRD do",
"    <strong>",
"     not",
"    </strong>",
"    vary substantially with age [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/12,35\">",
"     12,35",
"    </a>",
"    ]. In a meta-analysis that included approximately 1.5 million individuals from multiple cohorts, for example, the associations between lower levels of eGFR with the incidence of death, cardiovascular disease, ESRD, and progression of kidney disease were similar among those older and younger than 65 years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All-cause mortality ��� Compared with individuals who had an eGFR between 90 and 105",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      and an ACR less than 10",
"      <span class=\"nowrap\">",
"       mg/g,",
"      </span>",
"      the relative risks for all-cause mortality among those who had an eGFR between 45 and 59",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      and an ACR less than 10",
"      <span class=\"nowrap\">",
"       mg/g",
"      </span>",
"      (ie, those with an \"isolated\" reduction in eGFR) were 1.9 (95% CI, 1.4-2.5) in those younger than 65 years and 1.2 (95% CI, 1.0-1.5) in those older than 65 years.",
"     </li>",
"     <li>",
"      Cardiovascular mortality ��� Compared with individuals who had an eGFR between 90 and 105",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      and an ACR less than 10",
"      <span class=\"nowrap\">",
"       mg/g,",
"      </span>",
"      the relative risks for cardiovascular mortality among those who had an eGFR between 45 and 59",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      and an ACR less than 10",
"      <span class=\"nowrap\">",
"       mg/g",
"      </span>",
"      (ie, those with an \"isolated\" reduction in eGFR) were 1.3 (95% CI, 0.6-3.2) in those younger than 65 years and 1.4 (95% CI, 1.2-1.8) in those older than 65 years. In addition, absolute rates of cardiovascular mortality were higher in those older than 65 years.",
"     </li>",
"     <li>",
"      End-stage renal disease ��� Compared with individuals who had an eGFR of 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      or more, the relative risks for ESRD among those who had an eGFR between 45 and 59",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      were 3.1 (95% CI, 1.1-8.3) in those younger than 65 years and 3.4 (95% CI, 1.6-7.2) in those older than 65 years. In contrast to cardiovascular mortality, absolute rates of ESRD were lower in those older than 65 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, for elderly individuals, the relative risk for all-cause mortality associated with a reduction in eGFR is somewhat smaller than it is in younger individuals, but the relative risks are similar for cardiovascular mortality and ESRD in both younger and older individuals. A more detailed meta-analysis confirmed that the relative risks for all-cause mortality associated with a given eGFR were smaller among older individuals; however, the absolute risks associated with a given eGFR were higher among older individuals due to the elevated baseline risk for mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are limited data evaluating the association of isolated reductions in GFR with death and ESRD in the very elderly (ie, age 75 years and older). However, reductions in GFR are associated with other CKD complications in such patients. In a study of 2272 individuals 80 years of age and older from the general population, the prevalences anemia and hyperparathyroidism were both significantly higher in those whose eGFR was between 45 and 59",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    compared with those whose eGFR was greater than or equal to 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1053952\">",
"    <span class=\"h4\">",
"     GFR estimation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The various GFR estimating equations use serum creatinine along with some combination of age, sex, race and body size as surrogates for the non-GFR determinants of serum creatinine, and provide more accurate estimates of measured GFR than serum creatinine alone [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/31,37\">",
"     31,37",
"    </a>",
"    ]. Commonly used estimating equations are imperfect, providing GFR estimates that are usually lower than, and which can occasionally be widely disparate from, the measured GFR. A detailed discussion of the limitations of GFR estimation is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Modification of Diet in Renal Disease (MDRD) Study equation is the most frequently used GFR estimating equation in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/38\">",
"     38",
"    </a>",
"    ]. However, the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation is more accurate than the MDRD Study equation, especially at a GFR &gt;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    , and is replacing the MDRD Study equation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. Both equations use age, sex and race in addition to serum creatinine, and assign race as either black (eg, African American) versus non-black. Modifications of the equations for other geographical regions and racial-ethnic groups have been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link&amp;anchor=H20659769#H20659769\">",
"     \"Assessment of kidney function\", section on 'Estimation equations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cystatin C is an alternative endogenous filtration marker that may have advantages over creatinine for GFR estimation because its non-GFR determinants are less affected by race and muscle wasting, and because it is more predictive of subsequent cardiovascular disease and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. Use of cystatin C and creatinine together enables more accurate GFR estimates [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/45,48\">",
"     45,48",
"    </a>",
"    ], and more accurate predictions of risk [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], although we are not recommending this strategy at this time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link&amp;anchor=H23#H23\">",
"     \"Assessment of kidney function\", section on 'Serum cystatin C'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link&amp;anchor=H786389950#H786389950\">",
"     \"Chronic kidney disease and coronary heart disease\", section on 'Cystatin C and other markers of kidney function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Like all diagnostic tests, interpretation of the eGFR should be influenced by the prior probability of disease. An isolated decreased eGFR in an otherwise healthy individual is more likely to be a false positive than in individuals with other markers of kidney damage or who have known risk factors for kidney disease. Confirmation of decreased eGFR by measurement of GFR (clearance of creatinine or exogenous filtration markers) is warranted when decisions depend on more accurate knowledge of GFR, such as determining eligibility for kidney donation or adjusting the dose of toxic drugs that are excreted by the kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/37\">",
"     37",
"    </a>",
"    ]. In most cases, however, measuring GFR directly is unnecessary and eGFR is appropriate for diagnosis, staging, and management of CKD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22697785\">",
"    <span class=\"h3\">",
"     Confirming the chronicity of damage or decreased function",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the KDIGO guidelines require that the damage or decreased function be persistent for at least three months in order to make a diagnosis of CKD. Chronicity may be documented or inferred. When evidence of kidney damage or decreased function is first apparent, confirmation of chronicity can be obtained by one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Review of past measurements or estimates of GFR",
"     </li>",
"     <li>",
"      Review of past measurements of albuminuria or proteinuria",
"     </li>",
"     <li>",
"      Review of past urine dipstick and sediment examinations",
"     </li>",
"     <li>",
"      Imaging findings, such as reduced kidney volume and reduction in cortical thickness, or presence of multiple cysts",
"     </li>",
"     <li>",
"      Obtaining repeat measurements within and beyond the three-month point",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In clinical practice, it is usually not difficult to evaluate chronicity. For patients without evidence of chronicity, repeat testing is",
"    <strong>",
"     essential",
"    </strong>",
"    to rule out acute kidney disease. In addition, repeat testing is necessary in patients who have an eGFR or ACR near the threshold values for the CKD definition (ie, an eGFR just below 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    or an ACR just above 30",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    [3.4",
"    <span class=\"nowrap\">",
"     mg/mmol]).",
"    </span>",
"    In patients with these borderline values, both biological and analytical variations in serum creatinine and urinary albumin may result in the diagnosis of CKD not being confirmed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/26,51\">",
"     26,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have demonstrated the importance of repeat testing when evidence for chronicity is not already available at the time damage or decreased function is first recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of approximately 14,000 individuals from the general population with an eGFR greater than or equal to 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      who had repeated ACR measurements after a two-week interval, persistence of an ACR between 30 and 300",
"      <span class=\"nowrap\">",
"       mg/g",
"      </span>",
"      (3.4 to 34",
"      <span class=\"nowrap\">",
"       mg/mmol)",
"      </span>",
"      and an ACR greater than 300",
"      <span class=\"nowrap\">",
"       mg/g",
"      </span>",
"      at two weeks was 54 and 73 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another general population cohort of 18,066 individuals with repeat measurements of serum creatinine separated by a mean of three years, 1169 (6.5 percent) had an eGFR less than 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      at baseline [",
"      <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/55\">",
"       55",
"      </a>",
"      ]. At three years, 891 of these individuals (76 percent) still had a reduced eGFR. The risk of subsequent adverse cardiovascular events was higher in those with persistently low eGFR than in those whose eGFR rose to above 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      at three years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27258970\">",
"    <span class=\"h2\">",
"     Staging of CKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of CKD staging is to guide management, including stratification of risk for progression and complications of CKD. Risk stratification is used as a guide to inform appropriate treatments and the intensity of monitoring and patient education [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. In patients who are diagnosed with CKD using the criteria described above, staging of the CKD is done according to (",
"    <a class=\"graphic graphic_table graphicRef70597 \" href=\"UTD.htm?13/47/14076\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cause of disease",
"     </li>",
"     <li>",
"      Six categories of GFR (G stages)",
"     </li>",
"     <li>",
"      Three categories of albuminuria (A stages)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Staging patients with CKD according to cause, GFR, and albuminuria enhances risk stratification for the major complications of CKD (",
"    <a class=\"graphic graphic_figure graphicRef68921 \" href=\"UTD.htm?40/46/41701\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef58089 \" href=\"UTD.htm?27/44/28360\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef55646 \" href=\"UTD.htm?25/46/26348\">",
"     table 4",
"    </a>",
"    ). An overview of the management of patients with according to stage of CKD is provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27259103\">",
"    <span class=\"h3\">",
"     Cause of disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identifying the cause of kidney disease (eg, diabetes, drug toxicity, auto-immune diseases, urinary tract obstruction, kidney transplantation, etc.) enables specific therapy directed at preventing further injury. In addition, the cause of kidney disease has implications for the rate of progression and the risk of complications (",
"    <a class=\"graphic graphic_table graphicRef55646 \" href=\"UTD.htm?25/46/26348\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It can be difficult to ascertain the cause of kidney disease. In clinical practice, CKD is most often discovered as decreased eGFR during the evaluation and management of other medical conditions. The evaluation of patients diagnosed with CKD is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=see_link\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27259120\">",
"    <span class=\"h3\">",
"     GFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The GFR (G-stages) follow the original CKD classification scheme (",
"    <a class=\"graphic graphic_table graphicRef70597 \" href=\"UTD.htm?13/47/14076\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      G1 &minus; GFR &gt;90",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      G2 &minus; GFR 60 to 89",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      G3a &minus; GFR 45 to 59",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      G3b &minus; GFR 30 to 44",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      G4 &minus; GFR 15 to 29",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      G5 &minus; GFR &lt;15",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      or treatment by dialysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since the original KDOQI classification was published, stage 3 CKD (a GFR of 30 to 59",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ) has been subdivided into GFR stages 3a and 3b to more accurately reflect the continuous association between lower GFR and risk for mortality and adverse kidney outcomes (",
"    <a class=\"graphic graphic_figure graphicRef68921 \" href=\"UTD.htm?40/46/41701\">",
"     figure 2",
"    </a>",
"    ). Patients receiving treatment with dialysis are subclassified as GFR stage 5D to highlight the specialized care that they require.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27259169\">",
"    <span class=\"h3\">",
"     Albuminuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three albuminuria stages follow familiar definitions of \"normal\", \"high\" (formerly microalbuminuria), and \"very high\" (formerly macroalbuminuria and nephrotic range) albuminuria (",
"    <a class=\"graphic graphic_table graphicRef70597 \" href=\"UTD.htm?13/47/14076\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A1 &minus; ACR &lt;30",
"      <span class=\"nowrap\">",
"       mg/g",
"      </span>",
"      (&lt;3.4",
"      <span class=\"nowrap\">",
"       mg/mmol)",
"      </span>",
"     </li>",
"     <li>",
"      A2 &minus; ACR 30 to 299",
"      <span class=\"nowrap\">",
"       mg/g",
"      </span>",
"      (3.4 to 34.0",
"      <span class=\"nowrap\">",
"       mg/mmol)",
"      </span>",
"     </li>",
"     <li>",
"      A3 &minus; ACR &ge;300",
"      <span class=\"nowrap\">",
"       mg/g",
"      </span>",
"      (&gt;34.0",
"      <span class=\"nowrap\">",
"       mg/mmol)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The addition of albuminuria staging to GFR staging is new since the original KDOQI classification scheme was published [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Albuminuria staging has been added because of the graded increase in risk for mortality, progression of CKD, and ESRD at higher levels of albuminuria, independent of eGFR, without an apparent threshold value (",
"    <a class=\"graphic graphic_figure graphicRef68921 \" href=\"UTD.htm?40/46/41701\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef58089 \" href=\"UTD.htm?27/44/28360\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/12,23\">",
"     12,23",
"    </a>",
"    ]. The increase in risk is significant for urine ACR values &ge;30",
"    <span class=\"nowrap\">",
"     mg/g,",
"    </span>",
"    even when GFR is &gt;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    , consistent with the current threshold value for albuminuria (&ge;30",
"    <span class=\"nowrap\">",
"     mg/g)",
"    </span>",
"    as a marker of kidney damage. An increased risk is also apparent with urine ACR levels between 10 and 29",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    (\"high normal\" albuminuria), suggesting that levels below 30",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    may also warrant increased attention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1054193\">",
"    <span class=\"h3\">",
"     Purpose for and implications of CKD staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The staging system for CKD is intended to aid clinicians in the management of patients with CKD by identifying those with the most severe disease who are, therefore, at greatest risk for progression and complications. Staging according to cause, GFR, and albuminuria allows for a more complete description of risk for the major adverse outcomes of CKD.",
"   </p>",
"   <p>",
"    CKD staging is",
"    <strong>",
"     not",
"    </strong>",
"    meant to imply that there are GFR or albuminuria thresholds in CKD severity, or that all patients in the same GFR and albuminuria category will have the same prognosis. As an example, a patient with a GFR of 15",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    likely has more severe kidney disease, and may be at higher risk for complications, than someone with a GFR of 29",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    , even though both patients have GFR stage G4. A comparison can be made to the staging of hypertension; two patients with usual systolic pressures of 140 mmHg and 159 mmHg, respectively, have different cardiovascular risks although both have stage 1 hypertension.",
"   </p>",
"   <p>",
"    Patients with already diagnosed CKD can now be staged according to the cause of kidney disease and then into 18 separate categories with differing degrees of risk for progression to all-cause mortality, cardiovascular mortality, end-stage renal disease (ESRD), CKD progression, and acute kidney injury. The relative risk for each outcome is higher with more severe GFR and ACR stages. Based upon these findings, a \"heat map\" can be constructed that divides patients with CKD into the following three broad risk categories based upon the likelihood of developing future kidney and cardiovascular complications (eg, ESRD, cardiovascular death) (",
"    <a class=\"graphic graphic_figure graphicRef59716 \" href=\"UTD.htm?4/42/4768\">",
"     figure 5",
"    </a>",
"    ); the proportion of the population in the United States with CKD (ascertained by eGFR and albuminuria) that falls into these risk categories is also given [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Moderate risk (yellow) &mdash; 73 percent of patients with CKD",
"     </li>",
"     <li>",
"      High risk (orange) &mdash; 18 percent of patients with CKD",
"     </li>",
"     <li>",
"      Very high risk (red) &mdash; 9 percent of patients with CKD",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These three broad risk categories may help clinicians decide whether or not to refer their patients to a nephrologist or specialist with expertise in caring for patients with CKD, and to develop a clinical action plan. A similar definition of risk categories was proposed based upon analysis of a large cohort in Canada [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H923217\">",
"     'Referral to a specialist'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H923312\">",
"     'Clinical action plan'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, the heat map must be considered in the appropriate context:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First, it is derived from a meta-analysis in which approximately 1.5 million individuals were followed for a mean of five years. If a patient with CKD is staged initially as low risk, this does",
"      <strong>",
"       not",
"      </strong>",
"      mean the he or she will remain low risk and not progress over the next several decades. As an example, a patient with autosomal dominant polycystic kidney disease (ADPKD) who is diagnosed by imaging at a young age and who has a normal eGFR and no proteinuria may be low risk for developing ESRD in the short-term, but has a high long-term risk of progressive CKD.",
"     </li>",
"     <li>",
"      Second, the heat map applies to patients who have been diagnosed with CKD. Individuals who fall into the low risk (green) categories have CKD based upon markers of kidney damage other than albuminuria. Such individuals are generally not identified in population surveys.",
"     </li>",
"     <li>",
"      Third, the risk graduation displayed in the heat map is meant to compare patients with the same cause of CKD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional details describing the association between CKD and risk for cardiovascular disease are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H923134\">",
"    <span class=\"h1\">",
"     IMPLICATIONS FOR CLINICAL PRACTICE AND PUBLIC HEALTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition and classification of CKD has several important implications for public health and clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H923152\">",
"    <span class=\"h2\">",
"     Effect of the current definitions on the prevalence of CKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using the current definitions, the prevalence of CKD in the United States during the interval from 1999 to 2006 was 11.5 percent (42 percent in GFR stages 1-2 and 58 percent in GFR stages 3-4), equivalent to approximately 23 million adults [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/40\">",
"     40",
"    </a>",
"    ]. This is similar to the prevalence of other chronic non-communicable diseases, such as diabetes (10.6 percent, 23.4 million) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/57\">",
"     57",
"    </a>",
"    ]. Because patients with CKD have a high rate of ESRD, cardiovascular disease, and death, CKD is an appropriate target for prevention, early detection, and management by non-nephrologist physicians and public health agencies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H923181\">",
"    <span class=\"h2\">",
"     Application of the current definitions to the elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of CKD in people 70 years and older in the United States is high (approximately 45 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/40,59\">",
"     40,59",
"    </a>",
"    ]. It is possible that the association between advancing age and lower eGFR and higher albuminuria may be due to vascular disease rather than a natural aging process [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. The fact that lower eGFR values are associated with increased kidney and cardiovascular disease rates in older as well as younger individuals is not consistent with the interpretation that decreased eGFR with aging is \"normal\" or \"physiological.\" Rather, it suggests that decreased eGFR in the elderly is evidence of disease. Similarly, the increased risk for adverse kidney outcomes for individuals whose urine albumin-to-creatinine ratio is between 30 and 299",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    (3.4 to 34",
"    <span class=\"nowrap\">",
"     mg/mmol)",
"    </span>",
"    in older as well as younger adults is not consistent with the interpretation that \"microalbuminuria\" is only a marker for increased cardiovascular disease risk.",
"   </p>",
"   <p>",
"    As in diabetes, hypertension, or hypercholesterolemia, selecting a threshold value to define the disease must balance the risk of \"labeling\" low-risk individuals against the benefit of early detection of high-risk individuals. As an example, the systolic blood pressure threshold for the definition of hypertension, previously higher in the elderly than in the young, is now the same for all ages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H923198\">",
"    <span class=\"h2\">",
"     Using the current classification to assign prognosis for individuals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The staging system will help clinicians to determine how and how intensely to treat and monitor patients with established CKD. More accurate risk prediction for an individual patient can be accomplished by the development of risk-prediction instruments. In addition to eGFR and albuminuria, the cause of kidney disease, as well as other factors (eg, age, sex, race, cholesterol levels, smoking status, and others), should be considered in estimating prognosis. As an example, an instrument for predicting risk of progression of CKD to ESRD that used age, sex, eGFR, albuminuria, and other commonly measured laboratory values was developed from a large cohort of patients referred to nephrologists [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/62\">",
"     62",
"    </a>",
"    ]. This model was more accurate than a simpler model that included just age, sex, and eGFR and albuminuria. We think such models are could eventually be useful tools to help guide decision making for individual patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H923217\">",
"    <span class=\"h1\">",
"     REFERRAL TO A SPECIALIST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referral depends upon practice patterns, which are not uniform across health care systems or geographic regions, even within countries. As a result, there are numerous recommendations that propose indications for referral to nephrologists, and none have been universally adopted [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/63-67\">",
"     63-67",
"    </a>",
"    ]. However, one indication that is common to most guidelines is that all patients with severely decreased GFR (estimated GFR [eGFR] less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    , GFR stage 4) should be referred for co-management with a nephrologist. Patients at or below this level of eGFR have already demonstrated that they have progressive kidney disease, and therefore are at high risk for progression to ESRD. In such patients, late referral to a nephrologist (ie, less than three months before the start of dialysis therapy) is associated with higher mortality after the initiation of dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with severely decreased eGFR require preparation for the possible onset of ESRD. Preparation involves a discussion regarding kidney replacement therapy (dialysis and transplantation), and conservative therapy for those not willing or unable to undergo kidney replacement therapy. In patients electing replacement therapy, timely creation of vascular access for hemodialysis, home dialysis training, and donor evaluation for preemptive transplantation should occur. Several studies have demonstrated that patients who are referred to nephrology late are less likely to initiate dialysis with a functioning fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/65,70,71\">",
"     65,70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is less consensus about referral for patients with higher eGFR. Based in part upon current guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?5/29/5594/abstract/23,64,65\">",
"     23,64,65",
"    </a>",
"    ], we recommend that, in addition to referral of all patients who have an eGFR less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    , patients with CKD who meet one or more of the following criteria be referred to a nephrologist or other physician skilled in managing patients with CKD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urine albumin-to-creatinine ratio (ACR) &ge;300",
"      <span class=\"nowrap\">",
"       mg/g",
"      </span>",
"      (34",
"      <span class=\"nowrap\">",
"       mg/mmol)",
"      </span>",
"     </li>",
"     <li>",
"      Hematuria not secondary to urological conditions",
"     </li>",
"     <li>",
"      Inability to identify a presumed cause of CKD",
"     </li>",
"     <li>",
"      eGFR decline of more than 30 percent in fewer than four months without an obvious explanation",
"     </li>",
"     <li>",
"      Difficult to manage complications such as anemia requiring erythropoietin therapy, and abnormalities of bone and mineral metabolism requiring phosphorus binders or vitamin D preparations",
"     </li>",
"     <li>",
"      Serum potassium greater than 5.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"     </li>",
"     <li>",
"      Difficult to manage drug complications",
"     </li>",
"     <li>",
"      Patients under the age of 18 years",
"     </li>",
"     <li>",
"      Resistant hypertension",
"     </li>",
"     <li>",
"      Recurrent or extensive nephrolithiasis",
"     </li>",
"     <li>",
"      Confirmed or presumed hereditary kidney disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nephrologists can assist primary care physicians and other specialists in the diagnosis and care of patients at all stages of CKD. These functions include determination of the cause of CKD, recommendations for specific therapy, suggestions for treatments to slow progression in patients who have not responded to conventional therapies, identification and treatment for kidney disease&ndash;related complications, and preparation for dialysis. Because patients with CKD are at risk for a diverse set of adverse outcomes (not just kidney failure), referral to other appropriate specialists (eg, cardiologists for those with complex CVD) should also be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H923312\">",
"    <span class=\"h1\">",
"     CLINICAL ACTION PLAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suggestions for the treatment and monitoring of patients who are diagnosed with CKD vary according to the stage of CKD based upon cause, GFR, and albuminuria. A discussion of the recommended clinical action plan according to CKD stage is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6845174\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic kidney disease (CKD) is a heterogeneous group of disorders characterized by alterations in kidney structure and function, which manifest in various ways depending upon the underlying cause or causes and the severity of disease (",
"      <a class=\"graphic graphic_figure graphicRef77385 \" href=\"UTD.htm?1/55/1919\">",
"       figure 1",
"      </a>",
"      ). The term \"end-stage renal disease\" (ESRD) generally refers to CKD treated with either dialysis or transplantation. (See",
"      <a class=\"local\" href=\"#H27258373\">",
"       'Framework and conceptual model'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CKD is usually asymptomatic in its early stages. Symptoms appear in later stages in association with complications (",
"      <a class=\"graphic graphic_figure graphicRef77385 \" href=\"UTD.htm?1/55/1919\">",
"       figure 1",
"      </a>",
"      ). In addition to commonly recognized hormonal and metabolic complications such as anemia and hyperparathyroidism, CKD complications include increased risks for systemic drug toxicity, cardiovascular disease, infection, cognitive impairment, and impaired physical function. (See",
"      <a class=\"local\" href=\"#H27258373\">",
"       'Framework and conceptual model'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CKD is defined by the presence of kidney damage",
"      <strong>",
"       or",
"      </strong>",
"      decreased kidney function",
"      <strong>",
"       for three or more months",
"      </strong>",
"      , irrespective of the cause (",
"      <a class=\"graphic graphic_table graphicRef80632 \" href=\"UTD.htm?21/62/22509\">",
"       table 1",
"      </a>",
"      ). The persistence of the damage or decreased function for at least three months is",
"      <strong>",
"       necessary",
"      </strong>",
"      to distinguish CKD from acute kidney disease. Kidney damage refers to pathologic abnormalities, whether established via renal biopsy or imaging studies or inferred from markers such as urinary sediment abnormalities or increased rates of urinary albumin excretion. Decreased kidney function refers to a decreased glomerular filtration rate (GFR), which is usually estimated (eGFR) using serum creatinine and one of several available equations. (See",
"      <a class=\"local\" href=\"#H27258481\">",
"       'Definition of CKD'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Kidney damage is identified in most cases by the presence of albuminuria, urinary sediment abnormalities, anatomic abnormalities discovered with imaging studies, pathologic abnormalities discovered with kidney biopsy, or a history of kidney transplantation (",
"      <a class=\"graphic graphic_table graphicRef80632 \" href=\"UTD.htm?21/62/22509\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27258566\">",
"       'Kidney damage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Decreased kidney function is identified in most cases by an eGFR less than 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      (",
"      <a class=\"graphic graphic_table graphicRef80632 \" href=\"UTD.htm?21/62/22509\">",
"       table 1",
"      </a>",
"      ). Estimation of GFR is discussed in more detail elsewhere. (See",
"      <a class=\"local\" href=\"#H27258759\">",
"       'Decreased GFR'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link\">",
"       \"Assessment of kidney function\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Confirmation of chronicity can be obtained by one of the following (see",
"      <a class=\"local\" href=\"#H22697785\">",
"       'Confirming the chronicity of damage or decreased function'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Review of past measurements or estimates of GFR",
"     </li>",
"     <li>",
"      Review of past measurements of albuminuria or proteinuria",
"     </li>",
"     <li>",
"      Review of past urine dipstick and sediment examinations",
"     </li>",
"     <li>",
"      Imaging findings, such as reduced kidney volume and reduction in cortical thickness, or presence of multiple cysts",
"     </li>",
"     <li>",
"      Obtaining repeat measurements within and beyond the three-month point",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The purpose of CKD staging is to guide management, including stratification of risk for progression and complications of CKD (",
"      <a class=\"graphic graphic_figure graphicRef68921 \" href=\"UTD.htm?40/46/41701\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef58089 \" href=\"UTD.htm?27/44/28360\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef55646 \" href=\"UTD.htm?25/46/26348\">",
"       table 4",
"      </a>",
"      ). Risk stratification is used as a guide to inform appropriate treatments and the intensity of monitoring and patient education. In patients who are diagnosed with CKD using the criteria described above, staging of the CKD is done according to (",
"      <a class=\"graphic graphic_table graphicRef70597 \" href=\"UTD.htm?13/47/14076\">",
"       table 3",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H27258970\">",
"       'Staging of CKD'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cause of disease &ndash; Identifying the cause of kidney disease (eg, diabetes, drug toxicity, auto-immune diseases, urinary tract obstruction, kidney transplantation, etc.) enables specific therapy directed at preventing further injury and has implications for the rate of progression and the risk of complications (",
"      <a class=\"graphic graphic_table graphicRef55646 \" href=\"UTD.htm?25/46/26348\">",
"       table 4",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H27259103\">",
"       'Cause of disease'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Six categories of GFR (G stages) &ndash; The GFR (G-stages) are shown in the table (",
"      <a class=\"graphic graphic_table graphicRef70597 \" href=\"UTD.htm?13/47/14076\">",
"       table 3",
"      </a>",
"      ). Since the original KDOQI classification was published, stage 3 CKD (a GFR of 30 to 59",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      ) has been subdivided into GFR stages 3a and 3b to more accurately reflect the continuous association between lower GFR and risk for mortality and adverse kidney outcomes. (See",
"      <a class=\"local\" href=\"#H27259120\">",
"       'GFR'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Three categories of albuminuria (A stages) &ndash; The three albuminuria stages follow familiar definitions of \"normal\", \"high\" (formerly microalbuminuria), and \"very high\" (formerly macroalbuminuria and nephrotic range) albuminuria (",
"      <a class=\"graphic graphic_table graphicRef70597 \" href=\"UTD.htm?13/47/14076\">",
"       table 3",
"      </a>",
"      ). Albuminuria staging has been added because of the graded increase in risk for mortality, progression of CKD, and ESRD at higher levels of albuminuria, independent of eGFR. (See",
"      <a class=\"local\" href=\"#H27259169\">",
"       'Albuminuria'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Based upon this staging, a \"heat map\" can be constructed that divides patients with CKD into three broad risk categories (moderate, high, and very high) based upon the likelihood of developing future kidney and cardiovascular complications (eg, ESRD, cardiovascular death) (",
"      <a class=\"graphic graphic_figure graphicRef59716 \" href=\"UTD.htm?4/42/4768\">",
"       figure 5",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H1054193\">",
"       'Purpose for and implications of CKD staging'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      We recommend that, in addition to referral of all patients who have an eGFR less than 30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      , patients with CKD who meet one or more of the following criteria be referred to a nephrologist or other physician skilled in managing patients with CKD (see",
"      <a class=\"local\" href=\"#H923217\">",
"       'Referral to a specialist'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Urine albumin-to-creatinine ratio (ACR) &ge;300",
"      <span class=\"nowrap\">",
"       mg/g",
"      </span>",
"      (34",
"      <span class=\"nowrap\">",
"       mg/mmol)",
"      </span>",
"     </li>",
"     <li>",
"      Hematuria not secondary to urological conditions",
"     </li>",
"     <li>",
"      Inability to identify a presumed cause of CKD",
"     </li>",
"     <li>",
"      eGFR decline of more than 30 percent in fewer than four months without an obvious explanation",
"     </li>",
"     <li>",
"      Difficult to manage complications such as anemia requiring erythropoietin therapy, and abnormalities of bone and mineral metabolism requiring phosphorus binders or vitamin D preparations",
"     </li>",
"     <li>",
"      Serum potassium greater than 5.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"     </li>",
"     <li>",
"      Difficult to manage drug complications",
"     </li>",
"     <li>",
"      Patients under the age of 18 years",
"     </li>",
"     <li>",
"      Resistant hypertension",
"     </li>",
"     <li>",
"      Recurrent or extensive nephrolithiasis",
"     </li>",
"     <li>",
"      Confirmed or presumed hereditary kidney disease",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/1\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/2\">",
"      Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/3\">",
"      Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/4\">",
"      Levey AS, Stevens LA, Coresh J. Conceptual model of CKD: applications and implications. Am J Kidney Dis 2009; 53:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/5\">",
"      Rettig RA, Norris K, Nissenson AR. Chronic kidney disease in the United States: a public policy imperative. Clin J Am Soc Nephrol 2008; 3:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/6\">",
"      Bauer C, Melamed ML, Hostetter TH. Staging of chronic kidney disease: time for a course correction. J Am Soc Nephrol 2008; 19:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/7\">",
"      Glassock RJ. Is the presence of microalbuminuria a relevant marker of kidney disease? Curr Hypertens Rep 2010; 12:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/8\">",
"      Levey AS, Coresh J. Chronic kidney disease. Lancet 2012; 379:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/9\">",
"      James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet 2010; 375:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/10\">",
"      Winearls CG, Glassock RJ. Dissecting and refining the staging of chronic kidney disease. Kidney Int 2009; 75:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/11\">",
"      Eckardt KU, Berns JS, Rocco MV, Kasiske BL. Definition and classification of CKD: the debate should be about patient prognosis--a position statement from KDOQI and KDIGO. Am J Kidney Dis 2009; 53:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/12\">",
"      Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011; 80:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/13\">",
"      Astor BC, Matsushita K, Gansevoort RT, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int 2011; 79:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/14\">",
"      van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011; 79:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/15\">",
"      Gansevoort RT, Matsushita K, van der Velde M, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 2011; 80:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/16\">",
"      Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/17\">",
"      Hsu CY, Ordo&ntilde;ez JD, Chertow GM, et al. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int 2008; 74:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/18\">",
"      James MT, Hemmelgarn BR, Wiebe N, et al. Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: a cohort study. Lancet 2010; 376:2096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/19\">",
"      Fink JC, Brown J, Hsu VD, et al. CKD as an underrecognized threat to patient safety. Am J Kidney Dis 2009; 53:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/20\">",
"      James MT, Quan H, Tonelli M, et al. CKD and risk of hospitalization and death with pneumonia. Am J Kidney Dis 2009; 54:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/21\">",
"      Hailpern SM, Melamed ML, Cohen HW, Hostetter TH. Moderate chronic kidney disease and cognitive function in adults 20 to 59 years of age: Third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol 2007; 18:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/22\">",
"      Wilhelm-Leen ER, Hall YN, K Tamura M, Chertow GM. Frailty and chronic kidney disease: the Third National Health and Nutrition Evaluation Survey. Am J Med 2009; 122:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/23\">",
"      KDIGO. Chapter 1: Definition and classification of CKD. Kidney Int Suppl 2013; 3:19. file://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/24\">",
"      Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006; 116:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/25\">",
"      Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 2003; 42:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/26\">",
"      Miller WG, Bruns DE, Hortin GL, et al. Current issues in measurement and reporting of urinary albumin excretion. Clin Chem 2009; 55:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/27\">",
"      Mattix HJ, Hsu CY, Shaykevich S, Curhan G. Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race. J Am Soc Nephrol 2002; 13:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/28\">",
"      Warram JH, Gearin G, Laffel L, Krolewski AS. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 1996; 7:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/29\">",
"      Hostetter TH, Olson JL, Rennke HG, et al. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981; 241:F85.",
"     </a>",
"    </li>",
"    <li>",
"     Wesson, L. Physiology of the human kidney, Grune &amp; Stratton, New York 1969. p.96-108.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/31\">",
"      Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med 2006; 354:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/32\">",
"      Miller WG. Estimating glomerular filtration rate. Clin Chem Lab Med 2009; 47:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/33\">",
"      Jain AK, McLeod I, Huo C, et al. When laboratories report estimated glomerular filtration rates in addition to serum creatinines, nephrology consults increase. Kidney Int 2009; 76:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/34\">",
"      Hemmelgarn BR, Zhang J, Manns BJ, et al. Nephrology visits and health care resource use before and after reporting estimated glomerular filtration rate. JAMA 2010; 303:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/35\">",
"      Hallan SI, Matsushita K, Sang Y, et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA 2012; 308:2349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/36\">",
"      Bowling CB, Inker LA, Guti&eacute;rrez OM, et al. Age-specific associations of reduced estimated glomerular filtration rate with concurrent chronic kidney disease complications. Clin J Am Soc Nephrol 2011; 6:2822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/37\">",
"      Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol 2009; 20:2305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/38\">",
"      Stevens LA, Coresh J, Feldman HI, et al. Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol 2007; 18:2749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/39\">",
"      Earley A, Miskulin D, Lamb EJ, et al. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med 2012; 156:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/40\">",
"      Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/41\">",
"      Stevens LA, Schmid CH, Greene T, et al. Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2. Am J Kidney Dis 2010; 56:486.",
"     </a>",
"    </li>",
"    <li>",
"     Quest Diagnostics. eGFR equation update. 2011 [updated 2011; cited 2011 September 25]; Available from: file://www.wpakidneysupport.org/documents/Quest%20Estimated%20Glomerular%20Filtration%20Rate.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/43\">",
"      Rule AD, Teo BW. GFR estimation in Japan and China: what accounts for the difference? Am J Kidney Dis 2009; 53:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/44\">",
"      Teo BW, Xu H, Wang D, et al. GFR estimating equations in a multiethnic Asian population. Am J Kidney Dis 2011; 58:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/45\">",
"      Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008; 51:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/46\">",
"      Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/47\">",
"      Stevens LA, Schmid CH, Greene T, et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int 2009; 75:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/48\">",
"      Inker LA, Eckfeldt J, Levey AS, et al. Expressing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) cystatin C equations for estimating GFR with standardized serum cystatin C values. Am J Kidney Dis 2011; 58:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/49\">",
"      Peralta CA, Katz R, Sarnak MJ, et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol 2011; 22:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/50\">",
"      Peralta CA, Shlipak MG, Judd S, et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA 2011; 305:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/51\">",
"      Myers GL, Miller WG, Coresh J, et al. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem 2006; 52:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/52\">",
"      Brook MO, Bottomley MJ, Mevada C, et al. Repeat testing is essential when estimating chronic kidney disease prevalence and associated cardiovascular risk. QJM 2012; 105:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/53\">",
"      Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/54\">",
"      Coresh J, Astor BC, McQuillan G, et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 2002; 39:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/55\">",
"      Weiner DE, Krassilnikova M, Tighiouart H, et al. CKD classification based on estimated GFR over three years and subsequent cardiac and mortality outcomes: a cohort study. BMC Nephrol 2009; 10:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/56\">",
"      Tonelli M, Muntner P, Lloyd A, et al. Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study. Ann Intern Med 2011; 154:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/57\">",
"      Levey AS, Schoolwerth AC, Burrows NR, et al. Comprehensive public health strategies for preventing the development, progression, and complications of CKD: report of an expert panel convened by the Centers for Disease Control and Prevention. Am J Kidney Dis 2009; 53:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/58\">",
"      Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007; 72:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/59\">",
"      Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/60\">",
"      Wetzels JF, Kiemeney LA, Swinkels DW, et al. Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study. Kidney Int 2007; 72:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/61\">",
"      Darmady EM, Offer J, Woodhouse MA. The parameters of the ageing kidney. J Pathol 1973; 109:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/62\">",
"      Tangri N, Stevens LA, Griffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA 2011; 305:1553.",
"     </a>",
"    </li>",
"    <li>",
"     National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2):S1-266.  Available from: file://www.kidney.org/professionals/kdoqi/guidelines_ckd/toc.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/64\">",
"      Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43:S1.",
"     </a>",
"    </li>",
"    <li>",
"     Caring for Australasians with Renal Impairment (CARI). Dialysis Guidelines. Acceptance onto Dialysis. Timing of referral of chronic kidney disease patients to nephrology services (adult). 2010 [updated 2010; cited 2010 September 27]; Available from: file://www.cari.org.au/dialysis_accept_published.php.",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence (NICE) National Collaborating Centre for Chronic Conditions. Chronic kidney disease. Chronic kidney disease. Early identification and management of chronic kidney disease in adults in primary and secondary care. 2008 [updated 2008; cited 2010 October7]; Available from: file://www.nice.org.uk/nicemedia/live/12069/42119/42119.pdf.",
"    </li>",
"    <li>",
"     The Renal Assocation. Chronic Kidney Disease in Adults: UK Guidelines for Identification, Management and Referral.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/68\">",
"      Kinchen KS, Sadler J, Fink N, et al. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med 2002; 137:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/69\">",
"      Jungers P, Massy ZA, Nguyen-Khoa T, et al. Longer duration of predialysis nephrological care is associated with improved long-term survival of dialysis patients. Nephrol Dial Transplant 2001; 16:2357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/70\">",
"      Avorn J, Winkelmayer WC, Bohn RL, et al. Delayed nephrologist referral and inadequate vascular access in patients with advanced chronic kidney failure. J Clin Epidemiol 2002; 55:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/29/5594/abstract/71\">",
"      Astor BC, Eustace JA, Powe NR, et al. Timing of nephrologist referral and arteriovenous access use: the CHOICE Study. Am J Kidney Dis 2001; 38:494.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16406 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-4FABCF92AE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_29_5594=[""].join("\n");
var outline_f5_29_5594=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6845174\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27258226\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1054473\">",
"      CONTROVERSIES ADDRESSED BY THE NEW GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27258404\">",
"      DEFINITION AND STAGING OF CHRONIC KIDNEY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27258373\">",
"      Framework and conceptual model",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27258481\">",
"      Definition of CKD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27258566\">",
"      - Kidney damage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27258759\">",
"      - Decreased GFR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H26100367\">",
"      Similar thresholds for the elderly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1053952\">",
"      GFR estimation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22697785\">",
"      - Confirming the chronicity of damage or decreased function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27258970\">",
"      Staging of CKD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27259103\">",
"      - Cause of disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27259120\">",
"      - GFR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27259169\">",
"      - Albuminuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1054193\">",
"      - Purpose for and implications of CKD staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H923134\">",
"      IMPLICATIONS FOR CLINICAL PRACTICE AND PUBLIC HEALTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H923152\">",
"      Effect of the current definitions on the prevalence of CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H923181\">",
"      Application of the current definitions to the elderly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H923198\">",
"      Using the current classification to assign prognosis for individuals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H923217\">",
"      REFERRAL TO A SPECIALIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H923312\">",
"      CLINICAL ACTION PLAN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6845174\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/16406\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/16406|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/55/1919\" title=\"figure 1\">",
"      Conceptual model for chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/46/41701\" title=\"figure 2\">",
"      Relative risks of major complications of CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/44/28360\" title=\"figure 3\">",
"      Relative risks of the main complications of CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/31/42486\" title=\"figure 4\">",
"      Normal values for GFR in men and women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/42/4768\" title=\"figure 5\">",
"      Staging of patients who meet the definition of CKD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/16406|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/62/22509\" title=\"table 1\">",
"      Definition and criteria for CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/25/39324\" title=\"table 2\">",
"      Categories for albuminuria and proteinuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/47/14076\" title=\"table 3\">",
"      Revised CKD classification based upon GFR and albuminuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/46/26348\" title=\"table 4\">",
"      Risk of complications depending upon cause and degree of CKD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42773?source=related_link\">",
"      Definition of acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=related_link\">",
"      Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/32/521?source=related_link\">",
"      Epidemiology of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25640?source=related_link\">",
"      Late referral to nephrologists of patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42777?source=related_link\">",
"      Microalbuminuria in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=related_link\">",
"      Microalbuminuria in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32041?source=related_link\">",
"      Overview of heavy proteinuria and the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=related_link\">",
"      Overview of the management of chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=related_link\">",
"      Overview of the management of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39509?source=related_link\">",
"      Radiologic assessment of renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28966?source=related_link\">",
"      Screening for chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_29_5595="Interpretations serum CRP";
var content_f5_29_5595=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F67050&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F67050&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Interpretations of serum CRP levels and atherosclerotic cardiovascular disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Serum CRP levels",
"      </td>",
"      <td class=\"subtitle1\">",
"       Interpretation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &lt;1",
"      </td>",
"      <td>",
"       Normal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1-3",
"      </td>",
"      <td>",
"       Possibly increased cardiovascular risk (grey zone)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3-10",
"      </td>",
"      <td>",
"       Highly likely increased CV risk, common in moderate CKD",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10-50",
"      </td>",
"      <td>",
"       Common in maintenance dialysis patients",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &gt;50",
"      </td>",
"      <td>",
"       Acute infection/inflammation (usually temporary)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kalantar-Zadeh, K. Inflammatory marker mania in chronic kidney disease: pentraxins at the crossroad of universal soldiers of inflammation. Clin J Am Soc Nephrol 2007; 2:872. Copyright &copy;2007 American Society of Nephrology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_29_5595=[""].join("\n");
var outline_f5_29_5595=null;
var title_f5_29_5596="Comparison of KPC and NDM";
var content_f5_29_5596=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F60389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F60389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of the two most common causes of carbapenem resistance in Enterobacteriaceae: Klebsiella pneumoniae carbapenemase (KPC) and New Delhi Metallo-&beta;-Lactamase (NDM) type &beta;-lactamases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        KPC",
"       </td>",
"       <td class=\"subtitle1\">",
"        NDM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &beta;-lactamase type",
"       </td>",
"       <td>",
"        Serine",
"       </td>",
"       <td>",
"        Metallo-&beta;-lactamase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ambler cass",
"       </td>",
"       <td>",
"        A",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Most commonly affected species",
"       </td>",
"       <td>",
"        K. pneumoniae",
"       </td>",
"       <td>",
"        K. pneumoniae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other species commonly affected",
"       </td>",
"       <td>",
"        E. coli, E. cloacae",
"       </td>",
"       <td>",
"        E. coli, E. cloacae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Common MLST types",
"       </td>",
"       <td>",
"        ST258",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Geographic epicenter",
"       </td>",
"       <td>",
"        NE USA",
"       </td>",
"       <td>",
"        India, Pakistan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &beta;-lactam antibiotics affected",
"       </td>",
"       <td>",
"        Penicillins, cephalosporins, carbapenems",
"       </td>",
"       <td>",
"        Penicillins, cephalosporins, carbapenems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenotypic detection",
"       </td>",
"       <td>",
"        Modified Hodge Test (MHT) positive",
"       </td>",
"       <td>",
"        Unknown (positive MHT likely)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhibitors",
"       </td>",
"       <td>",
"        Boronic acid",
"       </td>",
"       <td>",
"        EDTA",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     EDTA: ethylene diaminete traacetic acid.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Sidjabat H, Nimmo GR, Walsh TR, et al. Carbapenem Resistance in Klebsiella pneumoniae Due to the New Delhi Metallo-&beta;-lactamase. Clin Infect Dis 2011; 52:481, by permission of Oxford University Press. Copyright &copy; 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_29_5596=[""].join("\n");
var outline_f5_29_5596=null;
var title_f5_29_5597="Insemination catheter";
var content_f5_29_5597=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Insemination catheter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 98px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_29_5597=[""].join("\n");
var outline_f5_29_5597=null;
var title_f5_29_5598="Laser photocoagulation of a carcinoid tumor";
var content_f5_29_5598=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/65910/brlaspho_conv.mp4?title=Laser+photocoagulation+of+a+carcinoid+tumor\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Laser photocoagulation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 246px; height: 232px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADoAPYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxsnOOKOe1IGyO/wCNJk9jUWHqOxQSO9NGe9Lxjk4qWTcD7UoPrTc0E4+tLUofxTabk0oNO1txjgT7/SlOPxpufWjtTsmAuTxTuvOMGmdqXJHYVT0HsOI49aBk9aUcjmlB+uKzcrhcQADtRjn2pcjsDSkk9qpajsNx+NIRjinUnJPQUuZIGhNtJjHSnH3NIeO9KLuwSE56HpTTTgfypM1q3YT1DtSHpzSZ7UnAqEwYpxikNLweRTcnvindkBnHrQcZozzxQD7ZqeVPcaDiikJ54FJnnniqsGg5sUUnXpRTv5gHfml6H1pvWlxjrRfsJATzyKapyT1p1HToaXKAh7Gl5BzmgnNJz7Uh7DiTjkUmaMetAHPpRfuF0OyCRkHNLznjmlxj1NWba0lnI2rxS21C1yr1PcVMkTPgKpP4VuWujgEF+fatWCyRQNsYxQ5dzaFJyOXisZnPC1o22hTS43ELXSW1rlh8uOa2ba0GBgVm6iOqng2zk4vDWeGc1YXwopHEhB+ldjDZktxWjHYsRnFSqttjrjgV1PPW8IOc7ZBVeXwbdAZXa1eopZAYyKtJarj1q1VXUl5fHoeJXnh+9tj88TAe3Ss2W1eP76kfUV73Paof4R+NY+oaJbXSEPCuT3FaKUDnngprY8UZGHbiozu6V6Hq3hB1DNbHIHODXIXthLbyMskZUj2p7nFKm4v3jJOR7U0noOatSRD/ACKgaMgdqWhGhFnselKSCKGBxTDnFO4rod75oLcUzOaDUtBe4uTjrScml9qT3A4p7ibFzzRTSfairVhXJPqfyoJ570hOD1pM5qYoVx2aB1OaTOBxTc0rvoNMfSgCm9acB370WEhy1JGhdsKCaW2hM0gVQTzzxXU6bpUcagkZajbc0jFtlHTdJL4eYfhXRWdiicRrirEMOBgCr0EJzkisZVLbHfSoLqRR2JI4GKSaDyxnArWjXC9qguEDsAvX2rCc2dlOGtiPTYPMXJFdBZWfTNR6XZMiAsOvIrobW36FsY9qx5z0oUivFaKOcD8q1beFdmMCnRxqMYFWo1FaRZTSRV+yg8ADrQLIAGr4THanKCvertfcz5zJe1GDgVWa0BOMV0MjDyyrBcHvjmqnlrnjt2NS422ZUZJ7oxnslx0rA1jQIL3IdcMf4hXayoCKrNbg54qo1GtDKrh41EeJ+IvC81gjSKC6e1cnNBgnI5zX0beWMc8RSQAqeCDXnPi3wlsDXFkBgclBXTGaZ4WJwjp6o8vkQAGq5GCOK0rmIo5XHQ45qnKpqkmedzdCuxANNzzT3X1qPoae4AT60oODgU0jnrmkJ59Kd7BqOJHNFNJIoqlqLmJCc9eKA3HvTd3rSnmktBpXDOaUe1JnNGPejZivYf1PGKlt42llVVBJJ4xUIx0ziuu8PaUY1W4lADHoM1DNYLmNDR9E+z26tKMSNyfatVYClSxMTjP6VYVCcYBNc85nfSpW1YlvDk81pQxqq8nFQRDbVhVLH1rncrnarIYfmkCjOM1bitfnUrzimwxAMCegrWs0RiP8KynI6KMbst2aMyqGxWzBCABUVlbqRk8VppHheOcVENXqdspqKsiFY/T9akjTDetSrGX9DVqC3wORXTBJ7HPOrZakIUkdKQoR/DWmkIFOeHjpzW/Kjm9urmM4PpUDqSD8taU0GWNRPHgdKzaN4VEZpQ9KChAq4Y1LDHFJJHkdKhxNvaGXcdDWTegEHit+eLg1lXUJIPy1ipuDKlTjUWp5R4t0HMklxADySSo7VwtzEUJDcV7nfWgcMGwQe1ebeMdH+ysJo1yjHH0NdtKvz6I+ex2D5PeicRKvvUByOKtyKdxBA4qtIOTXXFnlX7EZOKYzZNOYelRnFNO4N2FOSODRTcjOKK0AsHH40dqZk0ueBWSLQ7rS/SmAgf8A1qfGCzAAE+1K1wbubXhvTft14m/7inJNehGNeNuB7Cue8PWhtLQHADvyfUV0EAY4zWVRpKx24an1LVrADyeKtYA4AzUcKYGM1ajQA1ys9KMCNEY9qsxoVHPH0p6CpxHhc1PLc0UbESDkDNb+k24IDEVkRRkuCeK6TSk/d5GQKzlA6aKNJExj1q3CDj7o/OoYlzVuIAYranRT6DqSJ4I+e1WlYDioFIxx1qSLLHkV2QoxXQ4p66snQ+lK7EHpinBiq+lRSS46YH41bpowSuxkjDI4qrMMjpTpZjyB+dQ+YxABbipdJdjphFoRVJPSneX605WHfrSSPxxUOkuxpdlaYL0AqlLGGFWJnO7IxVd3JHpXLUpR7HVTTRj30KjPFcvrmnpe2rwuuQf0rs7hN4PWse8tuvHFRCKg9EOvRU4ngutWT2d1JE4wyn061juOua9P8faX+4+1KMFeua8zm4J713wlfc+SxFJ05lVwcdMCojnPTmpn4FQNz3rSy6GG40nNFIx6UVSDQmB+uKCeKbnPpQcZ65qFqWtR2cdK09CgNxfoOwOelZanBFdP4QiLPNJjoAKUtDSCuzsrdVAA/Cr0WCeKz4VIHNaFv061yTfY9ejFJF2Eev6VYVSOaZBgLgVKR15rLV7nQkPjbng1ficbfm61nIMdauwqCvJ5pq4JFlGUkA9K6XRyGgPXArmUXGDmtnR7jYWXNM6aS6HQIdvSplJPaqHngr1oNxx94V0w9S3TbNESBT1qaG4P0+tZUchI6/rUqSc4HWuqN+5lKl3Njzty/e61Xlx1LH86jilOMZ6UrMW74pu/cw5OVkTckgHv60rLj0P41IFAHPNROfQcVL9TRMhaTB5/nSGfNJKQBjPIqtu56/rSd+5vGCZO5GOtQOVNKW461C0nHBrGafc1jEa/XHSoLq2LRkggj2NSFie9QzN8p5rBxtubcraOY1yyFzbSxOMhx3rwvVoPs93NFjBRyMV9C3g3A55x6V4r4/tfs+syyYwJDwcYBrWFmfO5nQaXMjkpO1QPx1qYnj3+tQyHmt7o8JeZFmihgCaKvQCTnsBmg/SkHXmgfWs2n0NkOXBIrtvCaeXZMQv32zmuIU/MK7rw6SlhFhetQ9jooq7OjiycVft124zWfbuT1rShOSBg1gz1oF+Er3NTEdwKrouDU6k44qLI23ANjpipI3IYZxUe0mpIhhwD60WGjoNPthMuWwKYSsN0yKOPapYZxDGAMYxWdPPmfzMjOelDsjandM2oS7DuB71ZjhZyMVmW8sjjJzj2rRtZ/JZWBOQela02jv5ny6ErMIjghsimC4BYcmt+2ubHUcRTRGGduA4ArKvk1CynMLAunZlXjFda0VzljiE3yyVmPhuI1/iOfpVhbzug/nWO8kjDc8R/LFOtpxvC46+tT7VXsaulFq5urcZAyOabJIuPSoI5BtH86HcHpn8a2Tizm5NRJCCOD+dVnAXNWlQt1pJIBjqPxosjSMlHQp5x0NRsR3qaSLb05P1qtMrL/wDWqJWOiFmMdutQyHI6jFMZ+SDTGbjiuKbOpQKd0wUHmvNPiRbl4Y5zjahNek3aEpmuE8cxGTSpe2O9OnJbHk5jSvBnk0uCxIAxVd+OtWJshzjkVA5PfFdB8fKNmQMee4oobJPpRTshJMkyOaTjrScCgnjFEXc2siRCA2e1d5oqk2cO3oRXAJ15r0Xw+Q2mwFemKyndbHVQWprW6kda0rcseBVKI+1aEGMCudtnqR2LsQOOc1YUcDpUER4xnirMajGelRJs1VhSRUbnBHrUrfnTNpbrRdlNlyG43qAeCBioZD+8yPWqjt5Tbv5VDbz75nLlsdgKTZrCVmdlpjK0Sjac+ua0lhGzkHd9ay9Gnja2jCI/m55yeK3d5MBzgEVtTv2OvndtCC3QeZ81dNp13B9n8m5bb3y57VzOQo3OcAcn2rh9Y1ue/wBYdLEGSBAFIK5GfWuiFRxMcRSVRansN9paPEXtdh4zj1HtXIXl0jzrGF8p0PReCfrVLSr3VY4ImZykiDgJ0xSyXH2m53yx4m6F1GM1FWo7aIywsJRlq7o0kuCyjAz71Isx9s1XiDKo4z71IrAtitKVSVtjtcV0LKXTZxmpzNuXk1TGO+KeHXOAfwzXQpSe6MpQTHM4PQ1Uuehqd3C8dvrVW5IJ4NZzcktEaU1qUNm5ieetTJGSKci96njXviuVt9UdUp6FG4iO3pXFeN0B0O6UKAxB+bPSvSBavcHahAJ9TiuH8eBINKvo5FKyKpHqCaUIyvex5mNqJwPn6VQv8TN7moWPpUrK38R5zUbjBrpSPkpayZE2CeaKY5560VWhA8AHrRkZpG5owam0VsatX1HKTnIruvC0pawUYbKnHWuEGMgGut8HXAEE0ZPIII5+tYzbRvR3Oxhc4G7Gavwv05rLikXA45q7DycVi5dj1oGrC3I5q4jcVmwcHArQi4FTe5qrFhMGnjGCMHNQI3NTrnrmhyLsiKaEY5GazmQxy56A1sbyTg4qtcxhhx1pc1xJ2Z0HhUPcQuqLnYc9M8Vv/PjHB/DFct4UvfsEzrIf3bjBx1rr7PZcMGHTNdFFnUp6FPUFK2jBgcsNv50eHdE0vT9NSG4yJXbeznqT6VrX1oJQgwMK24A1Nb2pd186PcByM9Aa25neyMalVShYSWzS6XZECkanC44H1x3qM6KIpPvsVA6hQM1txo+clQAfShsiQLt6nrWjV9zh9s4vRnPzWflkhCxHviq7wEKWAOa6p7ZWBJFUbm22KcVF3DY6KeLvocw744IP0qMyYPHHtWhfW4IZh1rMwEJXmto1z06UlNXJGkOKhZmJGePpUisRnA4+tJwWFTKtfqarQfGhcjAJP0q7Hb8fMCDUumkKRgDPq1XXkgR8PIpJ79qN0cdau07IoXkcMEXE4yRnG3+teY/EW/t/7Buo5vNErEhSOc16LqmoxwEpB5MgH8Txg/zrxP4q6h522Ngo3sTmNQo/SjbY83E1LrU8vKEECRicd8YqKQgE81NI3JAz+NV3b0xisWmeHNa3IWbB7UVG/JoqiOUsYPWjrzRn8aCT9KlO2zNUg61s+GrjydQCH7sny1i8etSW7tFKrDqDkVMk7FwdmeooCvB4P8quwtgDnmsbTrn7TZxSLzkcn3rRhb1NczgepTldGrBIc8GtCGTsTzWPbnnitCNlHNZuNjdF5W561agZT61RVuMnFSwSemaVrmqLjJknHFGwjGelOh+bqathQB0puDFYoY2tlAdw711vha9Vm8qU4bPHvWA8APKrmrNopVlwSrLyD6UQjZlrax34mjWYKSOT0rZiiBZSOmBxXnUd1LHOsjHdj6811mn6wGgQtJknjBGcV6EIq25yV6Ta906IRjtTHiBPSobe8WTA3Ampi+R1rT2bPOcZReoxgRVK7YnIq3K4A7Vl3U6njIolSbRvRi2yheHaDx2rn7nIckH5a0tVufKTqATnGaq2rpPYrhVLBiP1rilRbla57mHfIrshtIZLiUJGM5PX0rVkskgxj5mxzV7T7dbKzDsMSPzx2FQXEm4HAxW6oci1IqYh1J2jsjNlZgTgHFZd7PIF6nFaVxIFBrA1a6VUIyaz5ZJlTmkjI1S7YKck4rxvxnd/aNQdSdwjyBzXf6/qQjjkcngCvI9RuBcXEkgJJLE1olJHjYqdym+R9TUD56YqSR8cCoG+Y5NNO+55zGHPrRSHkntRVWQrlvd3A/Kk+tIN/fkU7qKzu+gldjT9KUHml25HJxQBg1e6GjovC+oeU/2eRsK3TIrsI3AHPWvMImMciuv3lORXdaberd2ySBuejDFcs0z0MPU6M34JvQ8VfjlwvXPtWHA5z8o4rRiIOCcVmzuTNWGQEDINWYmIPFZ0LgdDVpH7mkolpmpBLgcmtCOUFevNc+ko3Zq9bz5PJpJvY00ZsxyYPOKtxspwQKyUlAHHNWoJwQM8VTEbduiyHCnPtVkWpWQYYpWPHdBSCrYNacGpKUxMcn1q1d7FxiXITdwTb0xIPqRV6PWZkysydPY1jG9QPlZCR6CtjRrE3+WuhIIR0BJ5rspNoqrGCjzVERXOtqTwSKoz6tGELbq7P+yLLywptose68/nXLeJvC0YtZ5rFWV1GdvJFObm9jmpYrDt8qVjj9V1b7TKXkOQowOelXvCV6blxCpyu7kVwupLcqWBidcHByMV0nw1aWG8YTrtV/uk1zqT5jrlOKWh6DqdwSyoDhRWTPegZGeal1Fx85B9q565mCMSWOfrW7fMciko7Et7eYDZauS12/8AlPzDNP1W/wCvzVw/iDUxGhO/6VNn3MKlZIyfEupbsop+tcfK+5iTU97ctLIxY5JqlIcDii/dnm1Z8z0GOTUROTxmnNyfem496rToc71GnJ4xRQWPbrRS5WBcBI4P60hzmnBQSc9aQqRSUUUkNLdQRR2GCRTuh6Z5o659aV0hNeYds4q/pOoNZXIbJKH7w9RVClHGazkkaQdtj0azuo5o1kjIw3bPIq/DJzXn+haobKVhJkxMQSP7tdtZzCaNXQjae9ZOJ6VKpdamrG+B71ZWXAzWSJcdealEwAx61B0bmj52G4NWIrjGCDWSkny5qRHPqBRqClY3obv3q5Fcc8nj2Ncus5HQ/lUqXe0deaVi1I6c3SgjGc08XhxjNcyt/lsE1It4WOM01dGimddo0gudWtoXPyu+DXr8DJCoQDoMADsK8A0e+MWrWrO2AJBk5r2eC78zLA5B6GuyjrucuJfPo2bjXqg42mq9zceYhC8E1ReX0qCeYhK6NDmjRSdzzv4gWgRjdQ4RxneuOtcjpWtvZ3SEtkIcivQfFi/bLOVDjcQccV4neO0UzKQwZTjmuWpFp3R0c9j1uXWUmj3I2cjNYmoagDnnmuFtNaeHCOx2/Wi+1cMv3xVxaMZzsT6xqIy/zeveuE1e+Mz4yMA07VdRaWRgp4yaxpGyevNErHNUnzCOxz1zULE9aViQeKTJ7VKRzWVxhPOaafvdKk25PSkxyMVpHYLDOQMkCinN1OaKdxFsLxSEY60/69aMA9alSsERuOuDRgd+tPwOuQPpRt55607obQwDHb86Xmn7QOuc0HHaspeQ/d6EeCT71o6Xqk9g3yMWjJ5Q9KpADccDmjGRyKnbccZuLO7gv47qPfGQfUelTKQcsSfYVwUMkkTAxnaa3dP1dSu25+VumR3qJRO+nXvozqY5ASMEVYzx1rJgmVk3xnK+tWY5+Dk1FrGykmWWfnrTWk54HNRF89DSbx+NS7sLjhI27GRT8yAgZ59qjXGRnirtns3Zbk07lKTJ7G3up3Ur8oz1xXsmi3LNpluHI3hcGvL11ARQARAK3Ymu58NztNp8THIPc11UbmdVo6xJTjrSTN+7PNGmxNduEiAOPvMTwKt6ra2tpZyPJcjco6DvXS2kYxm7nE604wQDz615B4ui8rUZXUcPzn3xXpWualAN5STgdM15f4nv4ZnYbgT146VnLVaBUnbc5u4uNo9DWXc3LuuATipbkhyelUnFYpPY5ZVGyBs1Gx98VO3UfSoymaWzMubUjPJ45FNIHXmpRxxSEfjWkkug2RrnPbFHfgfnUmPQUFaLsSIwAfvAYoqTHrRU3Y7FoJkjvSMmG60/I70cY6Vd0xRRGVANGD+FPA9qMA9AaXKDlYYfYZNBU+1Po6kEClzJEoZ2oHXpTx9DS+lRy9WVewwg9zzS8AU4D1FBGTjHFFrjUr7D7aeWBgYnK47DvWrBrLDHnLkeoNZAAHABzQFIHGKfIVGpKJ08GqwSgYkC/wC9x+tWBcBsYkDd+CK5A9jinKxHQkfSk4JmyxLOzScex/GrEFwF6nAriVuZwABM/HvTjez55lb61LptDeIO4mv+MA12WjeIBbaTEinB5BJNeKNdTsc72x9cU37RKVwZpMDtuNbQsiXU5j6BsviFaWEBSedYwPTkmuf8S/FqKS2kh063kkcjAfG0fnXjZbIJzn1zzUe7ptFErMI4iUdDe1HxJqF9M7zOq7v4V4FY8twXbJOSahI45B+uaTGB0P51SMpycnqDuSDxTCOnNPPSmgHuKi6uJ6DDxSEexqQgDil47USQkyIDIyetBXPNSEe9N5H0qVKwNMaBgUhHTIp+Ac8UvGKq4rWIwMjoKKdt570Uyrk4AxjJpQoPGTRRQu5imBUUje54ooq9ygA54NO6DniiiokkCYuOCc4HrTO/WiisluKQuPejtkk0UVskrgtx3HryfSkA65NFFNxRowx1oxjBJ4ooqDK7uBUE5DUpABwTRRSjuaoNq560hUBuoooq7EPQTsQCKaCB1PNFFRHRkqTbsOOOu5aaSoHWiirauaNgMHnIoIxg5/WiiptoMOevFGB64oopIlsQ7SaTB2jpRRSitQTAYA6ilwuOtFFVPQHJtCEAAHI/OiiijmC5/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Video shows photocoagulation of a smooth walled carcinoid tumor with a Nd:YAG laser. Tissue blanching is observed when the laser is used.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Henri G Colt, MD, and Praveen Mathur, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_29_5598=[""].join("\n");
var outline_f5_29_5598=null;
var title_f5_29_5599="A1C pramlin vs Pbo A";
var content_f5_29_5599=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mean change &plusmn; standard deviation in A1c and body weight in patients with type 1 diabetes treated with insulin plus either pramlintide or placebo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 440px; background-image: url(data:image/gif;base64,R0lGODlheAG4AdUAAP///4CAgAAAAAAz/0BAQMDAwP8AAMDN/4CZ/0Bm///AwP9AQHBwcP+AgBAQENDQ0CAgIDAwMPDw8FBQUODm/6CgoLCwsBBA/+Dg4CBN/2BgYJCQkKCz//8gIDBZ/1Bz/9DZ/2CA/7DA//8QEP/Q0HCN/5Cm//Dz///g4P9gYP+wsP+goP+/v/9PT/8wMP9QUP9wcP/w8P+vr/+QkP8/P//Pz/8vL//v7zBT3xAmgFBT30BNgN9mgAAfn982UE9DzyH5BAAAAAAALAAAAAB4AbgBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vbIgHwPCHxS+xqkSFQEVEkUgF8LRF8XH1aMRAgQCEUXB0dEf1uJwAQIADAwABARnFgITABMCFgAFAQHf+eP7bOXq7OvOlAsAYGC9e/m+8VuIxl/AgGYMGhySMBrDi2TKCdi4kZ2ZDQLSMRCwgYi3fOEwqvyikWO2MxgEQCgAQQAGIhSgfZu2coqC/58KhiyAQYXEghVbhlYxilRpqwo1IVQwQuHkDx49pxjYamAECQAGFlBRYKCBlAYojjRAOrYsgLV+HgR4cI4AvToBephAMSJoVihbAcww8AKsWBQpFgyNIWTFi8UxGix4oQIAWRiJKwMgkRgG4yMG/BaBq6CBisxCZiiGgaJ0WtdkzZI2jdoOAwgSQG4sgDdHCMEdPv9tEpis2LCWFzRIYSDFW8INOihwMaKBCwMkyHawjp2viwYjXCAJDVpsg64LtiI2AMN6afLnf7pFfn5EegNp6xBIp61CBA147eCBEE4Nx8RW3CGFHAArJIbcCB0IEYNxy5UVGwAqlDVYZTBgR//EeVwtOAR95HWowAvQBRXfc/KZRWJQJtpBAEECOFCQR3MgJARfohmYxFaKsYVchzAYZ9gQFDbQQIuWlbXiikO0RtYMCnxFxIssxpDCdQao8GRoF2IJJR0MOKDBOwBogKMc93hwQGrB+ahEYFeKlZ4KKyCHIpUvKDDCCCsoMEOgzU2HHQmEKdDBCOP1OKJ58IWWApUdzjDYdx2AOR+kKpJXBwYO7CaBAwTRcU8IJghllpzjGVAEciSMEBZyWsraAQokoGhAByqQJSugjWXqgpVGLEBsnSyyCF5XRMWQngsoMimmp2pMwA2opQ4hF29y3WRqACb8tqNXrMo5jxAMrNn/xz0HDDiEdeX6eG5dRxBAVwXpfAvAAEV8F+9wEziADklHCMBbAOpegcEGAdxlBAYFNJPEPQC4SQSix/6L0QM1bSOxEBAXQFIBam4BqgPY5DuEBBZgw9vEBKE6mngaS6LoVtLZUQBdRbTEUcJVjFRSqB/Xw9HLSFAcrhH+1vwIoi2wwEILHuo8lREG37iFNrxxbYTXQ9hzzz0zAtCuEYjm5zQjC9BABA1i2YFwwQcD/URLBXgNNhF7HzQ2wqXya4RkazdigAxEyOAqOS51dEQANxVwNRUhRywPPdjwzHfWMAthsREdzFB4ID95uZxiXNVARA2Lv1FB4y+Z8foE7kAg/8RLEhSAzQaaG0ExADIb4afao8eRnemJLSCrAS4opiSVCqR1eOKtv1GyEHOfUeY2PL8k8s+dA7D0ETDEXbwZ2ZXWQPkLZLrrag1ATzwSbb9t/huShz25H7+ffUQMoTtfElTgPl4xQUozUJJiCgi/JVXpClCTGtUyNoeirStbgjvC8ARohAxFbWpdmpCgFLgALtlnASlQUq8c5YWb7YqFcEhGBBJWgZdZwGFsytbnyHc/NLgwZ7CQUgdaQASqhWUyKvwJKkgWqtjxrVTpwku2gve/DtyHMPMDQwRBSMGxFBCGfZDSCpSUPPed0ACqGwILqrcKC3RsI9kSwvdcAg99Cf9hfEeIVYi6kkUv1G8IcPuJcKawxQneQYxkXOBWTviC5/0kYwZgwerYqIpySEUCnNMWARwAgXVMoHdx+J3Z3HUEXe2xMGOY3hAUhzquWFExKXTkI4vlNkD2MAoExJlmmoDI07VvkYppZPxmCYUhFjFCrtANBEaCNCLUMA+i3NeP9siVMZAljUJYI9qAksBEKpIrqEPcKsEElOg5wYMS7NKOfjJGX5oxmLLsohU8WAMQ7rIVGAhAxyKwPyE8YALr2I8UibDDV1GTTl9QgPJUKQTFWUGEaCTCGhVD0YXu8ZUVTYExh2BE9CBxmA9MQy53dU9YkMyJQ3gjSkMZRyoa9KD/CVVeA5xVSyHALQsMBYBDmZC+cg4GmwDQJgehkDus1fEO0cRjEUy5xxQM8gqIqc5nClm1K/zRprd8QiQnOVQmPAAbAjvCBFTWhYU17AgWuEczfRdH/xmBL3vsSwqkClXmzLQIPwSjFKgqzyZsVAgtQGZXk1ATAmAjjkLQgAMCSlaFOQBlISnCHOf1OMRm8K2mfEF+FAqsKawnBX0MQ17naYAW1JNqJR1sEeYF0K+5xG5TEBoAiEYEiAEAJDgS29jKRtA3SUFRQHRCZJoT2j+M1ICqTQIDrhaAo5JBb5l0pgAAJMe/Aa4ILo3CCuyj1yFEZgSgTa4lYLdSAEggXf/E/6EU8AbdtZoXAg7wVmWLoFQpfDe8RgEnCb67gO6KtxEBDXBj47EbDThXCpWTwOUAkLkicMwBoOwZYt1aBS01xwA0kAELZEAD9Pj3v5sgCQHsAVspzK52t2NHAUKlgWhK2AiXtQIKSluEwII4E7odWz8BMI8RE+DAV9heBLrHDp+ZI2mIrZhvsRBRiVLyxpIwcnkVy0kB7PgNLgZeqnAqSSdD+RJigwAE7rFjBddowORIcn2r8FfACvbLloAIWgmSzwhjOckUtgJZMrzhDn8YzoyQsxHGLIQfDxTGW8gvkPoKaEZIOWGcy16OkqzkRtfi0YPWgAQk8J9DY3fLlj6Gz//ce+cjrDnUvKjAj9XL0iPkGdW7qMCVc4iEGMNaF639gllZzbJ72HkIWfbckm+tC6gU4Ni/nsLJUtYzl5Aae5TWMrFhUYEmllcb4NOCbGkbtpucKdoFifapp42KUDHWCMrQ8day1jfsRQAC8s3xdV1NSnKvIqxKyJ2+rcBedke30GLWnLx5ewRb2/sUDKAuEl5nsAig+QkJXnCDjSAy2AZb2AdfBbYdVwQIvJvEWzixTFIcjxZjQ+FsTUJ2M16KdJ17tXkrQBS3IGQiF6SJmg6fqcXF8llAQAMRCAC+J52EV/ccFJBLN5mN4I6NxNfTBT96KQy28fICQC4bkC/Rk1D/UKl/ImIPODay55x1uYFb2l5/xUicnux+nH3caT/FOwpgAQcAudRFr3fcVRGBl0ma1kow+N43oe+IGSFdZJvRrNdw8SF0ffCaYLjuBlx1jrdaCSuHfBeAAQ5qyMHjM/m7P8Uu9ranofF35LnmvfCMfPBEDlSXeYm9sGsk5O7Z0F6C0VcPBQocQAQIQEACEqCTiqQkDj8P+tDJsOzIGuFMR0YyEwTP+yL4HvjCJ/4ALjD84IvgAMWoiDDm0PQaaX0M2xaABcuvBNRjvPoAuH7whw8N7ifA++APvPjpgPXzj6G9RDAqGkEEA3d2QpB5HMR5w+B5TyB/2Vd/3YcA38eA/08gftSnBmFHeklAMrjXBP3WNdFlLTwWfX6zWwYoPqrXVa23ExQ4BA5If9sXgRPIBSfxDccHB5X3dEbwAB1hekkQcecycbfTODqXd+JVg9GQAL83f9pnf/jXgl+QE64HhWxAAC2mTwGDcpK1DFkgcrbDYyp2bLtRhElwgaNjgTKYf25QFZ1HBw7gd2O1JudlL7TDBTVHckOwEe13gpU2WCdggbGAMnQ3Q38nDwZjYFCncqAmQCeAAMWXELHgMxYwASgnYiBnR0sAdxpDASXAfQeAhMMgC2JjZz2WN3fnBu4nBLv3LxQQAgMQAtQghSyoB7O3BrmhbkVAZTWxeG7nBP9m6COfeAGwaH0nQQx5QDvzcIpV+FpGYGbLB3hM8HiscgDEhwAncAgYoA0E4H9usA2lFwipeICLyCoc4AEZYALXiAgMgA0ORwdBpwT/9HJbxwSauBIckAEZwAGMwBvm0IFqcBu4SAQqVYunx4ejJCeNyH36GAUECQf+uAZVB2nKmGYVaCAU4IhKKAXIOImykIFjVwRjBQa1VwSVUwDcmHtOII0L0YqvCAKUo40nuQoeGWGKJY9Y0HyN5TPgFo7iuBIH4IrDGDTs+HCqsHaWNwQRSXMEw23YM13HFpM8iYIYQY0XYI1YwI/1IAuLJQD6RJReAIDAJhMz8jEF+AQiUHz/xmgNHJAAGWCVW/CQqGAw6tdcBCgBHrkz/HY0YCkE+KJPzleCZGOQKygNVIgL95iPrNJj1rImVMeMVQCEmCMAdlZxZJgEoDgAN5gLjZgBHrCQrMIADbMR+5N0f8OLUeCFJEeJfrmTBgmIupCQGek0D+CDXXCHYHhzZ7aHvrh/uMCSITBs8XKLS5eHsNOQAtGavFkLIACUhSknSYmUAbYOXsl4BnmZmQkLVIkAzZmYffeRf8CTskiYsyAC1ZiOxfOOSfBVBgMBJYGJTMCGwpAB18kKh+mZxXMPEzBmw0kEEfBYspeIT3AC52gIIJAASeiSYHACJoCP9nk+5AVpFjBi/6JHkVTwDA36BwdQEcCZBbC5oedDet9YBA6wAXbxcwAKBRmKoIGQARWRAVzQihfwAR46VCKILb7jbCcKBRxwASrqBxRggQhwAD3aBAfAogOQAeDHnFA2LzNXBCRahzkKBSXgAea5B41ogQNQAmx5pAlQAkE6pEQAAglxASWwnUPFpAkzm7dlmtS5BBIAOBZEBCGgd3ggAhmQACBgpPngokMAAgeAAFrKonfqpUIqBAaaDwnQaAEzMO3Jn6C5EaxmBSO5g2pVmbnIEVpYBB6QgnVQFRewkBmaEDPap38aqEeanF/GMRsRAXFKdREwARMZBTj5fGLJmktAhElwAh5QAv944IglUKUFeqBTIKYVEWp4WTDuAJrGyQTpVzSzwwTu90ZfmAQWWgdFiqdhgKrkZogVAKvrBoLNJA/a8IZhY10EhwR1VyOR6gwDMKpp4Knj6AWH+g2JmnEYMFYSYBd5uRt7qQ4kARLTWpZuanhNsKNgqgaOGAJVCgbE+g0HS2wzKaliZ2aR2TvywI8k+GJdsKALiwbtopJfUKTx6a7iFbFFYJRWRwWoeZuzg1uWigVz2rFkcAIhcAHxCn9QgLIJs5VdaYehMmR4uD0EEKfAZpBSkADzKQYmIIwyWwggYAIIwAHpeAIcELVN6wQFumQUALULubUSKAo1EpB5KDJvGqv/ahCVUaCreoqtYNAuSBoFbzqWeECvnjMABkqnUFCz6cgBMRgOOXEBHpCloUBoSaCYMxSlVxCq+UCyU0CzVTkF0DddeKCPP8ovIoCZABAMIkAEf1oMnQsA5BkCwTcEJyCMQvCjGWCeJTAAqQINVRq1QgC7ACB8XnqhiZAuIUoEoNl0bFqQYKCn38CnW7CjaSkFuHoHB7C6CDC7A7C8CNC8RPC8byK9l+sBCMCiQ8C3CGoCA+AB0JAqBvom4UsEdisE5bu6H/C89QpgjnkEaoq4VmCBjIu1bDm/hMUR00oFcRsARGsFaym4z+u80DsE0su81DgAxWCgjkdKzxsCZ4nA/+M7vhRRr+V7pOa7voygdFxYBHMIpe7JBRbIovdnv0ZwAp24vFeQrg6wrk8QuZmaBeHLvby6uotYwNKrwACAwz8Katy7vOGruRUzAD1avvuSqERMxJlQdSzci18AvNHgohQgAlNqtyUgAjKrgJhJATuaAGbqBPt2BceLBe0CqMJAAagrsgz4vCVwwMnbvHYqOKtrnqh7lhdAtZh5ucJrvhkgAnybqIHLx0icwdYGaQTBactaBmiLohpaBCcgxXdbxdQwmE+8uXYgrVtAAYF7pJR8j0faoM8rwu16AgaKj4JjukTAyRmAoJ3YvUO6fReAj4map3YbyIsgZtlgJl9zF/8TindfEKzCwLZFJ3xHOqfGhwcqvMRjUMAuyAEHsKMDwrckXHAYbDbfp8aPMA/mkHB8Y1idRAAQYLa+awcHwL3aSgdfzAbKLAQr+AEuCXxXQMt8u30Ke82601yMWZzw6wauibNh8B8aMZ1lxTCsdpfJlshosM/8LAYb0KhlMKubk23zhQfWmQkHUNHRnARaCgAFarvOkAAN2qVXsJYP2wQgLdLtADlzoT1LqX5EkIHa8MIoCQb7279KEJ7C8HqXsBMj7QQKfJEzWsA+XQS0nATM7GraWQXl+7llsHYFQIln0K8gsxHxZq5GC7mYOgXwmcWaMH7cGw5RCwLLu5ZIS8n/USt8HAAMH3CNPR2kAFC1IvAB7EwBBhoCHBDUs5sArlivYn2zOYzCRdC5F+nIKLycSFvXbB3USa2dga2lft0FZtJ3u7wFH+iv7nUmKCewYBDGsDB+GWrEOpG5Xsqi4de90MCZr5jD/JKhPnykgZvKLLqrqg0A6Ku+sp2lwXCz93cE0huq2lfX3YsAISCj0Bvb5bvbvwwNHA3GMXc9RLABgyyxx0axDCaZJCnVuhkGljwLwoAAgauP3euCwseib1Lc7VrEqG020IvDgWvA6L28r3zBAPDKwRfIimsR0duusX25CCCmGVAC6BjbxJ2oxr28+v0F3CwPDH07iyWdIfcO/yh2m/4K00UrBsdMC7/s0fAdf4DLAa443gJe3uWrwLGNwwpcwAEO30cafLIrBCdQ0Zta0UUw4O0NutrnJsMNveRd0Tfe2FvwAE3EqoNW1Tn7szYnMjr4sltwzrIwfuRbrxkqo+Ob4+Yt4uktOCXevDq+2oCcqMEQpFV7BLltBDKu2j/5fRfAo9snzMub4wA+wF9wrBSnnxs8j3gw05vA5BM8BK4IuCD+4R5+3iNu5fxCASwq3MsrywaaqI6b5kdQArY75s2LycLgAS65uhngimvu523O4zcJonA+BNgA0dCIBy6c0GGAaas1Abk76neg2aYu2atqk+gi4RSaB9n96v9d8KbwpQG/9px0fgcVjutgoBtI4HIM/sF3oOTCvgURKhMJzj9CvuyLoBEzsp8tHQBll8/S/gioLl1sp+3b3ggl6Z1DYHeDCM4NEe3hXgmRdshLMKnXHgAdaNDrTgnvFgBlAtAQ91jMJl22bKv1Tgo+vqo0LQXNujkWQJnSF/Cl8OlZ0K+vs1gQVq5/sw7WdfEYn/Eav/Ec3/Ee//EgH/IiP/IkX/Imf/IeD5dtIGj72pjgSoCQZWUUv1vVjvI2z/EWf/M6n/E5v/M+T/M/H/SJh/Eq3w/ujgSQOd29EypXp4cLrwf0Hs5Qr+5nS/VuMBKybgUr+xI1sdAj9/TQZPX/x8kHUS/1f+DrWWCbL6Ge71DQYh8Rb4/IcZ8Rc0/3gAA5e3BsfKD3eV/0bcD3fQ8IVFf3DG8NnMRJWV/4BlJtjXP0ir8Py/X4kj/5lF/5kJAMy1Dwf685D8AwzDAHZrUBH4P5hH8FnZ/5QoD5yIwGIAoyDCP6t4AN2sAN/FcOONK+OMgRtD/w3gx74MNp2/CXb4CrG0f7tOAO8LBgc4BtODIVMZGxbmABm1YTvFETtHkGzq+HIJEONRGTaLAbfC/9EkD9l8aVBWH+dKDwcjQSpa8F3c+DtozuZSBz5l8O/PFvbNARqt5xNgEEAOGQWDQekUnlktl0MgOCACA6fV6x/8SCgECsEASM7Pi6CQO2kUJEUCG/k98zRsB1CApwPXES0AgcMIbMxPYMDxGfCAEYBDYSDbe6isDyIN8aNYQeuKikLuEqAR4CKiAEQEPxhDJTXV/J6CAKTgVhrx7M1CTWAhoFbG+ZJgQgAgLyTi3YLIWTen8FKwqIC52fI/wAJQCIjZGvw69Ni93El8Dq8DDYii3Ok9Trph7YHMzhidjrIN4B+K3k09cuwgMh8j4JVLiQYUOHDyFGlDiRYkWLFzFm1LiRY0ePH0GGFDmSZEmTJ1GmVLmSZUuXL2HGlDmTZk2bN3Hm1Lnz3IMC3HjZKtBsCYNJPJEmpdhoSgUBE9AIiP/gBIxSq1cbWuj0x4EnMRICEJjgD4MGAhoMVgX76IHZCfiwxpWbCBAAB2weiIrgIABeDHcDOOhalYCDB3SyaYA6l3HjN2Ccat1wZxQXbQHMaAiLB0wUN5wgMNjAzXFp00zMnAIQ4RRUSceQRdF8DAOYU1YsFJZ6mndvIpyeenIkRPC0DRU4RbBQgEFeYKd8algu2Hd13nfY1jE4ipg7AMvqRKiNaguEeuG3W1e/nn179+/hx5c/n359+/fx59e/n39///8BDFDAAQks0MADEUxQwQUZbNDBByGMUMIJKazQwgsxzFDDDTns0MMPQQxRxBFJLNHEE1FMUcUVWWzRxRf/YYxRxhlprNHGG3HMUccdeezRxx+BZKmA9IbgZaghg4yQlE6K2EKdo5JsMB0ohUhjqO0KgO0YoqIcUBIjtnDgLKG0JCCgLr1k8jfNwJjKiGPQLPDLeFB588w4/8tFqp/+6SKAPsCgUgg48QwwnTry6MSCU54irQhCC7UQ0kgpnNRBBTBVYIgFYCCDhAVWQITTNz4NdVSNzGRlMYssbdCAVw0YgQQADFiADAUMaCCLBlA4ooFQb80VgF8zwiAACMzsS1CJWmXwVQBmMOAFWm1FIYUFOI1BiBVeyDaGBhZ4QQUAcIXh2nEBIOFaGLQ9wgBNjSBWgQZUOFeIGbCFAYV5/3vlF1dd5aXX3oiclOfOiZpd8Flcba2V3AUaSMGAFIaVtoEOFHBhhAZcMIAEXDvg2GMURnChgZKReNddWxuIdYFXrTUABo7nVbllTIV1uOURXjagV4h4iUCDKzNKWMFXRQ7VYQBWuNbhEToQIgaGI871XwBUyDXacWHwmIiWYV16CJ1V7lqBFyzW9OaKcdaVbE3Npsgnoi8yOsFXsQXW4a5hYJjaIahuoIG2yc117bWH2BfXGRSYlYi32Y4hhY4NUOHwd6+GHPGIfqkDyi8AqMANBqwRyG4En33c1pdVWMFhtBl/QYERRlhBgRlsnzhjj0mQVoEORkgZ3iI0fzcFxv+7niFakzvAPGeWbVZZIkBggysKAAjoInuGTj8w9bFtJWGEWh2WfPwOUCABbQM6UAHX8WvftnkXHDdigfpVZ5vtk2PtNIaXXYA2whVveBAxBhKut73tLaR7lGrJUMxyJCJFoTBiEhP3DuZAmSDEc0SIAkKWJY4GalAlWqqePo4kQQySECtB+U4AgqGQEbIwJYeqwwRIExgMaAUQMczHDGnIBBU0j33omggBIpC9uyTkLN0QgAYcULofZjCIWchaC1jAghZUjiKzYIUGzCKEVFEmLM5A0hGAWEUkdKAFRGhB1CbyRABIYAJmmoQGIuCULhjlFks6SpZgkyo1ZiFTuKr/ARFYYACK/EEdflhMwdwQmltMaQiAPIYgVfS7V2HsEoW8neAEdy1sLYBysHLBKA3AAiLUQJETAUv22BKML0yhAATgUirmZKcV9Q6LWvTaETw5A1BGbJSkDJsBTjnKFAyTcYVMAhvdCMfS5PJRVBzRAmhABBp0AFulfFUysbVMUDYzU5e4Yg18acSHEOABRskeAaQ4KEEUAC6uoKYHrbmhqQnTmAaQARFkgLkCMmSIm1TnQzgjj2Wtooyw0NMudNkhBViuW3h7Ab00ZYBDDoGV+GFoCBNhw1um0UAfawAMFjC+UzaAce0i3j+HEND1SMAoDxiLBzkI0muQ1D/7BFfH/3g2s8Y5AZvatJV6ulMAxaBwCxtQqk6dwdP7TLQBFa3VRd1HKgP0cov4840jbNnQInx0he7RJPsGmgSTolSlEGtpIs7KyfUIIDe1XBUR2Bm6eJ5DqlfhZRa7agSfGjOog/MqhKDogFPUE2H5PE1Rh0CDBVDVquHCKIfoCIi9zu1IZWWPPwGKTLcqwKUf8qERbNhDGTq2NDHQ6CpbaSIChOaWYpwNBCbgAE2YjrWMqderYCoEmZ7oWHXgixEcYIk/8ZG31alXyWaAAsgKQbIqco6g7lKAZdhxtbxRQAqgxqsh/NWXhxVRBexx00fJwwIT2O0US0MCGHSgAzAwb1zTOv+iQBGpScfgL3znIl/62jdHuWDDAYuAj3Z6libqg9ULfpa4GQAvBQfFEQYqQAxBiUUCk4GqMPoaEvHZQAYskIENRtArFMxAYxX+UXee4g8vAAIQMm5uTV5ggxsM4QY2cEHHxJUk91rAUUZ4ALKKfGOagDa0Kygtpd6JRC7sNQsSqEApkmwkulXzFQ5+FYQb8lpExpaEHFQTHNjQpiYptEpl6q2nRkBiE6M4wgJhckzJPEhDaAUqxLCxlc5oybC8eQw53rEQejwthaCgAzrmsQ0UredDVMETZwrTmNBI6CzcWbh5Doe1RgCDOJf4xCmOk03fSeVEUJrSQ2jLZtzEZVD/oEDMQ0gkPGLQtRSoeH3SqnOUGNVBWCyiEY84Qh0yfQX8ClYFMKBccDsNLGd8awS7rmJwmJDkN8iCFsDoExUAdeYhzJC8gSWXyEymKUM/2gX0lfYrTjbZQU5A1VowhrazQA4ImENRjMJhsomazcieEpkwUEFpSSbnUvdqBe52RcPlrWcopjoJ43GAjflKaE4HdAW/JgIKeg3mITS8A+82xBDbJ2kxsnkJQ+muE2oNgFvrgeQmv9UCSq7yJ5yHFsZ+eRM27mky1PwNCkiprnSOBglw9oxE2EtymfvzJcRgBAKn7lEPQfQrgLoBT5Z0Qp9kBLqG9cO3aCAKArhVwP4y/xFaX0LM2JV0D2JYS4x1wAYIsKj3KlmtoSYXEeUKCrcL9mTWlnsWPogoBh/BdTYXBskBrylqL8Djh1eEWDAOYCScLL/OKLcBZsCzzlv+I0ZLQQfMe43pAoAGIxg96ZtQgTsIW+pDiMGPvS6OoMNeCTyHgM+HcAeKM/BgJOgAxRgS85nz/ghPZw52653xIswO6cmH9nCZL/a6inUIDNg7gxv/kNVXN/vIxbveUcvyn4s69fn4fPt5n/hVFMGd2Yv+LUCAgwHsXwc+qPxClq38jgDv1GshrAzLigAELmD/GPACKEAAUQKGruyEYCHNdgMNjkH/GJABPwACOyK1/u0fav9J/VKBz5zoHQBpA1XQAzkCiZSIDazgJ5juvyCB1RJCCFRwA1lwI7yIEcBoElJIhV7BBs8kBxlwBzVCjuiIu/4hp4btDIqNCD7ACDsQCTGCkeZhqajAhEoBFritFoiAAhZwAx3QCjHilQggloqAF9jwFvSNsShAAwcgAS7gBMwQIzjrv5wCDyLg/swuID6gCu9wKUhQCCCANbKk7GABUk4gA0xgECmCeo6BsTjj+RgMBAYABCBRIhAMCSAAjwLDDxfxThDAA+xwEx/CKISQCHhItYjPCBIgBFBxnQpxEzDjtOChVU7gAjhgFhtiAifRCESHjr5P84jgAMrQFy3i9xj/CfiMkQhKwAOUUSFkL+zGag3gSRGH0Jo8oASmMR8g4BQKoxj5Qgq47xnD8AIO4BvPga5QwfuM4BfWoBilLwk4oA7ZMRz48E8EpcOILABoUIQcKwQSIB+vQWg+KJ46jAJrzwhOwAMQwCDDYQOcUQhgTNxykbUwURMP7wAyYP8yYB0pYiGDcawaoZY0LRUayAQy4BR1DhNVkCMlwoYEBQ8C4Rwz0gkCUe4SIAcLMo7UYMuCL8Mg4IL0AAM2IAAyDwNSCBe30Al2sRfV6ACokiqNcAAoIhuUQHQeQDAC8gn+YomkSP4CQtAwiQmQUSYvBAR6cv8SQC33oCqp0gQQoC4R/4AgEyAvPUAFPSAv8/IqmeVPvqELXyEK76DIZGMogsEsNa0EPnL/PuABJ+QAjFAkj1Eu6dIu8VIv+dIvY9EuEcAE5NIyjwAwI8LMBOU8omgPREEUxq0YzATfntIJFFAFkzFCHtM293ID+9IvQwA0RVMuQaEtN/AnISIIhdIQuQAGEU8dRjAPXFMIKoABiovKZmgKc1AQF+QATCAEdvMqSZMhYHID4fIh/gQAaiPz6MoitXEImHIoMusd8OII7mncCO0qsRJBQIADonEAMuADRBMA8FMiPBIkwxMi7kEIwoj+zOE84cApxqIYDqIL3Ku4qGiGBnRA9rMEevI/EeAAXP9SCHJzAzNAPeaP+1BzDxjgDgpiQqngDlYTge7zKhPgQO9jQzv0Az40RI2AMnPQRk0jApTDAmJUjKLM/hZPCbBTBRMAAS4gBCSTPihABBCgJy+gSUH0CtiSAd9yPVoxEDBihsTQNh/wBEpgAKD0Paa0Si/gShFABKK0QIxlA5wyIoCIApY0MsMwBAagBHjUNNaUDt0UTlkoxI6AAkLgAhDgBArUP4FUJxgVAT5gAROgBAhVjQwVCQ6ADnOwPG0iUj/gIyuVAzyVQ/IwSRHhO7n0JkBVVEuAVOXilQJANjPiIttTJVPyCkxTJUTgMTNABACAO0PgIz0gBGDVMbCQHh3/ohppbwikgiH5DhKu8k/PAQTyNE7HQASMsFgDtDcQoiKED0kpQRSjKlef4CoVFVvDoTbJUF0PlSrrkiBVlUTXI9ggAFzrrQDERFwbEhGIk0tBgE/T9ByWdAO1cy4RgEM59UorNTSpUkCN0EthNPNSUVmJoxbrERTGkwE5ElEv4AMeNRXwMwEesy9/80MPwF2HYFetow0rgiaRi1xBzFyfoFFDsghOwEkTQCqFAT8PoFSZYERBMkXqD57i0ZaSMycXggMyIAN4FhJwFD/zkwy0VQWBFRFAgC454BRPgAMQYGvhgC0tkwK0VgjI9k19A2ZfsSE4gA4XdQ8CdQA+dkcL/5YD9aBXQfJqEaE4hWAve1Ia3yBRT5ED5DYBOlAML2AvvdEqUI1fhwAYCbNfBeIAJnVgnyBQ27RJL3UIxrRdLaIXKWD/AEBbO3AK9TZYEeABDyB1R/czI1IIdlEWASB0W3IIzvQRFzBEv1YIdhcAqrQEercl2qFZ88GFZFQiEBVNQQBv/fN0W3UOLVVlOfdaMeIAzjQiEWAAsFd7iSB719F7tRUiP3IICJcjTWAAPGABH7En15F9iWAOcbAgz1RH4dcl2gAVNGMAMe8WqOEGIwp5nTQH6TJUofdYW6Jt+9R3uTd7X5d3B+B7H7gnH7Anh8ADAFeBQ0AEFpAC3Nd9V//2J+HXP+P3JfBgFqKu+9gLFhpJC9zMIoR2/0LABIC2Jdj3fL3xdrv3gRV4U/OTgmd3AB5RCM43ItnXdAFgL9WyfkMYhI2TJYyBke7qIKZgCc3OfxnTIlg2Jg4AIs90ACiAdgs0TrO3BHjYerUXb4XgTF2SdjW4Dgn3A7S1RN/3Vwm3IPdSBOr4JR7gAegoBIlgPRnhVqHAOQfFf2WNIrIYJihgN39VCJjWP59WgUX1gU+gQ8cXAJ60CB45AziyBBbQA+BSbi+gaQsSBCa5iVnCAmAIII1Aw9igIo/ySHLIkPHJhXNQjufCe8OQAw7gHqWRcEOWCep3CA5ABFY3gV3/Qh7dywgyq0jt6Q+G5ngromo38HSBZtBoVRh0eQjY9QM0kUr1YJgdef+elFpRQrfUACf3+Bq+FeCm2VetGSKSVUUqcUHxSpC38T3aGUWQCLeGowiWASIyNSnsFRKEcw84FADYMpKPYKGLoFL1oG1neAkgWqJ7YvYiQNvUVnJ9g0hrTFobcKKZgIIp4EORQJdLOjzFWQl4+QhWV3qFuSBfOh+ajv6iTGZxFT5cNhFE93w78GtBICLb1nCv9murlFQD0Q5J2qS9VgQCEQQ4GE05IKV5Nxbrd6iDGBYb+BhTt6RFgENfN2ANd6pNmqrh96W9Gqxf4T1TiEjwYBoEmmb7/0N0KbMg5VZ0PwB4P/IB9y99/XMvZZGCKZOI/9o/TRl9yZh75zd75bdPpzCriaBJj8B7fZRTpxp97xJkuXewBbQgKdstF5ChEUH+mlUKhGYVo5VB9q8UB6AX0Zdzq/Qj1xF+dRl+BZt7fXgvdzhYuXeUR3iU61KcfVQHc9gqI1JbEQATM6AETIBRN5t7afuBORu5XeGDkshxUwsjM3YksRkn3HJnR3h2E5cD+HS2PVuHbRsrOduHKViXOVuJ7ToD7PJpGXWLQ+Bhi5uzp5tTPUC/ofu8jZu3txoSwKIo0YKZNwBZoBUdI2Keb0J03/cnKRNk3Te6zRsAbpuwhaC9tf83wHsSj+F3Cj/Ua49Aso3gsyNysA8gg5HxAjBRUXsyIi3cvwccFMygToysTpW2Iva5JiD8g4eATxMXvQG8szFcvXG7h7GSAj5SsyPysHuyIE8gUeW2xgHgVSdbup87dXcTlK/cP/lUxgGcxl8hN4oBlhvrIgp6Bz8oWSK3Iga6zCcWCUlbu+1Urq9hp1mQrVGbIuJcIm3izwGdJgR90GWi0A09I4yXqRRTmhNdJvr3YMiyklr40TdoHt7kiRq9zQLJzbnw00E91EV91Em91E391FE91VV91Vm91V3902trJ1oNpxRcNgft1XGd1LMn13ld1He914G9TDw92Hv9LG//IvGUi5anszodHc7xfKeefWbDNNpHgq1n2Zrqc1CofRSLZtvzuW683SSUStNdtEJvo9n9PNyrW91BAdEvwd1Fop07ITA0KwngfdXYvd3zvQb3Hd/lw+UuAuADPtaPk+AfQuAtPeEVfuEZvuEd/uEh8AArIJsVoulyAQEZAikxw1EOsN+z4OInXggOkGJpOoWEQONHgz0sMNYewo+c1RoX4lDcpCu54F4dgs0kgA3YAKddoZ1l3kuDw88igpKkEz2RjSGITAJOIRkE4CvzwQ3oABUWAQwZAlEAPumXXj2IUCKoiTloWSFqATRa4ziZwiuwZ/4WwnMmgEuovjq2nmDO/0wOeN4VFsFK2ICxBELujd4O0F4h+oArgmER1IPY/vk4MTI6FaIVKsNPvl4hRIEUyGHo50/x1eMLvQ0iHuonoKEOdNwZvGFLAEAZmKEhNt/bpqEaSD8xtsGJvsHgHeMNZ1IeCmAfvKPqDWYU7AHv4YH2++EgisHjr4D2W7QJVxjijf/4kT/5lb8leGE7fOLkZ78J8kL3l18jJODooePsSX7NgL/6K3Ad6uAR6oAbqAGegCIsbmoLpkCVDQLv4KnzvZ97HEEX1l5RnqIRoGIv+qLp1R8ICgINQCNgBCIFALPpfEKj0im1ar1is9ott+v9gsPiMVY4mRAYjo0gAJi0A9YQwUNACBgDQnVE8hZM6JENEhYaHiImKi4yOswFWAjMPQAQxAXo2WHqCTl4+kloRAgIWDCeoqaqrrK2isHRAZA6MLFNFFgQeVYUbPAe2RZtFDAIbLgiJysvMzdXsdH+TTTJkU4/wEJYCLlZbgQ4CDgwOJebn6Onq6+zt7u/w8fLz9PX29/j5+vv8/f7/wMMKHAgwYIGDyJMqHAhw4YOH0KMKHEixYoWL2LMqHEjx44eP4IMKXIkyZImT6JMqXIly5YuX8KMKXMmzZo2b+LMqXMnz54+mwUBADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * p&lt;0.05.",
"     <br>",
"      &bull; p&lt;0.001.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Buse, J, Weyer, C, Maggs, D. Amylin replacement with pramlintide in type 1 and type 2 diabetes: A physiological approach to overcome barriers with insulin therapy. Clinical Diabetes 2002; 20:137. Copyright &copy; 2002 The American Diabetes Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_29_5599=[""].join("\n");
var outline_f5_29_5599=null;
